

EXCELLENCE IN QUALITY

We promote quality in medical laboratories by offering a wide range of external quality controls and continuous education.



www.instand-international.com



INSTAND

INSTAND International GMBH

Ubierstr. 20, 40223 Duesseldorf, Germany

T +49 [0] 211 876 3529 0

E info@instand-international.com

Represented by:

Chief Executive Officer: Prof. Dr. rer. nat. Ingo Schellenberg

Register:

Registered in the Registry of Associations

Register Court: Amtsgericht Düsseldorf Register

Number: HRB 95353

Sales tax identification number according to § 27a Sales Tax Act:

DE351329066

Version: 09/07/2026

Dear Colleagues,

INSTAND celebrates its 60th anniversary in 2026. We want to take this opportunity to thank you for your ongoing collaboration. Our success is based, among other things, on our close collaboration with the scientific community, our valued EQAS/PT experts, and laboratory teams worldwide, who ensure the high quality of our EQAS/PT and processes. To mark this special occasion, we have given our catalog a modern layout and optimized its individual sections.

INSTAND e.V., the Society for promoting Quality Assurance in Medical Laboratories e.V., has been conducting EQAS/PT in all areas of in-vitro diagnostics as a reference institution of the German Medical Association since 1970.

As an External Quality Assessment organization, we are **accredited according to DIN EN ISO/IEC 17043**. We offer **over 400 External Quality Assessment (EQA) schemes/Proficiency Tests (PT)** for external quality control in laboratory diagnostics, in accordance with the current version of the German Medical Association (Rili-BÄK) guidelines. For this purpose, we ship around 165,000 sample sets annually to approximately 12,000 participating laboratories in nearly 80 countries.

We have optimized our **2027 INSTAND EQA Scheme Program** to meet the highest quality standards. Our new features at a glance (see pages 11 and 12 for detailed information):

- **Molecular Genetics:** New EQAS/PT and EQAS/PT with new parameters
- **Immunology:** New EQAS/PT and EQAS/PT with new parameters
- **Clinical Chemistry:** EQAS/PT with new parameters
- **Virus Diagnostics:** New EQAS/PT
- Participation will have access to our EQAS/PT the **2027 Pricelist**, including shipping costs, on the INSTAND RV-Online.

The current EQAS/PT program is available on the **RV-Online System** and on our **Website**.

We are excited to continue our excellent and pleasant cooperation with you.



Your INSTAND Team



Prof. Dr. med.

Michael Spannagl

President of the Board



Prof. Dr. rer. nat.

Ingo Schellenberg

Vice President of the Board



Prof. Dr. med.

Klaus-Peter Hunfeld

Vice President of the Board

SAVE THE DATE



IGLD-INSTAND-Jahrestagung
04. – 06. März 2027
Kap Europa. Messe Frankfurt.

Geändertes
Datum und
Veranstaltungs-
ort



Weitere Informationen und Anmeldeformular ab Herbst 2026 auf www.igld.de

INSTAND ACADEMY

As a medical-scientific society, we offer an extensive program of continued education on various advanced topics. While the majority of our training programs are currently in German, our English program is growing continuously. New information will be posted on our website and on LinkedIn.



All courses are available on our website



CALIBRATION LABORATORY

Head: Dr. Patricia Kaiser
kaiser@instand-ev.de

Our calibration laboratory is accredited according to DIN EN ISO/IEC 17025 and DIN EN ISO 15195. We use internationally recognized calibration methods for the metrological traceability of measurement results for measurands in the field of laboratory medicine to SI units. In line with the requirements of the Rili-BÄK, target values in serum, plasma, whole blood, urine, and cerebrospinal fluid are determined in our laboratory as an evaluation standard in EQAS at the level of accuracy. In addition, we also offer our expertise in determining target values as a calibration service for the certification of control and calibration materials for external customers. Our calibration procedures and services are listed in the Joint Committee for Traceability in Laboratory Medicine (JCTLM) database.

Measurand	Sample Type	Range		Measuring Method	U ^a
Substrates/Metabolites:					
Cholesterol	Serum/Plasma	1-10	mmol/l	GC-IDMS	1.0%
Glucose	Serum/Plasma	1-60	mmol/l	GC-IDMS	1.0%
	Urine/Liquor	0.5-60	mmol/l		1.0%
Uric acid	Serum/Plasma	50-1000	μmol/l	GC-IDMS	1.0%
	Urine	20-2500	μmol/l		1.0%
Urea	Serum/Plasma	0.5-50	mmol/l	GC-IDMS	1.0%
	Urine	0.5-500	mmol/l		1.0%
Creatinine	Serum/Plasma	25-2000	μmol/l	GC-IDMS	1.0%
	Urine	0.05-40	mmol/l		1.0%
Total Bilirubin ^b	Serum/Plasma	7-600	μmol/l	Photometric Absorbance Measurement	2.5%
Total glycerol	Serum/Plasma	0.5-6	mmol/l	GC-IDMS	1.0%
Hormones:					
Cortisol	Serum/Plasma	30-2000	nmol/l	GC-IDMS	1.0%
Estradiol-17β	Serum/Plasma	37-2500	pmol/l	GC-IDMS	1.0%
Progesterone	Serum/Plasma	0.5-150	nmol/l	GC-IDMS	1.0%
Testosterone	Serum/Plasma	0.7-69	nmol/l	GC-IDMS	1.5%
Thyroxine	Serum/Plasma	6.4-283	nmol/l	GC-IDMS	1.0%
Ions:					
Calcium	Serum/Plasma	0.5-8	mmol/l	ICP-IDMS	1.0%
Chloride	Serum/Plasma	50-150	mmol/l	ICP-IDMS	1.0%
Potassium	Serum/Plasma	1-10	mmol/l	ICP-IDMS	1.0%
	Urine	1-200	mmol/l		1.0%
Lithium	Serum/Plasma	0.1-5	mmol/l	ICP-IDMS	1.0%
Magnesium	Serum/Plasma	0.1-5	mmol/l	ICP-IDMS	1.0%
Sodium	Serum/Plasma	70-200	mmol/l	ICP-MS	1.0%
	Urine	20-300	mmol/l		1.0%
Enzymes:					
Alanine aminotransferase (ALAT)	Serum/Plasma	0.33-6.67	μkat/l	Kinetic spectrophotometry	2.5%
Aspartate aminotransferase (ASAT)	Serum/Plasma	0.33-6.67	μkat/l		2.5%
Creatine kinase (CK)	Serum/Plasma	0.8-24	μkat/l		2.5%
γ-Glutamyl transferase (GGT)	Serum/Plasma	0.33-5	μkat/l		2.5%
Lactate dehydrogenase (LDH)	Serum/Plasma	1-12	μkat/l		2.5%
Glycated Proteins:					
HbA1c	Blood/Hemolysate	29-150	mmol/mol Hb	LC-MS	1.5%
Proteins:					
Total hemoglobin	Blood/Hemolysate	20-200	g/l	Spectrophotometry	1.1%
Total protein	Serum/Plasma	25-130	g/l		1.5%
Drugs:					
Digitoxin	Serum/Plasma	1-100	nmol/l	LC-IDMS	2.5%
Digoxin	Serum/Plasma	0.2-20	nmol/l	LC-IDMS	2.5%
Theophylline	Serum/Plasma	5-500	μmol/l	GC-IDMS	1.0%

^a best measurement capability

^b applied to be listed as a calibration service by the JCTLM



For more details about our calibration procedures, please visit our [website](#).

Service Information

INSTAND e.V.'s Mission and Vision

We promote quality in medical laboratories by offering a wide range of external quality control and continuous education. Our vision is to improve the reliability of measurement results in medical laboratories worldwide. In the Federal Republic of Germany, INSTAND e.V. is listed by the German Medical Association as a reference institution for external quality assurance.

Accreditation

INSTAND e.V.'s versatile EQA program is accredited in all represented disciplines of laboratory diagnostics by the German Accreditation Body (DAkkS) according to DIN EN ISO/IEC 17043.

Terms and Conditions, FAQ

Our "General Terms and Conditions for Participation in **INSTAND e.V.** EQA Schemes" shall apply to all participants of the INSTAND e.V. EQA schemes. These terms and conditions can be found at:

<https://www.instand-ev.de/en/terms-conditions/>

We would also be happy to send them to you upon request. We have compiled answers to frequently asked questions in our FAQ: <https://www.instand-ev.de/en/faq/>

Costumers of the **INSTAND International GMBH**, please find the terms and conditions here:

<https://www.instand-international.com/terms-conditions/>

The INSTAND International GMBH FAQ can be found at:

<https://www.instand-international.com/faq-1/>

Information about the RV-Online Portal

A user account for our RV-Online system is required to participate in INSTAND e.V. EQA schemes:

<https://rv-online.instandev.de/index.shtml?lang=en>

After signing into RV-Online, you will be able to manage your master data and orders, as well as enter your EQAS results, view reports and retrieve your certificates. On our YouTube channel you will find in-depth videos that explain the various features of RV-Online in English and German.

Fees for each INSTAND e.V. EQAS

Our prices are net prices which do not include VAT or shipping costs. Taxes and custom duties shall be borne by the participant. These prices apply exclusively to orders placed via INSTAND e.V. Prices and services may differ for orders placed via distributors.

You can find our current price catalog on RV-Online.

Scope of services

An EQA scheme includes the sample material, which is used to determine the measurement values by the participant, as well as an evaluation by INSTAND e.V. of the submitted EQAS results. After evaluating the

EQAS, participants who have submitted their results on time will receive an individual report, a general overview where applicable, a certificate of participation, and a certificate if they have passed. In the event the EQAS is not passed, residual samples may be available after completion of the respective EQAS for a fee, so the participant can check your test systems.

Note: Even if the participant orders more than one sample set per EQAS/PT, we will issue certificates for the specific parameter analyzed in each case, provided all results are deemed accurate. We cannot issue certificates for individual instruments.

Using this Catalog

EQAS/PT required/not required by Rili-BÄK (German Medical Association)

This catalog clearly indicates which EQAS/PT are subject to the Rili-BÄK requirement. The EQAS/PT highlighted in orange in the table of contents include parameters for which participation is mandatory, in accordance with the German Medical Association's guidelines on quality assurance for laboratory medical tests (<https://www.bundesaerztekammer.de/en/german-medical-association>).

The **orange highlighting of Rili-BÄK-mandated analytes** is also reflected in the EQAS/PT descriptions. The participant can view the new structure in a sample scenario on page 8.

Validity of Certificates

Certificates are dated with the closing date of the EQA scheme. Certificates for parameters which must undergo an EQAS are valid for twice as long as the mandatory EQAS interval. Certificates for parameters which are not subject to an EQAS in accordance with Rili-BÄK are usually valid for 12 months.

Registration / Cancellation Deadlines

Orders can be changed or cancelled up until the respective registration/cancellation deadline. After the registration/cancellation deadline, it is no longer possible to change the order.

Shipment Date

On the day of shipment, the packages will be picked up by the shipping service provider of our choice. Before every delivery, our shipping service provider will send a tracking number by e-mail. This e-mail is always sent to the main user registered with RV-Online. If the samples do not arrive within a very short period of time, customers of INSTAND should contact the customer service (info@instand-international.com) without delay. The sooner we are informed, the better we can respond to delivery delays.

Submission Deadlines

EQAS/PT results must be entered by midnight CET on the closing date. After the closing date, it is no longer possible to correct or change the values.

Prices

For 2027, we are offering a separate price list for our participants. The price list is available on the RV-Online.



Using this Catalog

A detailed explanation using a hypothetical EQAS/PT

1	Molecular Oncology – PML::RARA qualitative				2	NEW!	3	702
EQAS/PT Properties Samples: 2 samples of 30 µL Sample Properties: cDNA solution Max. number of sample sets: 1 Additional Information: As required by the RiliBÄK, the method used must have a detection limit of at least 5%.				4		5	6	
Requirement for EQAS/PT according to Rili-BAK: half-yearly Validity Certificate: 12 months Parameter / Analytes: PML::RARA gene fusion				9	Not subject to Rili-BAK: Validity Certificate: 12 months Parameter / Analytes: PML::RARA gene fusion			
Shipping Information: Shipping not cooled				11	Safety Information: Process as patient sample material			
				12	CMS-approved			
13	Dates	Q1	Q2	Q3	Q4			
		Apr.			Nov.			
	Registration Deadline:	27-01-08			27-08-06			
	Sample Shipment:	27-03-09			27-10-05			
	Closing Date:	27-04-09			27-11-05			

Depending on the EQAS/PT, there may be additional specific comments or notes, such as infectivity, suitable measuring devices, etc.

1. Name of the EQAS/PT
2. New EQAS/PT
3. Group number of the EQAS/PT
4. EQAS/PT groups suitable for POCT
5. EQAS/PT Expert / Deputy EQAS/PT Expert
6. Labeling of groups containing infectious sample material in accordance with UN3373, Category B biological substance, or UN2814, Category A infectious substance (only for EQAS/PT 425)
7. Detailed information about the sample material sent
8. Parameters examined in the EQAS/PT: **Parameters highlighted in orange indicate compliance with Rili-BÄK requirements**, as well as information on the frequency and validity period of the certificate as prescribed by Rili-BÄK.
9. Proficiency tests not subject to Rili-BÄK requirements: Parameters, black
10. Notes on Shipping Information
11. Important Safety Information regarding this EQAS/PT
12. Marking for EQAS/PT programs that are CMS-approved in the U.S. in accordance with CLIA
13. List of relevant dates by quarter. For Q1 and Q3, participants can take part in the EQAS/PT on two different dates each. The month listed for each EQAS/PT date refers to the submission deadline. The number of available dates may vary by EQAS/PT.

EQA Schemes suitable for POCT

The following EQAS/PT include analytes relevant to point-of-care testing (POCT) and are generally suitable for participation using corresponding POCT systems.

Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

The corresponding EQA schemes are tagged in the catalog with:

Also suitable for POCT:



Only POCT:



EQAS/PT also suitable for POCT



No.	EQAS/PT	Sample Material
100	Clinical Chemistry - Conventional Analysis	Lyophilised serum
131	Fecal Diagnostics - Hb, Hb-Hapto-complex	Lyophilised stool
145	HbA1c	Whole blood (EDTA), not stabilized
151	Lipids/Lipoproteins	Lyophilised serum
161	Blood Gas Analysis	Control solution
162	Blood Gas Analysis - Haemoglobin	Control solution
163	Blood Gas Analysis OPTI Systems	Control solution
171	Urine Chemistry Qualitative	Liquid urine
173	Urine Chemistry Quantitative	Lyophilised urine
174	Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative)	Lyophilised urine
176	Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative)	Lyophilised urine
177	Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative)	Lyophilised urine
179	Urine Chemistry Hormones	Lyophilised urine
203	Tricyclic Antidepressants 04 - Qualitative in Serum	Lyophilised serum
204	Tricyclic Antidepressants 05 - Qualitative in Urine	Lyophilised urine
209	Haematology - Blood Cell Count - QBC System	Whole blood (EDTA), not stabilized
211	Haematology - Blood Cell Count	Stabilized control blood
226	Haemostasis - D-Dimer	Lyophilised plasma
240	hsCRP	Serum

292	Tumor Markers	Liquid Serum
293	Tumor Markers - PSA and Testosterone	Liquid Serum
320	Infection Serology - Procalcitonin	Serum
322	Infection Serology - C-Reactive Protein	Serum
335	Virus Immunology - HIV-1/HIV-2 (Ab)	Liquid serum/plasma
337	Virus Immunology - HIV-1 p24 Antigen	Liquid Serum
344	Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, Anti-HBe)	Liquid Serum
346	Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen)	Liquid serum/plasma
350	Virus Immunology - Dengue Viruses (Ab and NS1 Antigen)	Liquid serum (inactivated in case of Dengue Virus RNA positive samples)
352	Virus Immunology - Epstein Barr Virus (Ab)	Liquid Serum
355	Virus Immunology - Hantaviruses (Ab)	Liquid serum (inactivated in case of Hantavirus RNA positive samples)
359	Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus	Lyophilised cell culture material
370	Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses	Lyophilised cell culture material or allantoic fluid
410	Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)	Liquid cell culture material (inactivated)
481	Mycoserology - Cryptococcus neoformans/ - gattii Antigen	Liquid Serum
539	Bacterial Genome Detection - MRSA or cMRSA	Lyophilised cell suspension
545	Bacterial Genome Detection - Clostridium difficile (Toxin Gene)	Lyophilised cell suspension
546	Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci)	Lyophilised cell suspension
612	Haematology - Differential Blood Count (Machine-Based Analysis)	Whole blood (EDTA), not stabilized
760	Myocardial Markers	Lyophilised Serum
761	Myocardial Markers BNP	Serum / Plasma

EQAS/PT only for POCT



No.	EQAS/PT	Sample Material
286	Haemostasis - POCT	Whole blood (Citrat), not stabilized
800	Dry Chemistry - POCT: Glucose	Whole blood
810	Dry Chemistry - POCT: Abaxis Piccolo System	Lyophilised Serum

NEW as of 2027**New as of 2027:**

1. We have optimized and modernized our layout for easier navigation.
 - Our experts are listed by full name for each EQAS/PT.
 - A new feature is the breakdown into “Rili-BÄK-mandatory” and “non-Rili-BÄK-mandatory” categories; see also page 8.
 - New symbols (NEW, Safety Notice, POCT Label) for quick reference.
2. CMS-approved EQAS/PT are clearly marked.
3. All shipping information is in a separate field.
4. Our separate 2027 price catalog is now available to you on RV-Online.
5. We expanded our index to make it easier to search for a specific EQAS/PT.

EQAS/PT newly added to the Program**Molecular Genetics**

- EQAS/PT 590 Molecular Pathology – PIK3CA and ESR1
- EQAS/PT 670 Molecular Genetics – Factor V-Gene (F5)
- EQAS/PT 671 Molecular Genetics – Factor VII-Gene (F7)
- EQAS/PT 672 Molecular Genetics – Factor VIII-Gene (F8)
- EQAS/PT 673 Molecular Genetics – Factor IX-Gene (F9)
- EQAS/PT 674 Molecular Genetics – Factor X-Gene (F10)
- EQAS/PT 675 Molecular Genetics – Factor XI-Gene (F11)
- EQAS/PT 676 Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)
- EQAS/PT 677 Molecular Genetics – Factor XIII-Gene (F13A1, F13B)
- EQAS/PT 678 Molecular Genetics – von Willebrand Factor-Gene (VWF)
- EQAS/PT 701 Molecular Genetics – FLT3 (internal tandem duplication)
- EQAS/PT 702 Molecular Oncology – PML::RARA qualitative
- EQAS/PT 706 Molecular Genetics – Hereditary Fever Syndroms
- EQAS/PT 726 Molecular Genetics – UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood
- EQAS/PT 728 Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction

Immunology

- EQAS/PT 256 Autoimmune Diseases – Myositis
- EQAS/PT 268 Autoimmune Diseases – Receptor Encephalitis
- EQAS/PT 657 NK-/ and T cell cytotoxicity

Virus Diagnostics

- EQAS/PT 435 Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens

New Parameter for the following EQAS/PT

Immunology

- EQAS/PT 251: Autoimmune Diseases - Connective Tissue Diseases (ANA)
- EQAS/PT 253: Autoimmune Diseases - Hepatic Syndromes
- EQAS/PT 255: Autoimmune Diseases - Connective Tissue Diseases (ENA)
- EQAS/PT 257: Autoimmune Diseases - Vasculitis / Glomerulopathies
- EQAS/PT 259: Autoimmune Diseases - Autoimmune Dermatitis
- EQAS/PT 265: Autoimmune Diseases - Paraneoplastic Neuropathies

Clinical Chemistry

- EQAS/PT 850: Added new parameters: Bictegravir, Cabotegravir, Doravirine, and Ganciclovir
- EQAS/PT 871: Added new parameters: Brivaracetam and Perampanel
- EQAS/PT 875: Added “Cariprazine” parameter

Virus Diagnostics

- EQAS/PT 410: Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)

CMS approved EQAS/PT

We submitted the documentation for conformity approval in accordance with the CLIA amendments for the following EQA/PT schemes: 344, 391, 409, 410, 421, 422, 423, 424, 435, 720. The decision of CMS is expected in autumn and the catalogue will be updated accordingly.

TABLE OF CONTENT

EQAS/PT	No.	Page
MOLECULAR GENETICS		
Engraftment- and Chimerism Diagnostics		
Engraftment- and Chimerism Diagnostics	618	26
Immunohematology		
Immunohaematology 06 - Molecular Diagnostic	235	26
Conventional Genetics		
Molecular Genetics - Aldolase B (ALDOB) Variants (A149P, A174D, N334K)	793	27
Molecular Genetics - Alpha-Globin and beta-Globin	794	27
Molecular Genetics - Alpha1-Antitrypsin (SERPINA1) Variants (PiM, PiS, PiZ)	743	28
Molecular Genetics - Angiotensin Converting Enzyme	763	28
Molecular Genetics - Antithrombin (AT3; SERPINC1 Gene)	792	29
Molecular Genetics - Apolipoprotein (APOE) Variants (E2, E3, E4) - Whole Blood	734	29
Molecular Genetics - Apolipoprotein B APOB, R3500Q (HGVS: c.10580G>A; p.Arg3527Gln), R3500W (HGVS: c.10579C>T; p.Arg3527Trp))	771	30
Molecular Genetics - Apolipoprotein E (APOE) Variants (E2, E3, E4)	744	30
Molecular Genetics - AZF (Y-Chromosome Microdeletions)	788	31
Molecular Genetics - BRCA1 BRCA2	779	31
Molecular Genetics - C-C Motif Chemokine Receptor 5	764	32
Molecular Genetics - CFTR Common Mutations	778	32
Molecular Genetics - Collagen Receptor (ITGA2) Variant C807T	739	33
Molecular Genetics - Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency (CY-P21A2 Gene)	773	33
Molecular Genetics - Connexin 26 (GJB2 Gene, GJB6 Gene)	782	34
Molecular Genetics - Copper-Binding Protein ATP7B Variant (H1069Q)	745	34
Molecular Genetics - ctDNA Tumour Panel	752	35
Molecular Genetics - CYP2C9 CYP2C19 VKORC1 TPMT	775	35
Molecular Genetics - CYP2D6 IL28B	777	36
Molecular Genetics - Dihydropyrimidin Dehydrogenase	762	36
Molecular Genetics - Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) (DMD Gene)	780	37
Molecular Genetics - Factor V-Leiden (F5) Variant	740	37
Molecular Genetics - Factor V-Leiden (F5) Variant - Whole Blood	730	38
Molecular Genetics - Fibrinogen Receptor (ITGB3) Variant HPA 1a/1b	749	38
Molecular Genetics - Fragile X Syndrome (FMR1 Gene, CGG Repeats)	781	39
Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C)	741	39
Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) - Whole Blood	733	40
Molecular Genetics - Huntington Disease (HTT Gene, CAG Repeats)	784	40
Molecular Genetics - Lactase-Variant -13910T>C (MCM6 Gene, IVS13 C-T, rs4988235, HGVS: C.1917+326 C>T)	770	41

TABLE OF CONTENT

EQAS/PT	No.	Page
Molecular Genetics - MLH1 MSH2 MSH6 PMS2 (Lynch)	783	41
Molecular Genetics - MTHFR Variants C677T (optional A1298C)	747	42
Molecular Genetics - MTHFR Variants C677T (optional A1298C) - Whole Blood	732	42
Molecular Genetics - NIPT - Determination of Fetal RhD Status	727	43
Molecular Genetics - NOD2	774	43
Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G)	748	44
Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) - Whole Blood	735	44
Molecular Genetics - Prader-Willi (PWS) und Angelman (AS) Syndromes (Chromosome region 15q11-13, SNRPN)	786	45
Molecular Genetics - Protein C (PROC Gene)	790	45
Molecular Genetics - Protein S (PROS1 Gene)	791	46
Molecular Genetics - Prothrombin (F2) Variant G20210A	746	46
Molecular Genetics - Prothrombin (F2) Variant G20210A - Whole Blood	731	47
Molecular Genetics - Spinal Muscular Atrophy (SMN1 and SMN2 Genes)	787	47
Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) Variants	742	48
Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood	726	48
Molecular Genetics – Factor IX-Gene (F9)	673	49
Molecular Genetics – Factor V-Gene (F5)	670	49
Molecular Genetics – Factor VII-Gene (F7)	671	50
Molecular Genetics – Factor VIII-Gene (F8)	672	50
Molecular Genetics – Factor X-Gene (F10)	674	51
Molecular Genetics – Factor XI-Gene (F11)	675	51
Molecular Genetics – Factor XIII-Gene (F13A1, F13B)	677	52
Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)	676	52
Molecular Genetics – FLT3 (internal tandem duplication)	701	53
Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction	728	53
Molecular Genetics – von Willebrand Factor-Gene (VWF)	678	54
Molecular Oncology – PML::RARA qualitative	702	54
Molecular Pathology – PIK3CA and ESR1	590	55
Oncology		
Molecular Genetics - Hereditary Fever Syndroms	706	56
Molecular Genetics - Ret Proto-Oncogene (Multiple Endocrine Neoplasia Type 2, MEN2, RET Gene)	738	56
Molecular Oncology - AML-Panel (NGS)	798	57
Molecular Oncology - BRAF	795	57
Molecular Oncology - BTK	796	58
Molecular Oncology - KIT	767	58
Molecular Oncology - MYD88	766	59
Molecular Oncology - Myeloproliferative Neoplasia	768	59
Molecular Oncology - SF3B1	797	60
Molecular Oncology - STAT3	769	60
Molecular Oncology - TP53	765	61

TABLE OF CONTENT

EQAS/PT	No.	Page
IMMUNOLOGY		
Allergy Diagnostics		
Allergy Diagnostic	720	62
Autoimmune Diseases		
Autoimmune Diseases - Antiphospholipid Syndrome	275	62
Autoimmune Diseases - Autoimmune Dermatitis	259	63
Autoimmune Diseases - Autoimmune Endocrinopathies	263	63
Autoimmune Diseases - Connective Tissue Diseases (ANA)	251	64
Autoimmune Diseases - Connective Tissue Diseases (ENA)	255	64
Autoimmune Diseases - Diabetes mellitus	261	65
Autoimmune Diseases - Gluten-Sensitive Enteropathies	271	65
Autoimmune Diseases - Hepatic Syndromes	253	66
Autoimmune Diseases - Myasthenia gravis	269	66
Autoimmune Diseases - Myositis	256	67
Autoimmune Diseases - Paraneoplastic Neuropathies	265	67
Autoimmune Diseases - Peripheral Neuropathies	267	68
Autoimmune Diseases - Receptor Encephalitis	268	68
Autoimmune Diseases - Rheumatoid Arthritis	273	69
Autoimmune Diseases - Vasculitis / Glomerulopathies	257	69
Basophil Activation Test	653	70
HLA Typing		
HLA Diagnostics - High resolution, molecular HLA typing class I and II	444	70
HLA Diagnostics - HLA Antibody Screening and Identification	445	71
HLA Diagnostics - HLA Crossmatching	443	71
HLA Diagnostics - HLA Typing Class I and II of Serological Equivalents	441	72
HLA Diagnostics - HLA-B27 Determination	440	72
HLA Diagnostics - HLA-DQ	772	73
HLA Diagnostics - Low resolution, molecular HLA typing class I and II	442	73
Immunophenotyping		
Immunophenotyping - Cellular Immunodeficiency Diagnostic	651	74
Functional Immunologic Assays		
Interferon Gamma Release Assay (IGRA)	650	75
Lymphocyte Transformation Test (LTT)	656	76
NK-/ and T cell cytotoxicity	657	76
Oxidative Burst / Phagocytosis Test	654	77

TABLE OF CONTENT

EQAS/PT	No.	Page
Complement Analysis		
Complement Analysis - Anti-C1 Inhibitor Autoantibody	250	77
Complement Analysis - Anti-C1q Autoantibody	245	78
Complement Analysis - Anti-factor H (FH) Autoantibody	249	78
Complement Analysis - C3 - Nephritic Factor	248	79
Complement Analysis - Complement activation products	247	79
Complement Analysis - Functions (F) and Proteins (P)	246	80
TRANSFUSION MEDICINE		
Immunohematology		
Immunohaematology 01	231	81
Immunohaematology 02 (incl. Antibody Identification)	232	81
Immunohaematology 03 - Platelet Immunology	233	82
Immunohaematology 04 - Granulocyte Immunology	234	82
Immunohaematology 05 - Machine-Based Analysis	237	83
Immunohaematology 07 - Machine-Based Analysis (incl. AB Quantitation)	238	83
Immunohaematology 08 - Compatibility Testing (Blood Transfusion)	239	84
CLINICAL CHEMISTRY		
Haematology		
CD19 CAR-T-Cells (quantitative)	822	85
CLL-MRD Immunophenotyping	820	86
Haematology - Blood Cell Count	211	86
Haematology - Blood Cell Count - QBC System	209	87
Haematology - Blood Smear Analysis	212	87
Haematology - Bone Marrow Cytology	218	88
Haematology - Differential Blood Count (Machine-Based Analysis)	612	88
Haematology - Free Haemoglobin	236	89
Haematology - Haemoglobinopathies	210	89
Haematology - Immunophenotyping	214	90
Haematology - Lymphocyte differentiation	213	90
Haematology - PNH Diagnostics	616	91
Haematology - Reticulocyte Analysis Machine-Based Analysis	216	91
Haematology - Reticulocyte Analysis Microscopy	215	92
Haematology - Stem/Progenitor Cells (CD34)	217	92
Haematology - Stem/Progenitor Cells (CD34) (stabilized)	660	93
Haematology - T, B and NK cells in cellular products (flow cytometry)	617	93

TABLE OF CONTENT

EQAS/PT	No.	Page
Hemostaseology		
Haemostasis - Apixaban	504	94
Haemostasis - Argatroban	230	94
Haemostasis - AT, Protein C, Protein S, C1-Inhibitor	225	95
Haemostasis - Compact	285	95
Haemostasis - D-Dimer	226	96
Haemostasis - Dabigatran	502	96
Haemostasis - Edoxaban	505	97
Haemostasis - Emicizumab	506	97
Haemostasis - Factor II, V, VII,X	223	98
Haemostasis - Factor IX, XI, XII, XIII	224	98
Haemostasis - Factor VIII, WF	227	99
Haemostasis - FIB, TZ, FSP	222	99
Haemostasis - Fondaparinux	501	100
Haemostasis - Functional APC Resistance	288	100
Haemostasis - LMW Heparin	281	101
Haemostasis - Orgaran	282	101
Haemostasis - POCT	286	102
Haemostasis - PT, INR, aPTT	221	102
Haemostasis - Rivaroxaban	503	103
Haemostasis - ROTEM Sigma	509	103
Haemostasis - TEG/ROTEM	283	104
Haemostasis - UF Heparin	280	104
Hormones		
Adrenal Gland / Pituitary	298	105
Aldosterone	304	105
Calcium Metabolism / Special Thyroid	301	106
Fertility	297	106
Gravidity - 1st Trimester Screening	305	107
Gravidity - 2nd Trimester Screening	306	107
Hematopoietic Growth Factors	626	108
Pancreas/Gastrointestinal Tract	300	108
Preeclampsia Marker	625	109
Steroid Hormones, Thyroid Gland	302	109
Thyroid Gland Antibodies	295	110
Thyroid Hormones	294	110
Virilization	309	111

TABLE OF CONTENT

EQAS/PT	No.	Page
IgG Subclasses		
IgG Subclasses	244	111
Cardiac Marker		
Myocardial Markers	760	112
Myocardial Markers BNP	761	112
Conventional Clinical Chemistry		
ACE (Angiotensin-Converting-Enzyme)	630	113
Amino Acid Analysis	710	113
Ammonia	118	114
Biogenic Amines in Plasma	185	114
Capillary Zone Electrophoresis	102	115
Clinical Chemistry - Conventional Analysis	100	115
Ethanol	700	116
Fructosamine	146	116
G6PDH (Glucose-6 Phosphate Dehydrogenase)	279	117
Gammopathies	243	117
Glucose - Conventional Analysis	111	118
HbA1c	145	118
Lipids/Lipoproteins	151	119
Markers of Ethanol Abuse - Carbohydrate-Deficient Transferrin (CDT)	750	119
Plasma Cell Neoplasia-MRD Immunophenotyping	821	120
Serum Proteins/Electrophoresis	141	120
Cerebrospinal Fluid		
Cerebrospinal Fluid Analysis - CSF Ferritin	467	121
Cerebrospinal Fluid Analysis - Dementia Markers	466	121
Cerebrospinal Fluid Analysis - Free light chains Kappa	468	122
Cerebrospinal Fluid Analysis - Lactate/ Glucose	464	122
Cerebrospinal Fluid Analysis - MRZ Reaction	463	123
Cerebrospinal Fluid Analysis - Neuroborreliosis	465	123
Cerebrospinal Fluid Analysis - Oligoclonal IgG	462	124
Cerebrospinal Fluid Analysis - Protein Analysis	460	124

TABLE OF CONTENT

EQAS/PT	No.	Page
Newborn Analytic		
Neonatal Bilirubin	110	125
Newborn screening	785	125
Pharmaceuticals		
Antiarrhythmics - Amiodaron	190	126
Antibacterials 01 - Teicoplanin	193	126
Antibacterials 02	890	127
Anticonvulsants 01	191	127
Anticonvulsants 02	192	128
Anticonvulsants 03	871	128
Anticonvulsants 04	872	129
Antifungals / Immunosuppressants	602	129
Antifungals and Chloramphenicol	198	130
Antipsychotics/Antidepressives 01	200	130
Antipsychotics/Antidepressives 02	873	131
Antipsychotics/Antidepressives 03	874	131
Antipsychotics/Antidepressives 04	875	132
Antivirals	850	132
Benzodiazepines 01	876	133
Benzodiazepines 02	877	133
Benzodiazepines 03	878	134
Immunosuppressants	601	134
Paracetamol and NSAIDs	194	135
Psychostimulants - ADHS-Treatment	879	135
Psychotherapeutic Drugs 01	860	136
Psychotherapeutic Drugs 02	861	136
Psychotherapeutic Drugs 03	862	137
Psychotherapeutic Drugs 04	863	137
Respiratory Stimulants - Caffeine	870	138
Therapeutic drugs - Antibiotics, Digitoxin, MTX	197	138
Therapeutic drugs - Antiepileptics, Digoxin, Lithium and others	195	139
Tri-/Tetracyclic Antidepressants 03 - Quantitative in Serum	202	139
Tricyclic Antidepressants 01 - Quantitative in Serum	199	140
Tricyclic Antidepressants 02 - Quantitative in Serum	201	140
Tricyclic Antidepressants 04 - Qualitative in Serum	203	141

TABLE OF CONTENT

EQAS/PT	No.	Page
Photometry		
Photometer Controls	181	141
Plasma Proteins		
Cystatin C	242	142
hsCRP	240	142
Infection Serology - C-Reactive Protein	322	143
Plasmaproteins	241	143
POCT		
Blood Gas Analysis	161	144
Blood Gas Analysis - Haemoglobin	162	144
Blood Gas Analysis OPTI Systems	163	145
Dry Chemistry - POCT: Abaxis Piccolo System	810	145
Dry Chemistry - POCT: Glucose	800	146
Trace Elements		
Trace Elements - whole blood	208	146
Trace Elements Plasma	206	147
Trace Elements Serum	207	147
Stool Diagnostics		
Fecal Diagnostics - Calprotectin / Fecal Elastase	130	148
Fecal Diagnostics - Hb, Hb-Hapto-complex	131	148
Tumor Marker		
Tumor Markers	292	149
Tumor Markers - Calcitonin, Pro-GRP, PIVKAI, AFP, AFP-L3	299	149
Tumor Markers - PSA and Testosterone	293	150
Urine Analysis		
Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative)	174	150
Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative)	176	151
Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative)	177	151
Markers of Ethanol Abuse - Ethylglucuronide	751	152
Systematic Toxicological Analysis (STA)	188	152
Trace Elements Urine	205	153

TABLE OF CONTENT

EQAS/PT	No.	Page
Tricyclic Antidepressants 05 - Qualitative in Urine	204	153
Urinary Stone Analyses	500	154
Urine Chemistry Aminolaevulinic Acid / Porphobilinogen	180	154
Urine Chemistry Biogene Amines	175	155
Urine Chemistry Hormones	179	155
Urine Chemistry Porphyrins	178	156
Urine Chemistry Qualitative	171	156
Urine Chemistry Quantitative	173	157
Urine Chemistry Sediment Pictures	172	157
Urine Protein Differentiation	182	158
Vitamins		
Vitamins - Methylmalonic Acid	187	158
Vitamins - Serum	290	159
Vitamins - Vitamin C	296	159
Vitamins - whole blood	291	160
MICROBIOLOGY		
Bacterial Genome Detection		
Bacterial Genome Detection - Bordetella pertussis	532	161
Bacterial Genome Detection - Borrelia burgdorferi	535	161
Bacterial Genome Detection - Carbapenemase-Genes	544	162
Bacterial Genome Detection - Chlamydia pneumoniae	540	162
Bacterial Genome Detection - Chlamydia trachomatis	531	163
Bacterial Genome Detection - Chlamydia trachomatis & Neisseria gonorrhoeae	530	163
Bacterial Genome Detection - Clostridium difficile (Toxin Gene)	545	164
Bacterial Genome Detection - Coxiella burnetii & Bacillus anthracis	542	164
Bacterial Genome Detection - EHEC / STEC	534	165
Bacterial Genome Detection - Francisella tularensis & Brucella spp.	543	165
Bacterial Genome Detection - Helicobacter pylori	533	166
Bacterial Genome Detection - Legionella pneumophila	536	166
Bacterial Genome Detection - Listeria spp.	538	167
Bacterial Genome Detection - MRSA or cMRSA	539	167
Bacterial Genome Detection - Mycoplasma pneumoniae	541	168
Bacterial Genome Detection - PCR/NAT Multiplex Detection Method for Gastrointestinal Pathogens	548	168
Bacterial Genome Detection - Salmonella enterica	537	169
Bacterial Genome Detection - Urogenital Panel	547	169
Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci)	546	170

TABLE OF CONTENT

EQAS/PT	No.	Page
Bacteriological Infection Serology		
Infection Serology - Bartonella Antibodies	326	170
Infection Serology - Bordetella pertussis Antibodies	317	171
Infection Serology - Borrelia burgdorferi Antibodies	332	171
Infection Serology - Brucella Antibodies	327	172
Infection Serology - Campylobacter Antibodies	319	172
Infection Serology - Chlamydia pneumoniae (Chlamydophila) Antibodies	314	173
Infection Serology - Chlamydia trachomatis Antibodies	312	173
Infection Serology - Chlamydia trachomatis Direct Detection (ELISA / PCR)	313	174
Infection Serology - Chlamydia trachomatis Direct Detection (Slide)	316	174
Infection Serology - Coxiella burnetii Antibodies	325	175
Infection Serology - Diphtheria Toxoid Antibodies	318	175
Infection Serology - Francisella tularensis Antibodies	328	176
Infection Serology - Helicobacter pylori Antibodies	334	176
Infection Serology - Leptospira Antibodies	329	177
Infection Serology - Mycoplasma pneumoniae Antibodies	324	177
Infection Serology - Procalcitonin	320	178
Infection Serology - Rheumatoid Factor	323	178
Infection Serology - Rickettsia Antibodies	330	179
Infection Serology - Salmonella Antibodies	331	180
Infection Serology - Streptococcal AB	321	181
Infection Serology - Tetanus Toxoid Antibodies	310	181
Infection Serology - Treponema pallidum Antibodies	311	182
Infection Serology - Yersinia Antibodies	315	183
Human Microbiome		
Bacterial Genome Detection - Molecular Genetic Analysis of the Human Microbiome	580	183
Conventional Bacteriology		
Bacteriology (3 Samples)	411	184
Bacteriology (5 Samples)	412	185
Bacteriology - Gram Stain	413	185
Mycobacteriology		
Mycobacterial Diagnostics - Cultivation	422	186
Mycobacterial Diagnostics - Drug Susceptibility Testing of Mycobacterium tuberculosis	425	186
Mycobacterial Diagnostics - Drug Susceptibility Testing of Nontuberculous Mycobacteria	427	187

TABLE OF CONTENT

EQAS/PT	No.	Page
Mycobacterial Diagnostics - Identification	423	187
Mycobacterial Diagnostics - Microscopy	421	188
Mycobacterial Diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria	426	188
Mycobacterial Diagnostics - NAT Mycobacterium tuberculosis	424	189
Mycology		
Fungal Genome Detection - Pneumocystis jirovecii	560	189
Genome Detection of Dermatophytes	492	190
Mycology Dermatophytes, Yeasts, Mould Fungus	491	190
Mycology Mucorales, Yeasts, Coelomycetes, Hyphomycetes, Basidiomycetes	490	191
Mycoserology - Candida (Antigen and Antibodies)	480	191
Mycoserology - Cryptococcus neoformans/ - gattii Antigen	481	192
Parasite Diagnostics		
Detection of Toxoplasma DNA (PCR)	457	192
Molecular Genetic Detection of Protozoa in Stool	458	193
Parasite Microscopy (Blood)	456	193
Parasite Serology - Amoebiasis and Echinococcosis	455	194
Parasite Serology - Malaria and Schistosomiasis	454	194
Parasite Serology - Toxoplasmosis	452	195
Virtual Parasite Microscopy (Blood)	906	195
Virtual Parasite Detection (Stool)	907	196
VIRUS DIAGNOSTICS		
Virus Genome Detection		
Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)	410	197
Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses	370	198
Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus	359	199
Virus Genome Detection - Adenoviruses	371	199
Virus Genome Detection - BK Polyomavirus (BKPv / BKV)	364	200
Virus Genome Detection - Borna Viruses	404	200
Virus Genome Detection - Chikungunya Virus	392	201
Virus Genome Detection - Coronaviruses incl. SARS-CoV-2	340	202
Virus Genome Detection - Cytomegalovirus Program 1	365	203
Virus Genome Detection - Cytomegalovirus Program 2 - additional Training Program (can only be ordered with program 365)	368	203

TABLE OF CONTENT

EQAS/PT	No.	Page
Virus Genome Detection - Cytomegalovirus Resistance Determination	349	204
Virus Genome Detection - Dengue Viruses	369	204
Virus Genome Detection - Enteroviruses	372	205
Virus Genome Detection - Epstein Barr Virus	376	205
Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests	430	206
Virus Genome Detection - Hepatitis A Virus	377	206
Virus Genome Detection - Hepatitis B Virus Genotyping	396	207
Virus Genome Detection - Hepatitis B Virus Program 1	361	207
Virus Genome Detection - Hepatitis B Virus Program 2 - additional Training Program (can only be ordered with program 361)	378	208
Virus Genome Detection - Hepatitis B Virus Resistance Determination	397	208
Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping	375	209
Virus Genome Detection - Hepatitis C Virus Program 1	362	209
Virus Genome Detection - Hepatitis C Virus Program 2 - additional Training Program (can only be ordered with program 362)	379	210
Virus Genome Detection - Hepatitis C Virus Resistance Determination	399	210
Virus Genome Detection - Hepatitis D Virus	400	211
Virus Genome Detection - Hepatitis E Virus	380	211
Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2	363	212
Virus Genome Detection - HIV-1 (RNA) Program 2 - additional Training Program (can only be ordered with program 360)	382	212
Virus Genome Detection - HIV-1 (RNA) Program 1	360	213
Virus Genome Detection - HIV-1 Drug Resistance Determination - Standard Program for Protease and Reverse Transcriptase Inhibitors	383	213
Virus Genome Detection - HIV-1 Drug Resistance Determination - additional Program for Integrase Inhibitors and Tropism Determination	384	214
Virus Genome Detection - HIV-2 (RNA)	395	214
Virus Genome Detection - Human Herpesvirus 6 (HHV-6)	405	215
Virus Genome Detection - Human Herpesvirus 8 (HHV-8)	406	215
Virus Genome Detection - Human Metapneumovirus	385	216
Virus Genome Detection - Human Papillomaviruses (HPV)	373	216
Virus Genome Detection - Human Rhinoviruses	393	217
Virus Genome Detection - JC Polyomavirus (JCPyV / JCV)	394	217
Virus Genome Detection - Measles Virus	386	218
Virus Genome Detection - MPXV / Orthopoxviruses	418	219
Virus Genome Detection - Mumps Virus	387	220
Virus Genome Detection - Norovirus	381	220
Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens	435	221
Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests	433	221
Virus Genome Detection - Parainfluenza Viruses	388	222
Virus Genome Detection - Parechovirus	407	222
Virus Genome Detection - Parvovirus B19	367	223

TABLE OF CONTENT

EQAS/PT	No.	Page
Virus Genome Detection - Rabies Virus (Tollwutvirus)	390	223
Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests	431	224
Virus Genome Detection - Respiratory Virus Panel 2	432	225
Virus Genome Detection - Rotaviruses	401	226
Virus Genome Detection - Rubella Virus	389	226
Virus Genome Detection - SARS-CoV-2	409	227
Virus Genome Detection - SARS-CoV-2 sequence analysis	417	227
Virus Genome Detection - Torque Teno Virus (TTV)	408	228
Virus Genome Detection - Varicella Zoster Virus	366	228
Virus Genome Detection - West Nile Virus	391	229
Virus Genome Detection - Zika Virus	403	229
Virus Immunology		
Virus Immunology - Borna Viruses (Ab)	415	230
Virus Immunology - Chikungunya Virus (Ab)	402	230
Virus Immunology - Cytomegalovirus (Ab)	351	231
Virus Immunology - Dengue Viruses (Ab and NS1 Antigen)	350	231
Virus Immunology - Epstein Barr Virus (Ab)	352	232
Virus Immunology - Hantaviruses (Ab)	355	232
Virus Immunology - Hepatitis A Virus (Ab)	343	233
Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, An-	344	233
Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM)	345	234
Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen)	346	234
Virus Immunology - Hepatitis D Virus (Ab)	347	235
Virus Immunology - Hepatitis E Virus (Ab)	348	235
Virus Immunology - Herpes Simplex Viruses (Ab)	354	236
Virus Immunology - HIV-1 p24 Antigen	337	236
Virus Immunology - HIV-1/HIV-2 (Ab)	335	237
Virus Immunology - HTLV-1/HTLV-2 (Ab)	339	237
Virus Immunology - Measles Virus (Ab)	357	238
Virus Immunology - Mumps Virus (Ab)	356	238
Virus Immunology - Parvovirus B19 (Ab)	342	239
Virus Immunology - Rabies Virus (Tollwutvirus) (Ab)	336	239
Virus Immunology - Rubella Virus (Ab)	341	240
Virus Immunology - SARS-CoV-2 (Ab)	416	240
Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab)	358	241
Virus Immunology - Varicella Zoster Virus (Ab)	353	241
Virus Immunology - Zika Virus (Ab)	338	242

MOLECULAR GENETICS

Engraftment- and Chimerism Diagnostics

Engraftment- and Chimerism Diagnostics

618

EQAS/PT Properties Samples: 5 samples of 1.5 mL Sample Properties: Whole blood (CPD),not stabilized Max. Number of Sample Sets: 1 Additional Information: - Sample from donors, patients before and after transplantation are sent per appointment. Only annual subscription possible! - EQAS/PT results can only be submitted online! - Successful participation in both EQAS rounds is necessary for the award of a certificate (10 samples per year). Due to longer shipment times, labs using FISH-Analyses, cannot participate in this EQA.			EQAS/PT Experts: Dr. med. Roland Reibke Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick Prof. Dr. med. Michael Spannagl			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Evaluation and diagnosis Receiver			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-11 27-05-28			27-08-13 27-10-12 27-10-29

Immunoematology

Immunohaematology 06 - Molecular Diagnostic

235

EQAS/PT Properties Samples: 4 samples Sample Properties: DNA Max. number of sample sets: 1 Additional Information: A list of the alleles necessary for successful participation can be found at: www.instand-ev.de/mandatory-alleles				EQAS/PT Experts: Prof. Dr. med. Ulrich Sachs Deputy EQAS/PT Experts: Prof. Dr. med. Willy A. Flegel Dr. med. Christof Weinstock		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Red cells: ABO, MNS, RHD, RHD-Deletion, RHCE, LU, KEL, FY, JK, DI, YT, DO, CO, LW, KN, VEL. Platelets: HPA-1, 2, 3, 4, 5, 6, 9, 15. Granulocytes: HNA-1a, -1b, -1c; HNA-3, HNA-4, HNA-5.			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Conventional Genetics

Molecular Genetics - Aldolase B (ALDOB) Variants (A149P, A174D, N334K)

793

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aldolase B: A 149 P Aldolase B: A 174 D Aldolase B: N 334 K		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Alpha-Globin and beta-Globin

794

EQAS/PT Properties Samples: 2 samples of 40 µL Sample Properties: DNA solution (approx. 50 ng/µL)			EQAS/PT Experts: Dr. med. Claudia Frömmel Deputy EQAS/PT Experts: Dr. Adriana Méndez		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: • Mutations in the alpha-globin gene (max. 4) • Genotype of the alpha-globin gene (hemoglobinopathy nomenclature) • Evaluation of the alpha-globin gene • Mutations in the beta-globin gene (max. 4) • Beta-globin gene genotype (hemoglobinopathy nomenclature) • Beta-globin gene evaluation • Report with findings from both the alpha- and beta-globin genes • Report		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Alpha1-Antitrypsin (SERPINA1) Variants (PiM, PiS, PiZ)

743

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Alpha-1 antitrypsin S-Locus Alpha-1 antitrypsin Z-Locus			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Angiotensin Converting Enzyme

763

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: ACE Insertions/ Deletions (I/D)- Polymorphismus			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Antithrombin (AT3; SERPINC1 Gene)

792

EQAS/PT Properties Samples: 2 Samples of 50 µl Sample Properties: DNA solution (approx. 15 ng/µL) Max. number of sample sets: 1			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Analysis of the SERPINC1 gene for small base variations (SNVs) and/or copy number variations (CNVs)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Apolipoprotein (APOE) Variants (E2, E3, E4) - Whole Blood

734

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood Max. number of sample sets: 3			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Apo E (genotypes 2, 3, 4)			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.			Oct.
Registration Deadline:		27-01-08			27-07-02
Sample Shipment:		27-03-09			27-08-31
Closing Date:		27-04-09			27-10-01


Molecular Genetics - Apolipoprotein B APOB, R3500Q (HGVS: c.10580G>A; p.Arg-3527Gln), R3500W (HGVS: c.10579C>T; p.Arg3527Trp))

771

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL) Additional Information: Annotation for the evaluation: The successful participation requires the correct identification if the variants R3500Q (HGVS: c.10580G>A; p.Arg3527Gln) und R3500W (HGVS: c.10579C>T; p.Arg3527Trp) are present (homozygous/heterozygous) or not (negative) in the DNA samples.			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Apo B-100 (R3500Q; R3500W)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Apolipoprotein E (APOE) Variants (E2, E3, E4)

744

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Apo E (genotypes 2, 3, 4)			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05



Molecular Genetics - AZF (Y-Chromosome Microdeletions)

788

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: PD Dr. rer. nat. Julia Hentschel Deputy EQAS/PT Experts: MSc. Simone Ahting		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Y-Chromosome AZFa deletion Y-Chromosome AZFb deletion Y-Chromosome AZFc deletion			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - BRCA1 BRCA2

779

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Analysis of the BRCA1/BRCA2 genes for small base variations (SNVs) and/or copy number variations (CNVs)			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - C-C Motif Chemokine Receptor 5

764

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: CCR5 gene (Δ32)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - CFTR Common Mutations

778

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL) Additional Information: - CFTR gene (NM_000492.4). The 34 most common variants detected by standard screening methods will be tested. Participants must be able to identify at least the 34 most common variants. See here for a list of mandatory mutations: www.instand-ev.de/cftr-mandatory-mutations - Exception: Participants who only test the 31 variants of the child guidelines for CF. These participants are requested to communicate this in the comment field. Participants who only test for F508del cannot participate in this EQA scheme. - Participants who analyze the complete CFTR gene are also welcome to participate. These participants please communicate variants that are not among the 34 most common variants via the comment field. Participants are asked to comment on the possibility of CFTR modulator therapy.			EQAS/PT Experts: PD Dr. rer. nat. Julia Hentschel Deputy EQAS/PT Experts: MSc. Simone Ahting		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: CFTR gene			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: - ACMG classification - Interpretation of results / recommendation		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Collagen Receptor (ITGA2) Variant C807T

739

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Collagen receptor GP Ia/IIa (C 807 T)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency (CYP21A2 Gene)

773

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Analysis of the CYP21A2 gene for small base variations (SNVs) and/or copy number variations (CNVs)			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05



Molecular Genetics - Connexin 26 (GJB2 Gene, GJB6 Gene)

782

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Analysis of the GJB2 gene for small base variations (SNVs) and/or copy number variations (CNVs)			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: - Analysis of the GJB6 gene for copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Copper-Binding Protein ATP7B Variant (H1069Q)

745

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: ATP 7 B: H 1069 Q			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05



Molecular Genetics - ctDNA Tumour Panel

NEW!

752

EQAS/PT Properties Samples: 2 samples of 3 ml (30 ng/ml cfDNA) Sample Properties: DNA solution Max. number of sample sets: 1 Additional Information: Due to the complex nature of sample preparation, INSTAND e.V. reserves the right to no longer supply EQA samples to laboratories that have repeatedly failed to submit results. Link to the list of mutations: www.instand-ev.de/ctDNA_mutations			EQAS/PT Experts: Prof. Dr. med. Stefan Holdenrieder Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: BRAF V600-variant(s) KRAS Codon 13-variant(s) EGFR T790M-variant(s) KRAS Codon 61-variant(s) KRAS Codon 12-variant(s) NRAS Codon 61-variant(s)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: ESR1-variant(s) PIK3CA-variant(s)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - CYP2C9 CYP2C19 VKORC1 TPMT

775

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: CYP2C19*2 Allele: G 681 A CYP2C19*3 Allele: G 636 A CYP2C9*2 Allele: C 430 T CYP2C9*3 Allele: A 1075 C TPMT (nt. A 719 G) TPMT (nt. G 460 A) TPMT*2 Allele (nt. G 238 C)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: VKORC1: C 1173 T VKORC1: G -1639 A		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - CYP2D6 IL28B

777

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: CYP2D6 gene Duplication CYP2D6*3: A2637 del CYP2D6*4: G 1934 A CYP2D6*5: complete Deletion CYP2D6*6: T1795 del			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: IL-28B C/T: rs 12979860		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Dihydropyrimidin Dehydrogenase

762

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Susanna Schubert Deputy EQAS/PT Experts: PD Dr. rer. nat. Julia Hentschel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: The following variants are tested in this EQA scheme: Haplotype B3 (c.1236G>A; c.1129-5923C>G) c.1679T>G c.1905+1G>A c.2846A>T			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Assessment of the influence on enzyme function as well as the dose recommendation		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) (DMD Gene)

780

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Analysis of the DMD gene for small base variations (SNVs) and/or copy number variations (CNVs)			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Factor V-Leiden (F5) Variant

740

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL) Additional Information: Please note that this EQA scheme is intended for laboratories that test only for the Factor V Leiden SNP. If you perform a complete genetic analysis of the F5 gene, please participate in EQA scheme 670 - Molecular Genetics – Factor V-Gene (F5).			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Factor V-Leiden			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Factor V-Leiden (F5) Variant - Whole Blood

730

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood Max. number of sample sets: 3 Additional Information: Please note that this EQA scheme is intended for laboratories that test only for the Factor V Leiden SNP. If you perform a complete genetic analysis of the F5 gene, please participate in EQA scheme 670 - Molecular Genetics – Factor V-Gene (F5).			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Factor V-Leiden			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.			Oct.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01

Molecular Genetics - Fibrinogen Receptor (ITGB3) Variant HPA 1a/1b

749

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Fibrinogen Receptor HPA: 1a, 1b		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - Fragile X Syndrome (FMR1 Gene, CGG Repeats)

781

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: FMR1: determination of CGG-repeats in 5' UTR			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: - FMR1: determination of the variant category - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C)

741

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: HFE: C 282 Y HFE: H 63 D HFE: S 65 C			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05



Molecular Genetics - HFE Variants H63D, C282Y (optional: S65C) - Whole Blood

733

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood Max. number of sample sets: 3			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: HFE: C 282 Y HFE: H 63 D HFE: S 65 C			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.			Oct.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01

Molecular Genetics - Huntington Disease (HTT Gene, CAG Repeats)

784

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Determination of CAG-repeats			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05



Molecular Genetics - Lactase-Variant -13910T>C (MCM6 Gene, IVS13 C-T, rs4988235, HGVS: C.1917+326 C>T)

770

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)		EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Laktase-Gene (LCT) (-13910 C>T; HGVS: c.1917+326C>T)		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interpretation of results			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - MLH1 MSH2 MSH6 PMS2 (Lynch)

783

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)		EQAS/PT Experts: PD Dr. rer. nat. Julia Hentschel Deputy EQAS/PT Experts: MSc. Simone Ahting			
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: MLH1 gene MSH2 gene MSH6 gene PMS2 gene - gene analysis (SNVs und CNVs)		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: - HNPCC interpretation - Interpretation of results / recommendation			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05



Molecular Genetics - MTHFR Variants C677T (optional A1298C)

747

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)				EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK:: bi-annual Validity Certificate: 12 months Parameter / Analytes: MTHFR (A 1298 C)MTHFR (C 677 T)				Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05

Molecular Genetics - MTHFR Variants C677T (optional A1298C) - Whole Blood

732

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood Max. number of sample sets: 3				EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: MTHFR (A 1298 C) MTHFR (C 677 T)				Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01	



Molecular Genetics - NIPT - Determination of Fetal RhD Status

727

EQAS/PT Properties Samples: 2 samples of 1.5 ml Sample Properties: Liquid plasma (Plasma) Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Determination of the fetal RhD status			
Shipping Information: - Shipping not cooled - Shipping is limited to EU, Switzerland and UK.			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14			27-08-06 27-10-05 27-10-22

Molecular Genetics - NOD2

774

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)				EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: NOD2 mutation(s) NOD2 Nomenclature cDNA			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28			27-08-06 27-10-05 27-11-05



Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G)

748

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK: Validity Certificate: 12 months Parameter / Analytes: Plasminogenactivator-Inhibitor (PAI-1): 4G, 5G		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - PAI-1 (SERPINE1) Variant (4G/5G) - Whole Blood

735

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood Max. number of sample sets: 3			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Plasminogenactivator-Inhibitor (PAI-1): 4G, 5G		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.		Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09		27-07-02 27-08-31 27-10-01	



Molecular Genetics - Prader-Willi (PWS) und Angelman (AS) Syndromes (Chromosome region 15q11-13, SNRPN)

786

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL)		EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert			
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Methylation analysis deletion analysis		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3	Q4	
		May		Nov.	
Registration Deadline: Sample Shipment: Closing Date:		27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05	

Molecular Genetics - Protein C (PROC Gene)

790

EQAS/PT Properties Samples: 2 Samples of 50 µl Sample Properties: DNA solution (approx. 15 ng/µL) Max. number of sample sets: 1		EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the PROC gene for single-nucleotide variants (SNVs) and/or copy number variations (CNVs) - Interpretation of Results			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3	Q4	
		May		Nov.	
Registration Deadline: Sample Shipment: Closing Date:		27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05	

Molecular Genetics - Protein S (PROS1 Gene)

791

EQAS/PT Properties Samples: 2 Samples of 50 µl Sample Properties: DNA solution (approx. 15 ng/µL) Max. number of sample sets: 1			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the PROS1 gene for single-nucleotide variants (SNVs) and/or copy number variations (CNVs) - Interpretation of Results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Prothrombin (F2) Variant G20210A

746

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Prothrombin G20210A			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Prothrombin (F2) Variant G20210A - Whole Blood

731

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood Max. number of sample sets: 3			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Prothrombin G20210A			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.			Oct.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09			27-07-02 27-08-31 27-10-01

Molecular Genetics - Spinal Muscular Atrophy (SMN1 and SMN2 Genes)

787

EQAS/PT Properties Samples: 2 samples of 40 µl Sample Properties: DNA solution (approx. 15 ng/µL) Max. number of sample sets: 9			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Determination of the copy numbers of the SMN1 and SMN2 genes SMN2 Gen			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) Variants

742

EQAS/PT Properties Samples: 3 samples of 20 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: UDP-G1 UGT1A1*28 UDP-G1 UGT1A1*6			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics - UDP-Glucuronyltransferase 1 (UGT1A1) variants – Whole Blood

NEW!

726

EQAS/PT Properties Samples: 2 samples of 0.5 mL Sample Properties: Whole blood			EQAS/PT Experts: Dr. rer. nat. Ralf Flörke Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: UDP-G1 UGT1A1*28 UDP-G1 UGT1A1*6			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.		Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09		27-07-02 27-08-31 27-10-01	

Molecular Genetics – Factor IX-Gene (F9)

NEW!

673

EQAS/PT Properties Samples: 2 samples of 50 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F9 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics – Factor V-Gene (F5)

NEW!

670

EQAS/PT Properties Samples: 2 samples of 80 µL Sample Properties: DNA solution (approx. 25 ng/µL) Additional Information: - Please note that this EQA scheme is intended for laboratories that perform a complete genetic analysis of the F5 gene. - If you are only testing for the Factor V Leiden SNP, please participate in scheme 730 or 740.			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F5 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics – Factor VII-Gene (F7)

NEW!

671

EQAS/PT Properties Samples: 2 samples of 50 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F7 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor VIII-Gene (F8)

NEW!

672

EQAS/PT Properties Samples: 2 samples of 100 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F8 gene for intron 1 and intron 22 inversions and/or small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics – Factor X-Gene (F10)

NEW!

674

EQAS/PT Properties Samples: 2 samples of 50 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F7 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics – Factor XI-Gene (F11)

NEW!

675

EQAS/PT Properties Samples: 2 samples of 50 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F11 gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05



Molecular Genetics – Factor XIII-Gene (F13A1, F13B)

NEW!

677

EQAS/PT Properties Samples: 2 samples of 80 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the F13A1 and F13B genes for small nucleotide variations (SNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05

Molecular Genetics – Fibrinogen-Gene (FGA, FGB, FGG)

NEW!

676

EQAS/PT Properties Samples: 2 samples of 80 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the FGA, FGB, and FGG genes for small nucleotide variations (SNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-28		27-08-06 27-10-05 27-11-05



Molecular Genetics – FLT3 (internal tandem duplication)

NEW!

701

EQAS/PT Properties Samples: 2 samples of 10 µL Sample Properties: DNA solution (approx. 100 ng/µL) Max. number of sample sets: 1 Additional Information: - As required by the RiliBÄK, the method used must have a detection limit of at least 5%. - Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: 12 months Parameter / Analytes: FLT3 internal tandem duplication			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline:	26-11-13			27-04-23		
Sample Shipment:	27-01-12			27-06-22		
Closing Date:	27-02-12			27-07-23		

Molecular Genetics – NIPT - Aneuploidies, fetal sex and fetal fraction

NEW!

728

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Plasma			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg			
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: 12 months Parameter / Analytes: Aneuploidy Determination of fetal fraction Determination of fetal sex			Not subject to Rili-BÄK not applicable			
Shipping Information: - Shipping not cooled - Shipping is limited to EU, Switzerland and UK - Please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-07-02	
Sample Shipment:		27-03-09			27-08-31	
Closing Date:		27-03-19			27-09-10	

Molecular Genetics – von Willebrand Factor-Gene (VWF)

NEW!

678

EQAS/PT Properties Samples: 2 samples of 100 µL Sample Properties: DNA solution (approx. 25 ng/µL)			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: not applicable Parameter / Analytes:			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the VWF gene for small nucleotide variations (SNVs) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Oncology – PML::RARA qualitative

NEW!

702

EQAS/PT Properties Samples: 2 samples of 30 µL Sample Properties: cDNA solution Max. number of sample sets: 1 Additional Information: As required by the RiliBÄK, the method used must have a detection limit of at least 5%.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy		
Requirement for EQAS/PT according to Rili-BÄK: half-yearly Validity Certificate: 12 months Parameter / Analytes: PML::RARA gene fusion			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Apr.			Nov.
Registration Deadline:		27-01-08			27-08-06
Sample Shipment:		27-03-09			27-10-05
Closing Date:		27-04-09			27-11-05

Molecular Pathology – PIK3CA and ESR1

NEW!

590

EQAS/PT Properties Samples: 2 samples of 35 µL Sample Properties: DNA (approx. 5 ng/µL) Max. number of sample sets: 1 Additional Information: This EQA scheme addresses the requirements of EBM codes 19463 (PIK3CA) and 19466 (ESR1), which call for the targeted detection of activating mutations in circulating tumor DNA to guide treatment in advanced breast cancer.		EQAS/PT Experts: Dr. Harald Bartsch Deputy EQAS/PT Experts: N.N.			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: ESR1-variant(s) PIK3CA-variant(s)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
					Nov.
Registration Deadline: Sample Shipment: Closing Date:					27-08-13 27-10-12 27-11-19

Oncology

Molecular Genetics - Hereditary Fever Syndroms

NEW!

706

EQAS/PT Properties Samples: 2 samples of 40 µL Sample Properties: DNA solution (approx. 15 ng/µL)			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the MEFV, NLRP3, MVK, and TNFRSF1A genes, - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Genetics - Ret Proto-Oncogene (Multiple Endocrine Neoplasia Type 2, MEN2, RET Gene)

738

EQAS/PT Properties Samples: 2 Samples of 50 µl Sample Properties: DNA solution (approx. 15 ng/µL) Max. number of sample sets: 1			EQAS/PT Experts: Dr. rer. nat. Morten O. Christensen Deputy EQAS/PT Experts: Dr. med. Günther Kappert		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Analysis of the RET gene for small base variations (SNVs) (complete gene or the exons 5, 8, 10, 11, 13-16) and/or copy number variations (CNVs) - Interpretation of results		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Nov.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-28		27-11-05

Molecular Oncology - AML-Panel (NGS)

798

EQAS/PT Properties Samples: 1 samples of 10 µl Sample Properties: DNA solution (approx. 50 ng/µL)		EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: not applicable Parameter / Analytes: ASXL1 (NM_015338.6) Exon 13 Mutation(s) ASXL1 Nomenclature CEBPA (NM_004364.5) Mutation(s) CEBPA Nomenclature FLT3 (NM_004119.3) Mutation(s) Exon 20 FLT3 Nomenclature IDH1 (NM_005896.4) Exon 4 Mutation(s) IDH1 Nomenclature IDH2 (NM_002168.4) Exon 4 Mutation(s) IDH2 Nomenclature NPM1 (NM_002520.7) Exon 11 Mutation(s) NPM1 Nomenclature RUNX1 (NM_001754.5) Mutation(s) RUNX1 Nomenclature TP53 (NM_000546.6) Mutation(s) TP53 Nomenclature			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
	Feb.			July	
Registration Deadline:	26-11-13			27-04-23	
Sample Shipment:	27-01-12			27-06-22	
Closing Date:	27-02-12			27-07-23	

Molecular Oncology - BRAF

795

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 20 ng/µL) Additional Information: As required by the RiliBÄK, the method used must have a detection limit of at least 5%.		EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: BRAF p.V600 BRAF Nomenclature		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
	Feb.			July	
Registration Deadline:	26-11-13			27-04-23	
Sample Shipment:	27-01-12			27-06-22	
Closing Date:	27-02-12			27-07-23	

Molecular Oncology - BTK

796

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: BTK p.C481 BTK Nomenclature			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - KIT

767

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 20 ng/µL) Additional Information: As required by the RiliBÄK, the method used must have a detection limit of at least 0,1%.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: KIT p.D816V			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		

Molecular Oncology - MYD88

766

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: MYD88 p.L265P			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline:	26-11-13			27-04-23		
Sample Shipment:	27-01-12			27-06-22		
Closing Date:	27-02-12			27-07-23		

Molecular Oncology - Myeloproliferative Neoplasia

768

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 50 ng/µL) Additional Information: As required by the RiliBÄK, the method used must have a detection limit of at least 5%.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: JAK2 p.V617F JAK2 Exon 12 mutation JAK2 Exon 12 nomenclature			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: CALR Exon 9 Mutation(s) CALR Nomenclature MPL p.W515 MPL Nomenclature			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline:	26-11-13			27-04-23		
Sample Shipment:	27-01-12			27-06-22		
Closing Date:	27-02-12			27-07-23		

Molecular Oncology - SF3B1

797

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 30 ng/µL)			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: SF3B1 Exon 14-15 Mutation(s) SF3B1 Nomenclature		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Feb.			July	
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23	

Molecular Oncology - STAT3

769

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 20 ng/µL)			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: STAT3 Exon 21 Mutation(s) STAT3 Nomenclature		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Feb.			July	
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23	

Molecular Oncology - TP53

765

EQAS/PT Properties Samples: 2 samples of 10 µl Sample Properties: DNA solution (approx. 30 ng/µL) Additional Information: As required by the RiliBÄK, the method used must have a detection limit of at least 5%.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. rer. nat. Eva Lorsy			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: TP53 Mutation(s) TP53 Nomenclature			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.			July		
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-02-12			27-04-23 27-06-22 27-07-23		



IMMUNOLOGY

Allergy Diagnostics

Allergy Diagnostic

720

EQAS/PT Properties Samples: 5 samples of 1.0 or 0.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. Nathalie Weiss			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Qualitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Quantitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples), determination of total IgE (5 samples)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material Information will be updated at the end of autumn.			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Autoimmune Diseases

Autoimmune Diseases - Antiphospholipid Syndrome

275

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma				EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 24 months / 24 months Parameter / Analytes: anti-Cardiolipin (IgG) anti-β2-Glycoprotein (IgG) anti-Cardiolipin (IgM) anti-β2-Glycoprotein (IgM) anti-Cardiolipin (IgA) anti-β2-Glycoprotein (IgA) anti-Cardiolipin (polyvalent) anti-β2-Glykoprotein (polyvalent)		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline: Sample Shipment: Closing Date:					27-06-11 27-08-10 27-08-27	





Autoimmune Diseases - Autoimmune Dermatitis

259

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti- Desmosomes anti-Hemidesmosomes anti-Desmoglein 1 anti-Desmoglein 3 anti-BPAG 230 anti-BPAG 180 anti-Desmoplakin I / II anti-Kollagen Typ VII			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12				

Autoimmune Diseases - Autoimmune Endocrinopathies

263

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-adrenal cortex		



Autoimmune Diseases - Connective Tissue Diseases (ANA)

251

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Autoantibodies against ANA Autoantibodies against dsDNA			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Collagenosis Screening anti-DFS70 / LEDGF Autoantibodies against nucleosomes Autoantibodies against histones		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.		Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12		27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Connective Tissue Diseases (ENA)

255

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-U1-snRNP anti-SmD anti-Sm anti-SS-A / Ro anti-SS-A / Ro (52 kD - proteins) anti-SS-A / Ro (60 kD - proteins) anti-SS-B / La anti-Topoisomerase-1 (Scl 70)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
				Aug.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-11 27-08-10 27-08-27	





Autoimmune Diseases - Diabetes mellitus

261

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-Islet cells - JDFU Diabetes Screen anti-Islet cells (ICA) anti-Insulin (IAA) anti-Glutamic Acid Decarboxylase (GAD) anti-Tyrosine Phosphatase (IA2) anti-Zinc Transporter 8 (ZnT8A)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
					Aug.	
Registration Deadline: Sample Shipment: Closing Date:					27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Gluten-Sensitive Enteropathies

271

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: anti-Transglutaminase IgA			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: anti-Gliadin IgG anti-Gliadin IgA anti-deamidated Gliadin IgG anti-deamidated Gliadin IgA anti-Endomysium IgA			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	



Autoimmune Diseases - Hepatic Syndromes

253

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Plasma / Serum			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: anti-Mitochondria anti-H+/K+-ATPase anti-Microsomes (LKM 1) anti-gp210 anti-smooth muscle anti-SLA/LP anti-Actin anti-Sp100 anti-Parietal cells anti-Intrinsic factor			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Myasthenia gravis

269

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-Acetylcholin receptors anti-musclespecific Receptor Tyrosinkinase (MuSK) anti-skeletal muscle anti-Titin anti-calcium channel P/Q			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12				





Autoimmune Diseases - Myositis

NEW!

256

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma		EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-cN-1A anti-PM / Scl anti-Jo1 (Histidyl-tRNA synthetase) anti-PL7 (Threonyl-tRNA synthetase) anti-PL12 (Alanyl-tRNA synthetase) anti-EJ (Glycyl-tRNA synthetase) anti-OJ (Isoleucyl-tRNA synthetase) anti-KS (Asparaginyl-tRNA synthetase)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
				Aug.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Paraneoplastic Neuropathies

265

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma		EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-Purkinje cells anti-Neuronal nuclei anti-Yo (CDR62) anti-HuD anti-Ri / Nova 1 anti-Amphiphysin 1 anti-Ta (Ma 2) anti - Glia Cell nuclear Antibody			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			



Autoimmune Diseases - Peripheral Neuropathies

267

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Plasma / Serum			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-Myelin-associated Glycoprotein (MAG) anti-Asialoganglioside (AGA1) anti-Monosialoganglioside (GM1) anti-Monosialoganglioside (GM2) anti-Monosialoganglioside (GM3) anti-Disialoganglioside (GD1a) anti-Disialoganglioside (GD1b) anti-Quadrosialoganglioside (GQ1b) anti-Trisialoganglioside (GT1b)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			

Autoimmune Diseases - Receptor Encephalitis

NEW!

268

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Plasma / Serum			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: anti-MOG anti-Aquaporin 4 anti-CASPR2 anti-LGI1		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			





Autoimmune Diseases - Rheumatoid Arthritis

273

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Serum / Plasma Additional Information: Additional terms for the rheuma factor see EQA scheme 323 - Infection Serology - Rheumatoid Factor!			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Rheumatoid Factor Rheumatoid Factor (isotypes)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: anti-CCP (cyclic citrulline peptide) anti-MCV (mutated citrullinated Vimentin)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	

Autoimmune Diseases - Vasculitis / Glomerulopathies

257

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Plasma / Serum			EQAS/PT Experts: Dr. rer. nat. Martin Blüthner Deputy EQAS/PT Experts: Dr. Marie Mayrhofer			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: c-ANCA anti-PR3 p-ANCA anti-MPO			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: anti-glomerular basement membrane (GBM) anti-PLA2R anti-THSD7A			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12			27-06-11 27-08-10 27-08-27	



Basophil Activation Test

653

EQAS/PT Properties Samples: 2 samples of 2.6 ml Sample Properties: Whole blood (EDTA), not stabilized Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Ulrich Sack Deputy EQAS/PT Experts: Dr. Uwe Kölsch			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Basophil activation by allergens bee and wasp.			
Shipping Information: - Overnight delivery. - Cooled shipping - Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours! - The stimulants are not sent with the samples!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.	May		Sep.	Oct.
Registration Deadline:		27-01-08	27-03-12		27-07-02	27-08-13
Sample Shipment:		27-03-02	27-05-11		27-08-31	27-10-12
Closing Date:		27-03-12	27-05-21		27-09-10	27-10-22

HLA Typing

HLA Diagnostics - High resolution, molecular HLA typing class I and II

444

EQAS/PT Properties Samples: 5 samples of 1.5 mL Sample Properties: Isolated lymphocytes (buffy coat) Max. number of sample sets: 1 Additional Information: • Molecular HLA typing class I and II in high resolution according to standards of the European Federation for Immunogenetics (EFI). • In addition, HLA-B*57:01 associated with Abacavir hypersensitivity and HLA-DR epitopes associated with rheumatoid arthritis may be reported. • It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).			EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: HLA-B 57:01 typing of DNA			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HLA-A typing of DNA (high resolution) HLA-B typing of DNA (high resolution) HLA-C typing of DNA (high resolution) HLA-DPA1 typing of DNA (high resolution) HLA-DPB1 typing of DNA (high resolution) HLA-DQA1 typing of DNA (high resolution) HLA-DQB1 typing of DNA (high resolution) HLA-DRB 3/4/5 DNA-Typisierung (high resolution) HLA-DRB1 typing of DNA (Shared Epitope) HLA-DRB1 typing of DNA (high resolution)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03





HLA Diagnostics - HLA Antibody Screening and Identification

445

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Liquid serum Max. number of sample sets: 2		EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HLA antibody determination: • HLA antibody screening by complement-dependent cytotoxicity test (CDC) and/or with solid phase immunoassays • antibody identification by CDC and/or antibody identification by solid phase immunoassays (ELISA, Luminex) • solid phase complement binding assays (C1q, C3d, C4d etc.).			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
	Feb.			Aug.	
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-11 27-02-19			27-05-14 27-07-12 27-08-20	

HLA Diagnostics - HLA Crossmatching

443

EQAS/PT Properties Samples: 1 serum set (20 Sera à 100 µL and 2x ACD blood à 8 ml) Sample Properties: Liquid serum and platelet-depleted blood (ACD) Max. number of sample sets: 1		EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HLA crossmatching			
Shipping Information: • Shipping not cooled • Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
			Apr.		
Registration Deadline: Sample Shipment: Closing Date:			27-01-15 27-03-15 27-04-16		



HLA Diagnostics - HLA Typing Class I and II of Serological Equivalents

441

EQAS/PT Properties Samples: 5 samples of 8 mL Sample Properties: Platelet-depleted blood (ACD) Max. number of sample sets: 1 Additional Information: It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).			EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HLA Typing of serological equivalents of class I (HLA A, B) and/or HLA class II (HLA-DR, DQ) by serological and/or molecular means on the level of serological equivalents.			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03

HLA Diagnostics - HLA-B27 Determination

440

EQAS/PT Properties Samples: 5 blood samples of 3 mL Sample Properties: Whole blood (EDTA), not stabilized Max. number of sample sets: 1 Additional Information: Determination of HLA-B27 by molecular and/or serological means			EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Determination of HLA-B27			Not subject to Rili-BÄK: not applicable			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03





HLA Diagnostics - HLA-DQ

772

EQAS/PT Properties Samples: 2 samples of 1-1.5 ml Sample Properties: Whole blood (EDTA), not stabilized				EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu		
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: not applicable Parameter / Analytes:			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HLA DQA1*05 HLA DQB1*02 HLA DQB1*03:02			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			Apr.			Dec.
Registration Deadline: Sample Shipment: Closing Date:			27-01-15 27-03-15 27-04-09			27-09-10 27-11-08 27-12-03

HLA Diagnostics - Low resolution, molecular HLA typing class I and II

442

EQAS/PT Properties Samples: 5 samples of 7 mL Sample Properties: Whole blood (ACD), not stabilized Max. number of sample sets: 1 Additional Information: • Molecular HLA typing class I and II in low resolution (1-field). • It is not possible to report individual antigens, e.g. in the context of HLA disease associations (HLA-A29, HLA-B51, etc.).			EQAS/PT Experts: Dr.-Ing. Nils Lachmann Deputy EQAS/PT Experts: Sükran Zaralioglu			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HLA-A DNA Typing (low resolution) HLA-B DNA Typing (low resolution) HLA-C DNA Typing (low resolution) HLA-DPA1 DNA Typing (low resolution) HLA-DPB1 DNA Typing (low resolution) HLA-DQA1 DNA Typing (low resolution) HLA-DQB1 DNA typing (low resolution) HLA-DRB1 DNA typing (low resolution) HLA-DRB3,4,5 DNA typing (low resolution) HLA-DRB3,4,5 DNA typing (phenotypic)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Feb.		Apr.	Aug.		Dec.
Registration Deadline:	26-11-13		27-01-15	27-05-14		27-09-10
Sample Shipment:	27-01-11		27-03-15	27-07-12		27-11-08
Closing Date:	27-02-05		27-04-09	27-08-06		27-12-03



Immunophenotyping

Immunophenotyping - Cellular Immunodeficiency Diagnostic

651

EQAS/PT Properties Samples: 2 samples of 4 mL Sample Properties: Whole blood (EDTA), not stabilized Max. number of sample sets: 1		EQAS/PT Experts: Prof. Dr. med. Ulrich Sack Deputy EQAS/PT Experts: Dr. Uwe Kölsch				
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: • Analysis based on the case description for T-, NK-, and B-cell subpopulations, as well as monocytes and granulocytes, including naive, memory, effector, and activated T cells, TH1/2, TH17, and regulatory cells, with the markers CD11a, CD18, HLA-DR, TCR alpha/beta, TCR gamma/delta, CD45RA/CD45RO, CCR7, and CD31. • Possible B-cell subpopulations: transitional, naive, non-switched, switched, IgM-only, IgA+, IgG+, CD21low/CD38low, and plasmablasts. • NK subpopulations based on expression of: CD94, Nkp30, Nkp44, Nkp46, CD56 bright, cytolytic NK, NK-like • Monocytes: classical/non-classical monocytes • Granulocytes: expression of CD11a, CD18 on granulocytes • TCR Vβ typing • Only individual markers or subsets of these markers may also be used.				
Shipping Information: • Shipping not cooled • Overnight delivery • Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!		Safety Information: Process as patient sample material				
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-03-19			27-08-13
Sample Shipment:			27-05-18			27-10-12
Closing Date:			27-05-28			27-10-22





Functional Immunologic Assays

Interferon Gamma Release Assay (IGRA)

650

EQAS/PT Properties Samples: 2 samples of approx. 4 ml Sample Properties: Whole blood (Heparin), not stabilized Max. number of sample sets: 1 Additional Information: • Due to high demand three different sets of samples will be sent (Gr. 650 = Gr. 950 or Gr. 951). INSTAND e. V. reassigns the group number you receive before each EQAS/PT shipment. All groups are equivalent! • Please note: This EQA scheme is based on stimulation with Mycobacterium Tuberculosis antigens and is designed for participants who use a TB Elispot (e.g., T-SPOT®.TB) or a test with pre-stimulation in a tube (e.g. QuantiFeron®-TB Gold Plus) or RIDA-SCREEN® TB Assay.				EQAS/PT Experts: Prof. Dr. med. Ulrich Sack Deputy EQAS/PT Experts: Dr. Uwe Kölsch		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interferon Gamma Release Assay (IGRA)			
Shipping Information: • Shipping not cooled • Overnight delivery • Before registering for this EQAS/PT, please note that the samples have a limited stability of 24 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29



Lymphocyte Transformation Test (LTT)

656

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Whole blood (Heparin), not stabilized Max. number of sample sets: 1 Additional Information: This EQA scheme is intended for laboratories that perform lymphocyte proliferation assays to clarify lymphocyte dysfunction. Proliferation can be measured with cell tracer dyes, by 3H-thymidine incorporation or by MTT. Stimulation indices (3H-thymidine method and MTT) or proliferation indices (flow cytometric methods) and an evaluation can be reported.			EQAS/PT Experts: Dr. Uwe Kölsch Deputy EQAS/PT Experts: Prof. Dr. Dr. med. Fabian Hauck			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Proliferation index after stimulation with PHA, PMA/ionomycin, anti-CD3 and anti-CD3/anti-CD28 - Evaluation.			
Shipping Information: - Shipping not cooled - Shipping within the DACH region only - Overnight delivery. The samples should ideally be stimulated and measured within 24-36 h after blood collection. The stimulants are not sent with the samples! - Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-10 27-06-04			27-07-30 27-09-27 27-10-22

NK-/ and T cell cytotoxicity

NEW!

657

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Whole blood (Heparin) not stabilized Max. number of sample sets: 1			EQAS/PT Experts: Dr. Uwe Kölsch Deputy EQAS/PT Experts: Dr. rer. physiol. Eva-Maria Jacobsen			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: CD107a expression or lysis indices and evaluation			
Shipping Information: - Shipping not cooled - Shipping is only available in the DACH- region Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-10 27-06-04			27-07-30 27-09-27 27-10-22





Oxidative Burst / Phagocytosis Test

654

EQAS/PT Properties Samples: 4 samples of 2 ml Sample Properties: Whole blood (Heparin), not stabilized Max. number of sample sets: 1 Additional Information: • The samples should ideally be stimulated and measured within 24-36 h after blood collection. The stimulants are not sent with the samples! • This EQA scheme is intended for laboratories that determine oxygen radical production in granulocytes to clarify a granulocyte dysfunction.				EQAS/PT Experts: Dr. Uwe Kölsch Deputy EQAS/PT Experts: Prof. Dr. Dr. med. Fabian Hauck		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Oxygen radical production in granulocytes after stimulation with PMA and with E. coli (also individually) Stimulation index (DHR) and evaluation (DHR/ NBT) as well as phagocytosis of opsonised E. coli in granulocytes Stimulation index and evaluation.			
Shipping Information: • Shipping not cooled • Overnight delivery • Shipping within the DACH region only • Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-10 27-06-04			27-07-30 27-09-27 27-10-22

Complement Analysis

Complement Analysis - Anti-C1 Inhibitor Autoantibody

250

EQAS/PT Properties Samples: 2 samples of 300 µl Sample Properties: Serum Max. number of sample sets: 1				EQAS/PT Experts: Prof. Dr. Zoltan Prohaszka Deputy EQAS/PT Experts: Prof. Dr. Michael Kirschfink		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Auto-anti-C1 inhibitor IgA (qualitative) Auto-anti-C1 inhibitor IgG (qualitative) Auto-anti-C1 inhibitor IgM (qualitative)		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
						Nov.
Registration Deadline: Sample Shipment: Closing Date:						27-08-06 27-10-05 27-11-05



Complement Analysis - Anti-C1q Autoantibody

245

EQAS/PT Properties Samples: 2 samples of 300 µl Sample Properties: Serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. Zoltan Prohaszka Deputy EQAS/PT Experts: Prof. Dr. Michael Kirschfink		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Auto-anti C1q (IgG) Auto-anti C1q (IgG) (qualitative)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Nov.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-26			27-08-06 27-10-05 27-11-05

Complement Analysis - Anti-factor H (FH) Autoantibody

249

EQAS/PT Properties Samples: 2 samples of 300 µl Sample Properties: Serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. Zoltan Prohaszka Deputy EQAS/PT Experts: Prof. Dr. Michael Kirschfink		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Auto-anti FH-(qualitative) Auto-anti-FH (quantitative)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
					Nov.
Registration Deadline: Sample Shipment: Closing Date:					27-08-06 27-10-05 27-11-05





Complement Analysis - C3 - Nephritic Factor

248

EQAS/PT Properties Samples: 2 samples of 300 µl Sample Properties: Lyophilised serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. Zoltan Prohaszka Deputy EQAS/PT Experts: Prof. Dr. Michael Kirschfink		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: C3-nephritic factor (qualitative)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
					Nov.
Registration Deadline: Sample Shipment: Closing Date:					27-08-06 27-10-05 27-11-05

Complement Analysis - Complement activation products

247

EQAS/PT Properties Samples: 2 samples of 300 µl Sample Properties: Lyophilised plasma Max. number of sample sets: 3 Additional Information: Participation with one parameter (e.g. sC5b-9) possible			EQAS/PT Experts: Prof. Dr. Zoltan Prohaszka Deputy EQAS/PT Experts: Prof. Dr. Michael Kirschfink		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: C3a, C3d, Bb, sC5b-9		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
					Nov.
Registration Deadline: Sample Shipment: Closing Date:					27-08-06 27-10-05 27-11-05



Complement Analysis - Functions (F) and Proteins (P)

246

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum Max. number of sample sets: 3 Additional Information: Analysis of the total function of the 3 complement activation pathways (classical, alternative and lectin pathways) either by functional ELISA (WIELISA), by haemolytic (CH50, AH50) or by liposome-based assay (classical pathway). Participation with one parameter (e.g. CH50) is possible.			EQAS/PT Experts: Prof. Dr. Zoltan Prohaszka Deputy EQAS/PT Experts: Prof. Dr. Michael Kirschfink		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Classical pathway (F), Alternative pathway (F), Lectin pathway (FH), C1q, (P) C4 (P), C3 (P), C1 Inhibitor (F) (P), Factor H (P), Factor I (P)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Nov.
Registration Deadline:		26-12-18			27-08-06
Sample Shipment:		27-02-23			27-10-05
Closing Date:		27-03-26			27-11-05





TRANSFUSION MEDICINE

Immunohematology

Immunohaematology 01

231

EQAS/PT Properties Samples: 2 x 5 ml serum / 2 x 5 ml erythrocytes suspension Sample Properties: Serum + Erythrocytes suspension				EQAS/PT Experts: PD Dr. med. Franz F. Wagner Deputy EQAS/PT Experts: Dr. Nathalie Weiss		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: A B 0 - Typing Rh (D) Factor A - Subtyping				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Kell antigen		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline: Sample Shipment: Closing Date:		26-11-27 27-02-23 27-03-12	27-01-29 27-04-27 27-05-14	27-03-26 27-06-22 27-07-09		27-07-09 27-10-05 27-10-22

Immunohaematology 02 (incl. Antibody Identification)

232

EQAS/PT Properties Samples: 2 x 5 ml serum / 2 x 3 ml serum / 2 x 5 ml erythrocytes suspension Sample Properties: Serum + Erythrocytes suspension				EQAS/PT Experts: PD Dr. med. Franz F. Wagner Deputy EQAS/PT Experts: Dr. Nathalie Weiss		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: A B 0 - Typing Rh - Subtyping (without Cw) Rh (D) Factor Antibody Screening A - Subtyping Direct Antiglobulin Test			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Kell antigen Antibody identification AB quantitation			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.	May	July		Oct.
Registration Deadline: Sample Shipment: Closing Date:		26-11-27 27-02-23 27-03-12	27-01-29 27-04-27 27-05-14	27-03-26 27-06-22 27-07-09		27-07-09 27-10-05 27-10-22

Immunohaematology 03 - Platelet Immunology

233

EQAS/PT Properties Samples: 3 serum samples, 2 samples of DNA, 2 samples of platelet suspension Sample Properties: Serum + Cell suspension + DNA Max. number of sample sets: 1 Additional Information: This EQA scheme is intended for laboratories which are able to detect platelet alloantibodies and antigens. The EQA scheme 235 - Immunohaematology 06 - Molecular Diagnostic was designed for laboratories which only want to carry out platelet antigen genotyping.			EQAS/PT Experts: Prof. Dr. med. Ulrich Sachs Deputy EQAS/PT Experts: Dr. med. Hartmut Kroll		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Platelet antibodies Platelet antigens		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates		Q1	Q2	Q3	Q4
		Mar.		Sep.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-26		27-06-11 27-08-10 27-09-10	

Immunohaematology 04 - Granulocyte Immunology

234

EQAS/PT Properties Samples: 3 samples of plasma, 2 samples of DNA Sample Properties: Plasma + DNA Max. number of sample sets: 1 Additional Information: - This EQA scheme includes all HNA specifications. It is dedicated to laboratories which are able to detect granulocyte alloantibodies and antigens. The EQA scheme - 235 Immunohaematology 06 - Molecular Diagnostic was designed for laboratories which only want to perform HNA genotyping. - Because of the complicated preparation of the samples, INSTAND e.V. reserves the right to no longer supply laboratories with EQAS/PT samples, which have repeatedly not sent back any results.			EQAS/PT Experts: Dr. Torsten J. Schulze Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: HNA/granulocyte antibodies HNA/granulocyte (neutrophil) antigens		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates		Q1	Q2	Q3	Q4
		Mar.		Sep.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-26		27-06-11 27-08-10 27-09-10	

Immunohaematology 05 - Machine-Based Analysis

237

EQAS/PT Properties Samples: 2 samples of 5 mL Sample Properties: Whole blood			EQAS/PT Experts: PD Dr. med. Franz F. Wagner Deputy EQAS/PT Experts: Dr. Nathalie Weiss		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: A B 0 - Typing Rh - Subtyping (without Cw) Rh (D) Factor Antibody Screening A - Subtyping Direct Antiglobulin Test			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Kell antigen Antibody identification		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May	July	Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26	27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22	27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09	27-10-22

Immunohaematology 07 - Machine-Based Analysis (incl. AB Quantitation)

238

EQAS/PT Properties Samples: 2 x 5 ml whole blood + 2 x 5 ml serum Sample Properties: Whole blood + Serum			EQAS/PT Experts: PD Dr. med. Franz F. Wagner Deputy EQAS/PT Experts: Dr. Nathalie Weiss		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: A B 0 - Typing Rh - Subtyping (without Cw) Rh (D) Factor Antibody Screening A - Subtyping Direct Antiglobulin Test			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Kell antigen Antibody identification AB quantitation		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May	July	Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26	27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22	27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09	27-10-22

Immunohaematology 08 - Compatibility Testing (Blood Transfusion)

239

EQAS/PT Properties Samples: serum + erythrocytes suspension Sample Properties: serum + erythrocytes suspension Max. number of sample sets: 1			EQAS/PT Experts: PD Dr. med. Franz F. Wagner Deputy EQAS/PT Experts: Dr. Nathalie Weiss		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Antibody Screening			Not subject to Rili-BÄK Validity Certificate: 12 months / 12 months Parameter / Analytes: Blood type check (AB0 without isoagglutinins, RhD) Cross-match		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May	July	Oct.
Registration Deadline:		26-11-27	27-01-29	27-03-26	27-07-09
Sample Shipment:		27-02-23	27-04-27	27-06-22	27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09	27-10-22



CLINICAL CHEMISTRY

Haematology

CD19 CAR-T-Cells (quantitative)

822

EQAS/PT Properties Samples: 2 samples á 2 ml Sample Properties: Whole blood(EDTA), stabilized Max. number of sample sets: 1 Additional Information: - The number of participants is currently limited to a maximum of 40 per term. Note: The planned date may be postponed if donor availability cannot be realised at short notice. - Due to the time-consuming nature of sample preparation, INSTAND reserves the right to discontinue supplying interlaboratory comparison samples to laboratories that have repeatedly failed to submit results.			EQAS/PT Experts: Prof. Dr. Marion Subklewe Deputy EQAS/PT Experts: Dr. Gerulf Hänel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: CD19 CAR-T-cells		
Shipping Information: - Shipping not cooled - Shipping to the DACH region only. - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-07		27-08-27 27-10-26 27-11-05



CLL-MRD Immunophenotyping

820

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood (EDTA), not stabilized Max. number of sample sets: 1 Additional Information: • To successfully participate in the EQAS/PT, your method must have a minimum limit of detection (LoD) of 0.01%. • Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early. • Because of the complicated preparation of the samples, INSTAND e.V. reserves the right to no longer supply laboratories with EQAS/PT samples, which have repeatedly not sent back any results.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. Michaela Patz			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: % CLL-cells Rating of MRD			
Shipping Information: • Cooled shipping • Cooled shipping to Germany and Austria only. • Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Feb.			Sep.	
Registration Deadline:		26-12-04			27-07-23	
Sample Shipment:		27-02-02			27-09-21	
Closing Date:		27-02-05			27-09-24	

Haematology - Blood Cell Count

211

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Stabilized control blood Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Analysis of Haemoglobin with HemoCue systems is possible!			 EQAS/PT Experts: Dr. med. Benedikt Lohr Deputy EQAS/PT Experts: Dr. med. Thomas Nebe			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Erythrocytes Haemoglobin Haematocrit centrif. Leucocytes Haematocrit el.count Thrombocytes			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: MCV			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22





Haematology - Blood Cell Count - QBC System

209

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood (EDTA), not stabilized Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - This EQA scheme is only for participants with hematology systems based on QBC (Quantitative Buffy Coat) technology.			 EQAS/PT Experts: Dr. med. Benedikt Lohr Deputy EQAS/PT Experts: Dr. med. Thomas Nebe			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Haematocrit centrif. Leucocytes Haemoglobin Thrombocytes			Not subject to Rili-BÄK: not applicable			
Shipping Information: Cooled shipping Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Sep.	Oct.
Registration Deadline:	26-11-13		27-03-12		27-07-09	27-08-13
Sample Shipment:	27-01-12		27-05-11		27-09-07	27-10-12
Closing Date:	27-01-22		27-05-21		27-09-17	27-10-22

Haematology - Blood Smear Analysis

212

EQAS/PT Properties Samples: 2 peripheral blood smears Sample Properties: Slides Max. number of sample sets: 1 Additional Information: plus one special case for internal training purposes			EQAS/PT Experts: Prof. Dr. med. Dr. phil. Torsten Haferlach Deputy EQAS/PT Experts: Prof. Dr. med. Wolfgang Kern			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Blood Cell Differentiation in %			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Diagnostic comment - Morphology of erythrocytes, leucocytes and platelets			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22



Haematology - Bone Marrow Cytology

218

EQAS/PT Properties Samples: Digital slides in a virtual microscope of bone marrow aspirate Sample Properties: Digital slides Max. number of sample sets: 1 Additional Information: Available online in digital microscopy! - No shipment!			EQAS/PT Experts: Prof. Dr. med. Dr. phil. Torsten Haferlach Deputy EQAS/PT Experts: Prof. Dr. med. Winfried Gassmann		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Evaluation and diagnosis		
Shipping Information: No shipment!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Aug.
Registration Deadline: Sample Shipment: Closing Date:		27-02-19 27-02-23 27-03-12			27-08-06 27-08-10 27-08-27

Haematology - Differential Blood Count (Machine-Based Analysis)

612

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood (EDTA), not stabilized Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Due to high demand, two different sets of samples will be sent (Gr. 612 = Gr. 912). The group number you receive will be set by INSTAND e.V. before each EQAS shipment. Both groups are equivalent.			 EQAS/PT Experts: Dr. med. Benedikt Lohr Deputy EQAS/PT Experts: Dr. med. Thomas Nebe		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Erythrocytes Haemoglobin Haematocrit centrif. Leucocytes Haematocrit el.count Thrombocytes			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Basophilic Granulocytes Monocytes Eosinophilic Granulocytes Neutrophilic Lymphocytes Granulocytes MCV		
Shipping Information: Cooled shipping Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May		Sep.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-22		27-03-12 27-05-11 27-05-21	27-07-09 27-09-07 27-09-17	27-08-13 27-10-12 27-10-22





Haematology - Free Haemoglobin

236

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised erythrocytes preparation Additional Information: The samples are not suitable for methods based on photometric measurements of the oxyhaemoglobin peaks around 540 nm and/or 577 nm. The Harboe method (415 nm peak) is suitable. The quantitative hemolysis index from automated chemistry analysers can also provide a suitable result.			EQAS/PT Experts: Prof. Dr. med. Nicolas von Ahsen Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Haemoglobin (free)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22

Haematology - Haemoglobinopathies

210

EQAS/PT Properties Samples: 2 samples of 0.8 mL Sample Properties: Whole blood, stabilized Max. number of sample sets: 1			EQAS/PT Experts: Dr. med. Claudia Frömmel Deputy EQAS/PT Experts: Dr. Adriana Méndez		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Hemoglobin analysis with evaluation and presumptive diagnosis		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline:			27-04-09		27-08-13
Sample Shipment:			27-06-08		27-10-12
Closing Date:			27-06-25		27-10-29



Haematology - Immunophenotyping

214

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood (EDTA), not stabilized			EQAS/PT Experts: Dr. med. Richard Schabath Deputy EQAS/PT Experts: Prof. Dr. med. Wolfgang Kern			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Immunophenotyping of leukamias/lymphomas Immunophenotyping of hematologic neoplasms			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-03-12	27-04-30		27-08-13
Sample Shipment:	27-01-12		27-05-11	27-06-29		27-10-12
Closing Date:	27-01-22		27-05-21	27-07-09		27-10-22

Haematology - Lymphocyte differentiation

213

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood (EDTA), not stabilized			EQAS/PT Experts: Prof. Dr. med. Wolfgang Kern Deputy EQAS/PT Experts: Dr. med. Richard Schabath			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Lymphocyte-immunophenotyping - peripheral blood: CD4 pos. lymphocytes with CD3-expression (%) CD8 pos. lymphocytes with CD3-expression (%)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Lymphocyte-immunophenotyping - peripheral blood: B-Lymphocytes CD4 pos. lymphocytes with CD3-expression (/nl) CD8 pos. lymphocytes with CD3-expression (/nl) Leucocytes Lymphocytes NK-cells without CD3-expression T-lymphocytes			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.		July		
Registration Deadline:	26-11-13	27-01-15		27-04-30		27-08-13
Sample Shipment:	27-01-12	27-03-16		27-06-29		27-10-12
Closing Date:	27-01-22	27-03-26		27-07-09		27-10-22





Haematology - PNH Diagnostics

616

EQAS/PT Properties Samples: 2 samples of 1.5 mL Sample Properties: Whole blood (EDTA), not stabilized Additional Information: Due to high demand 3 different sets of samples will be sent (No. 616 = No. 916 or No. 917). The group number you receive will be set by INSTAND e.V. before each EQAS shipment. All groups are equivalent!				EQAS/PT Experts: Dr. med. Britta Höchsmann Deputy EQAS/PT Experts: Dr. med. Thomas Nebe		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: GPI-deficient cells			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 56 hours!			Safety Information: Process as patient sample material			
Dates		Q1	Q2	Q3		Q4
			May			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-12 27-05-11 27-05-28			27-07-23 27-09-21 27-10-08

Haematology - Reticulocyte Analysis Machine-Based Analysis

216

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood (EDTA), not stabilized			EQAS/PT Experts: Prof. Dr. med. Kai Gutensohn Deputy EQAS/PT Experts: Dr. med. Thomas Nebe			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Concentration of Hb in reticulocytes Immature reticulocytes Reticulated Platelets Reticulocyte production Index (RPI) Reticulocytes Reticulocytes concentration			
Shipping Information: - Cooled shipping - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Sep.	Oct.
Registration Deadline:	26-11-13		27-03-12		27-07-09	27-08-13
Sample Shipment:	27-01-12		27-05-11		27-09-07	27-10-12
Closing Date:	27-01-22		27-05-21		27-09-17	27-10-22



Haematology - Reticulocyte Analysis Microscopy

215

EQAS/PT Properties Samples: 2 blood smears for microscopic analysis Sample Properties: Slides			EQAS/PT Experts: Prof. Dr. med. Kai Gutensohn Deputy EQAS/PT Experts: Dr. med. Thomas Nebe		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Reticulocytes		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.			July	
Registration Deadline:	26-11-13			27-04-30	
Sample Shipment:	27-01-12			27-06-29	
Closing Date:	27-01-22			27-07-09	

Haematology - Stem/Progenitor Cells (CD34)

217

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood (EDTA), not stabilized			EQAS/PT Experts: Prof. Dr. med. Kai Gutensohn Deputy EQAS/PT Experts: Prof. Dr. med. Andreas Humpe		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Flow cytometric determination of CD34+ stem and progenitor cells and viability measurements		
Shipping Information: - Cooled shipping - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.		July	Sep.
Registration Deadline:	26-11-13	27-01-15		27-04-30	27-07-09
Sample Shipment:	27-01-12	27-03-16		27-06-29	27-09-07
Closing Date:	27-01-22	27-03-26		27-07-09	27-09-17





Haematology - Stem/Progenitor Cells (CD34) (stabilized)

660

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Whole blood(EDTA), stabilized Additional Information: For determination of CD34+ events plus vital CD34+ events, see Group 217 (native sample material).			EQAS/PT Experts: Prof. Dr. med. Kai Gutensohn Deputy EQAS/PT Experts: Prof. Dr. med. Andreas Humpe		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Flow cytometric analysis of stem and progenitor cells (CD34) without vitality measurement.		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.		July	Sep.
Registration Deadline:	26-11-13	27-01-15		27-04-30	27-07-09
Sample Shipment:	27-01-12	27-03-16		27-06-29	27-09-07
Closing Date:	27-01-22	27-03-26		27-07-09	27-09-17

Haematology - T, B and NK cells in cellular products (flow cytometry)

617

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Cellular products (CPD)			EQAS/PT Experts: Prof. Dr. med. Andreas Humpe Deputy EQAS/PT Experts: Prof. Dr. med. Kai Gutensohn		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: For flow cytometric determination of T, B and NK cells in cellular products only		
Shipping Information: - Cooled shipping - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline:			27-03-12		27-08-13
Sample Shipment:			27-05-11		27-10-12
Closing Date:			27-05-21		27-10-22



Hemostaseology

Haemostasis - Apixaban

504

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Apixaban		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Haemostasis - Argatroban

230

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Argatroban Thrombin Time aPTT		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May		Aug.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22





Haemostasis - AT, Protein C, Protein S, C1-Inhibitor

225

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Inhibitors (AT, PC, PS) Free Protein S funct. (act.) Antithrombin Protein S total C1-Inhibitor Total Protein C Free Protein S immun. (conc.)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22

Haemostasis - Compact

285

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Prothrombintime (PT, INR) Prothrombintime (PT, Quick) aPTT			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Antithrombin D-Dimer (quantitative) Fibrinogen Thrombin Time		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22



Haemostasis - D-Dimer

226

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2 Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick Dr. rer. biol. hum. Andrea Dick			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: D-Dimer (qualitative)D-Dimer (quantitative)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Haemostasis - Dabigatran

502

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Dabigatran			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22





Haemostasis - Edoxaban

505

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Edoxaban		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-14		27-10-22

Haemostasis - Emicizumab

506

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Emicizumab		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May		Aug.
Registration Deadline:	26-11-13		27-02-26		27-06-11
Sample Shipment:	27-01-12		27-04-27		27-08-10
Closing Date:	27-01-29		27-05-14		27-08-27
					27-10-22



Haemostasis - Factor II, V, VII,X

223

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Single factors A (via PT): factor II, factor V, factor VII, factor X		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22

Haemostasis - Factor IX, XI, XII, XIII

224

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Single factors B (via APTT, etc.): factor IX, factor XI, factor XII, factor XIII		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22



227

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2				EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Factor VIII akt.			

222

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Global test II: TZ, FIB, FSP screening FSP screening, using batro-xobin time or heparin-independent thrombin time			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22



Haemostasis - Fondaparinux

501

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Fondaparinux		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Haemostasis - Functional APC Resistance

288

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: APC resistance Diagnostic comments		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May		Aug.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22





Haemostasis - LMW Heparin

281

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: LMW Heparin			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22

Haemostasis - Organan

282

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2				EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Organan		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22



Haemostasis - POCT

286

EQAS/PT Properties**Samples:** 2 samples of 1 ml; Starting reagent of 1 ml**Sample Properties:** Whole blood (Citrat), not stabilized**Max. number of sample sets:** 2**Additional Information:**

- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
- Please note the short completion time!
- Due to different detection techniques that are applied, not every sample material can be guaranteed to be suitable for every POCT machine. The machines microINR by Axon Lab as well as Xprecia Stride by Siemens are not suitable for this EQAS!

**EQAS/PT Experts:**

Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:

Dr. med. Georg Wittmann

Requirement for EQAS/PT according to Rili-BÄK: quarterly**Validity Certificate:** 6 months**Parameter / Analytes:**Prothrombintime (PT, INR) Prothrombintime (PT, Quick)
aPTT**Not subject to Rili-BÄK****Validity Certificate:** 12 months**Parameter / Analytes:**

ACT

Shipping Information:

- Shipping not cooled
- Before registering for this EQAS/PT, please note that the samples have a limited stability of 48 hours!

Safety Information:

Process as patient sample material

Dates**Q1****Q2****Q3****Q4**

Jan.

June

Sep.

Nov.

Registration Deadline:**Sample Shipment:****Closing Date:**26-11-13
27-01-12
27-01-1427-04-16
27-06-15
27-06-1727-07-30
27-09-28
27-09-3027-09-10
27-11-09
27-11-11

Haemostasis - PT, INR, aPTT

221

EQAS/PT Properties**Samples:** 2 samples of 1 ml**Sample Properties:** Lyophilised plasma**Max. number of sample sets:** 2**Additional Information:**

No. 221 is only for measuring in plasma samples. For measurements of whole blood in POCT systems, please register for No. 286!

EQAS/PT Experts:

Prof. Dr. med. Michael Spannagl

Deputy EQAS/PT Experts:

Dr. rer. biol. hum. Andrea Dick

Requirement for EQAS/PT according to Rili-BÄK: quarterly**Validity Certificate:** 6 months**Parameter / Analytes:**Prothrombintime (PT, INR) Prothrombintime (PT, Quick)
aPTT**Not subject to Rili-BÄK:** not applicable**Shipping Information:**

Shipping not cooled

Safety Information:

Process as patient sample material

Dates**Q1****Q2****Q3****Q4**

Jan.

Mar.

May

July

Aug.

Oct.

Registration Deadline:**Sample Shipment:****Closing Date:**26-11-13
27-01-12
27-01-2926-12-18
27-02-23
27-03-1227-02-26
27-04-27
27-05-1427-04-23
27-06-22
27-07-0927-06-11
27-08-10
27-08-2727-08-06
27-10-05
27-10-22



Haemostasis - Rivaroxaban

503

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Rivaroxaban		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Haemostasis - ROTEM Sigma

509

EQAS/PT Properties Samples: 2 x 3 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Extrinsic: A20 [mm] Intrinsic: A20 [mm] Extrinsic: CT[s] r[min] Intrinsic: CT[s] r[min] Extrinsic: MCF [mm] Intrinsic: MCF [mm]		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22



Haemostasis - TEG/ROTEM

283

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Extrinsic: A20 [mm] Intrinsic: A20 [mm] Extrinsic: CT[s] r[min] Intrinsic: CT[s] r[min] Extrinsic: MCF [mm] Intrinsic: MCF [mm]		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22

Haemostasis - UF Heparin

280

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma Max. number of sample sets: 2			EQAS/PT Experts: Prof. Dr. med. Michael Spannagl Deputy EQAS/PT Experts: Dr. rer. biol. hum. Andrea Dick		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Thrombin Time UF Heparin aPTT		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22





Hormones

Adrenal Gland / Pituitary

298

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Peter B. Lippa Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 1-39 ACTH DHEA-S Prolactin DHEA HGH		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline:		26-12-18	27-02-26		27-06-11
Sample Shipment:		27-02-23	27-04-27		27-08-10
Closing Date:		27-03-12	27-05-14		27-08-27
					27-10-22

Aldosterone

304

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Peter B. Lippa Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aldosterone		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-22



Calcium Metabolism / Special Thyroid

301

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Prof. Dr. med. Peter B. Lippa		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 1-84 PTH Calcitonin Thyreoglobulin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22

Fertility

297

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Dr. med. Thomas Lutz		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: FSH			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: LH anti-Mullerian hormone		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline:		26-12-18	27-02-26		27-06-11
Sample Shipment:		27-02-23	27-04-27		27-08-10
Closing Date:		27-03-12	27-05-14		27-08-27
					27-10-22





Gravidity - 1st Trimester Screening

305

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Dr. med. Thomas Lutz		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Free beta-chain hCG			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PAPP-A		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline:		26-12-18	27-02-26		27-06-11
Sample Shipment:		27-02-23	27-04-27		27-08-10
Closing Date:		27-03-12	27-05-14		27-08-27
					27-10-22

Gravidity - 2nd Trimester Screening

306

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Dr. med. Thomas Lutz		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: AFP hCG intact hCG intact +beta-hCG free			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline:		26-12-18	27-02-26		27-06-11
Sample Shipment:		27-02-23	27-04-27		27-08-10
Closing Date:		27-03-12	27-05-14		27-08-27
					27-10-22



Hematopoietic Growth Factors

626

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: M.Sc. Luisa Toll		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Erythropoietin Thrombopoietin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-14		27-10-22

Pancreas/Gastrointestinal Tract

300

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Prof. Dr. med. Peter B. Luppä		
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: not applicable Parameter / Analytes:			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: C-Peptide Glucagon Pro-insuline Gastrin Insulin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22





Preeclampsia Marker

625

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Peter B. Luppá Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PIGF (placental growth factor) sFLT-1 (soluble fms-like tyrosine kinase-1)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Steroid Hormones, Thyroid Gland

302

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Liquid serum			EQAS/PT Experts: Prof. Dr. med. Peter B. Luppá Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: 17-beta-Estradiol Cortisol Progesterone TSH Testosterone free T3 (f-triiodothyronine) free T4 (f-thyroxine)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: T3 total (triiodothyronine) T4 total (thyroxine)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29	26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-06-11 27-08-10 27-08-27



Thyroid Gland Antibodies

295

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Prof. Dr. med. Peter B. Luppä		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: TRAK/THYBIA anti-TPO anti-Microsome anti-Thyroglobuline		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22

Thyroid Hormones

294

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Prof. Dr. med. Peter B. Luppä		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: TSH free T3 (f-triiodothyronine) free T4 (f-thyroxine)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: T3 total (triiodothyronine) T4 total (thyroxine)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27





Virilization

309

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Folker Wenzel Deputy EQAS/PT Experts: Dr. med. Thomas Lutz		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 17-Hydroxyprogesterone Androstendion		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline:		26-12-18	27-02-26		27-06-11
Sample Shipment:		27-02-23	27-04-27		27-08-10
Closing Date:		27-03-12	27-05-14		27-08-27
					27-10-05
					27-10-22

IgG Subclasses

IgG Subclasses

244

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: IgG1 IgG2 IgG3 IgG4		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-14		27-10-22



Cardiac Marker

Myocardial Markers

760

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Lyophilised serum Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Please note that this EQA scheme is not suitable for methods that require whole blood.			 EQAS/PT Experts: Prof. Dr. med. Hannsjörg Baum Deputy EQAS/PT Experts: N.N			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Troponin I Troponin T			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: CK-MB (activity) Myoglobin (qualitative) CK-MB (mass) NT-pro BNP CK-MB (qualitative) Troponin I (qualitative) Myoglobin Troponin T (qualitative)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Myocardial Markers BNP

761

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Serum / Plasma Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Before registering for this EQAS/PT, please note that the samples have a limited stability of 5 Days!		 EQAS/PT Experts: Prof. Dr. med. Hannsjörg Baum Deputy EQAS/PT Experts: N.N.				
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: BNP				
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material				
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22





Conventional Clinical Chemistry

ACE (Angiotensin-Converting-Enzyme)

630

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Dr. Patricia Kaiser (PhD)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: ACE		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May	July	Oct.
Registration Deadline:		26-12-18	27-02-26	27-04-23	27-08-06
Sample Shipment:		27-02-23	27-04-27	27-06-22	27-10-05
Closing Date:		27-03-12	27-05-14	27-07-09	27-10-22

Amino Acid Analysis

710

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: M. Sc. Irina Keßel Deputy EQAS/PT Experts: Dr. Gernot Brauers		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 4-Hydroxyproline (free) Alanine Arginine Argininosuccinic acid Asparagine Aspartic acid Citrulline Cystathionine Cysteine-Homocysteine-disulfide Cystine Glutamic acid Glutamine Glycine Histidine Isoleucine Leucine		
			Lysine Methionine Ornithine Phenylalanine Phosphoethanolamine Proline Sarcosine Serine Taurine Threonine Tryptophan Tyrosine Valine allo-Isoleucine alpha-Aminoadipic acid b-Alanine proposed diagnosis		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-14		27-10-22



Ammonia

118

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Liquid controls			EQAS/PT Experts: Dr. rer. nat. Manfred Falck Deputy EQAS/PT Experts: Prof. Dr. med. Matthias Nauck		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Ammonia		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-05
					27-10-22

Biogenic Amines in Plasma

185

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised Plasma			EQAS/PT Experts: Dr. rer. nat Heike Schneider Deputy EQAS/PT Experts: Prof. Dr. med. Peter B. Lippa		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 3-Methoxytyramine Norepinephrine Dopamine Normetanephrine Epinephrine Serotonin Metanephrine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Aug.
Registration Deadline:		26-12-18			27-06-11
Sample Shipment:		27-02-23			27-08-10
Closing Date:		27-03-12			27-08-27





Capillary Zone Electrophoresis

102

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised serum			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Albumin (electrophoresis) beta-Globulins a1-Globulins gamma-Globulins a2-Globulins		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-22

Clinical Chemistry - Conventional Analysis

100

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. rer. nat. Manfred Falck Deputy EQAS/PT Experts: Dr. med. Christoph Niederau		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: AP GOT (ASAT) Magnesium Albumin GPT (ALAT) Phosphate Bilirubin Glucose Potassium CK IgA Protein Calcium IgG Sodium Chloride IgM Transferrine Cholesterol LDH Triglycerides Creatinine Lactate Urea GGT Lithium Uric Acid			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Acid phosphatase Iron binding capacity Albumin (electrophoresis) Lipase Aldolase Osmolality Bilirubin conj. Pancreas amylase CHE Prostatic acid Copper Posphatase GLDH alpha-Amylase HBDH gamma-Globulins Iron		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-22



Ethanol

700

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Liquid serum				EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Ethanol				Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Fructosamine

146

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised serum			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Dr. Patricia Kaiser (PhD)			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Fructosamine			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22





G6PDH (Glucose-6 Phosphate Dehydrogenase)

279

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Lyophilised whole blood			EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: G6PDH		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.		Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12		27-06-11 27-08-10 27-08-27	

Gammopathies

243

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: 6 months Parameter / Analytes: IgA IgG IgM			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Free light chains type kappa (quantitative) Free light chains type lambda (quantitative) Gammopathies kappa/lambda (ratio)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-08-06 27-10-05 27-10-22



Glucose - Conventional Analysis

111

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Glucose			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

HbA1c

145

EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Whole blood (EDTA), not stabilized Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - The samples must be measured within 2 days of receipt!			 EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: HbA1c			Not subject to Rili-BÄK: not applicable			
Shipping Information: - Cooled shipping - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Sep.	Oct.
Registration Deadline:	26-11-20	27-01-15	27-03-12	27-05-07	27-07-09	27-08-20
Sample Shipment:	27-01-19	27-03-16	27-05-11	27-07-06	27-09-07	27-10-19
Closing Date:	27-01-22	27-03-19	27-05-14	27-07-09	27-09-10	27-10-22





Lipids/Lipoproteins

151

EQAS/PT Properties Samples: 2 samples of 3 mL Sample Properties: Lyophilised serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. med. Michael Spannagl		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Apolipoprotein A1 Cholesterol Apolipoprotein B Triglycerides			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Apolipoprotein E Homocystein Lp (a) HDL-cholesterol LDL-cholesterol Phospholipids		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-05
					27-10-22

Markers of Ethanol Abuse - Carbohydrate-Deficient Transferrin (CDT)

750

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Peter B. Lippa Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Asialotransferrin Asialotransferrin+Disialotransferrin Disialotransferrin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline:		26-12-18	27-02-26		27-06-11
Sample Shipment:		27-02-23	27-04-27		27-08-10
Closing Date:		27-03-12	27-05-14		27-08-27
					27-10-05
					27-10-22



Plasma Cell Neoplasia-MRD Immunophenotyping

821

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Whole blood (EDTA), not stabilized Additional Information: - To successfully participate in the interlaboratory test, your method must have a minimum limit of detection (LoD) of 0.01%. - Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.			EQAS/PT Experts: Prof. Dr. Karl-Anton Kreuzer Deputy EQAS/PT Experts: Dr. Michaela Patz			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: % Plasma cell neoplasia-cells Rating of MRD			
Shipping Information: - Cooled shipping - Cooled shipping to Germany and Austria only. - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			Apr.			Nov.
Registration Deadline:			27-02-19			27-09-17
Sample Shipment:			27-04-20			27-11-16
Closing Date:			27-04-23			27-11-19

Serum Proteins/Electrophoresis

141

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum Additional Information: Participants using the method capillary zone electrophoresis please order EQA scheme 102 - Capillary Zone Electrophoresis			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Albumin Protein		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Albumin (electrophoresis) beta-Globulins a1-Globulins gamma-Globulins a2-Globulins				
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material				
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22





Cerebrospinal Fluid

Cerebrospinal Fluid Analysis - CSF Ferritin

467

EQAS/PT Properties Samples: 1 CSF sample of 1 ml Sample Properties: CSF Max. number of sample sets: 1 Additional Information: Neurochemical diagnostics of hemorrhages			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Prof. Dr. med. Inga Zerr		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Ferritin - CSF		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		

Cerebrospinal Fluid Analysis - Dementia Markers

466

EQAS/PT Properties Samples: 1 sample of 1 ml Sample Properties: CSF Max. number of sample sets: 1 Additional Information: Neurochemical dementia diagnostics: Support for differential diagnosis of dementia by interpretation of the combined analysis of different marker proteins in CSF.			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Prof. Dr. med. Inga Zerr		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amyloid β Peptid 40 (A β 40) PhosphoTau Protein (pTau) Amyloid β Peptid 42 (A β 42) Total Tau Protein (Tau) Amyloid β Peptid Ratio (A β 42/40) p-Tau/ β -Amyloid (1-42) Ratio		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22



Cerebrospinal Fluid Analysis - Free light chains Kappa

468

EQAS/PT Properties Samples: 2 sets = CSF + serum of 1 ml Sample Properties: CSF + serum Max. number of sample sets: 1 Additional Information: Neurochemical diagnostics of inflammatory CNS processes			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Prof. Dr. med. Inga Zerr		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: kappa-free light chains - CSF kappa-free light chains - serum		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		

Cerebrospinal Fluid Analysis - Lactate/ Glucose

464

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: CSF + Serum (Lyophilised) Max. number of sample sets: 1 Additional Information: Calculation of the CSF/serum ratio of glucose. Interpretation with respect to the reference range.			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Dr. rer. nat. Thomas Zimmermann		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Glucose - CSF Lactate			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Glucose quotient (CSF/Serum) Glucose quotient - diagnostic comment Interpretation of the report Lactate - diagnostic comment		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22





Cerebrospinal Fluid Analysis - MRZ Reaction

463

EQAS/PT Properties Samples: 4 samples of 1ml Sample Properties: Serum / Plasma Max. number of sample sets: 1 Additional Information: Detection of titers is not suitable. Evaluation as antibody index and interpretation of combined data.			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Dr. rer. nat. Thomas Zimmermann		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Antibodies against Measles viruses, Rubella viruses, Varicella zoster viruses, Herpes simplex viruses (1+2). Analysis of virus-specific antibodies in CSF and serum for detection of specific antibody response in central nervous system (MRZ reaction).		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Cerebrospinal Fluid Analysis - Neuroborreliosis

465

EQAS/PT Properties Samples: 2 samples of 0.5ml Sample Properties: CSF + Serum Max. number of sample sets: 1 Additional Information: Detection of titers is not suitable. Calculation of antibody index (Certificate) and interpretation (Certificate of Participation).			EQAS/PT Experts: Dr. rer. nat. Thomas Zimmermann Deputy EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Borrelia IgG Antibody Index (AI) calculation Interpretation of the report		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22



Cerebrospinal Fluid Analysis - Oligoclonal IgG

462

EQAS/PT Properties Samples: 2 samples of 100 µl Sample Properties: CSF + Serum Max. number of sample sets: 1 Additional Information: The acquisition of samples is demanding, as it is not possible to use pooled CSF, i.e. the samples are from individual patients (catheter, drainage, etc.).			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Dr. rer. nat. Thomas Zimmermann		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Oligoclonal IgG			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Interpretation of the report		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline:			27-02-26		27-08-06
Sample Shipment:			27-04-27		27-10-05
Closing Date:			27-05-14		27-10-22

Cerebrospinal Fluid Analysis - Protein Analysis

460

EQAS/PT Properties Samples: 4 samples of 1ml Sample Properties: Serum / Plasma Max. number of sample sets: 1 Additional Information: Sample volumes in the CSF EQAS/PTs are limited as it is difficult to acquire large volumes of CSF.			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Manfred Uhr Deputy EQAS/PT Experts: Dr. rer. nat. Thomas Zimmermann		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Albumin IgA - CSF IgM Albumin - CSF IgG IgM - CSF IgA IgG - CSF Protein - CSF			Not subject to Rili-BÄK Validity Certificate: 6 months Parameter / Analytes: Evaluation of CSF/serum quotients in diagrams and age-related interpretation		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22





Newborn Analytic

Neonatal Bilirubin

110

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Neonatal Bilirubin				Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Newborn screening

785

EQAS/PT Properties Samples: 2 samples Sample Properties: Filter papers, each with 2 dried blood spots Max. number of sample sets: 1 Additional Information: This EQAS/PT scheme is currently in the planning stages, and we will share details on the website and in the INSTAND e.V. newsletter.			EQAS/PT Experts: N.N. Deputy EQAS/PT Experts: N.N			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: TSH 17-hydroxy Progesteron IRT PAP			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
Registration Deadline: Sample Shipment: Closing Date:						



Pharmaceuticals

Antiarrhythmics - Amiodaron

190

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amiodarone Desethylamiodarone		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22

Antibacterials 01 - Teicoplanin

193

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Teicoplanin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample materia		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22





Antibacterials 02

890

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Dr. rer. nat. Heike Schneider Deputy EQAS/PT Experts: Prof. Dr. med. Werner Steimer		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Ampicillin		

Anticonvulsants 01

191

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Lamotrigine Levetiracetam Sulthiame		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22



Anticonvulsants 02

192

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 10-OH-Carbamazepine Carbamazepine-epoxide N-DesmethyImethsuximide		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May		Aug.
Registration Deadline:	26-11-13		27-02-26		27-06-11
Sample Shipment:	27-01-12		27-04-27		27-08-10
Closing Date:	27-01-29		27-05-14		27-08-27
					27-10-05
					27-10-22

Anticonvulsants 03

871

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat. Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Brivaracetam Eslicarbazepine Felbamate Lacosamide Perampanel Rufinamide		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May		Aug.
Registration Deadline:	26-11-13		27-02-26		27-06-11
Sample Shipment:	27-01-12		27-04-27		27-08-10
Closing Date:	27-01-29		27-05-14		27-08-27
					27-10-05
					27-10-22





Anticonvulsants 04

872

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Gabapentin Pregabalin Tiagabine Topiramate Vigabatrin Zonisamide		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26	27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14	27-08-27	27-10-22

Antifungals / Immunosuppressants

602

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Lyophilised plasma			EQAS/PT Experts: Prof. Dr. med. Nicolas von Ahsen Deputy EQAS/PT Experts: Dr. Patricia Kaiser (PhD)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Hydroxy-Itraconazole Itraconazole Mycophenolic acid		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Oct.
Registration Deadline:		26-12-18			27-08-06
Sample Shipment:		27-02-23			27-10-05
Closing Date:		27-03-12			27-10-22



Antifungals and Chloramphenicol

198

EQAS/PT Properties Samples: 2 samples of 5 ml (+ 2 samples of 3 ml antibiotics) Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Chloramphenicol Posaconazole Fluconazole Voriconazole Flucytosine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Antipsychotics/Antidepressives 01

200

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Clozapine N-Desmethylozapine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29	26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-06-11 27-08-10 27-08-27





Antipsychotics/Antidepressives 02

873

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amisulpride			

Antipsychotics/Antidepressives 03

874

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Desmethylfluoxetine Mianserine Fluoxetine Perazine		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22



Antipsychotics/Antidepressives 04

875

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Cariprazine		

Antivirals

850

EQAS/PT Properties Samples: 2 samples of 1 - 3 ml Sample Properties: Lyophilised serum Additional Information: Please note that some analytes may interfere with the HPLC methods with UV detection. For this reason, the schedule-based composition will be adjusted as shown in the following pdf-download-link: https://www.instand-ev.de/EQA850-Analytes				EQAS/PT Experts: Dr. rer. nat Heike Schneider Deputy EQAS/PT Experts: Prof. Dr. med. Werner Steimer																							
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: <table><tr><td>Aciclovir</td><td>Efavirenz</td><td>Raltegravir</td></tr><tr><td>Atazanavir</td><td>Elvitegravir</td><td>Ribavirin</td></tr><tr><td>Bictegravir</td><td>Etravirine</td><td>Rilpivirin</td></tr><tr><td>Cabotegravir</td><td>Ganciclovir</td><td>Ritonavir T</td></tr><tr><td>Darunavir</td><td>Lopinavir</td><td>enofovir</td></tr><tr><td>Dolutegravir</td><td>Maraviroc</td><td></td></tr><tr><td>Doravirine</td><td>Nevirapine</td><td></td></tr></table>			Aciclovir	Efavirenz	Raltegravir	Atazanavir	Elvitegravir	Ribavirin	Bictegravir	Etravirine	Rilpivirin	Cabotegravir	Ganciclovir	Ritonavir T	Darunavir	Lopinavir	enofovir	Dolutegravir	Maraviroc		Doravirine	Nevirapine	
Aciclovir	Efavirenz	Raltegravir																									
Atazanavir	Elvitegravir	Ribavirin																									
Bictegravir	Etravirine	Rilpivirin																									
Cabotegravir	Ganciclovir	Ritonavir T																									
Darunavir	Lopinavir	enofovir																									
Dolutegravir	Maraviroc																										
Doravirine	Nevirapine																										
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material																							
Dates	Q1		Q2	Q3		Q4																					
		Mar.	May		Aug.	Oct.																					
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06																					
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05																					
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22																					



Benzodiazepines 01

876

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Alprazolam			

Benzodiazepines 02

877

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Clonazepam Nitrazepam Flunitrazepam Temazepam Flurazepam 			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27	27-08-06 27-10-05 27-10-22



Benzodiazepines 03

878

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Bromazepam Clobazam (Clobazepam) Lorazepam			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Immunosuppressants

601

EQAS/PT Properties Samples: 4 samples of 1 ml Sample Properties: Lyophilised whole blood			EQAS/PT Experts: Prof. Dr. med. Nicolas von Ahsen Deputy EQAS/PT Experts: Dr. Patricia Kaiser (PhD)			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Cyclosporine A Sirolimus Everolimus Tacrolimus			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-12				27-10-22





Paracetamol and NSAIDs

194

EQAS/PT Properties Samples: 4 samples of 1 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Paracetamol Salicylic acid			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Psychostimulants - ADHS-Treatment

879

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Atomoxetine Methylphenidate Ritalinic acid			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22



Psychotherapeutic Drugs 01

860

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen Deputy EQAS/PT Experts: Florian Ridders			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 10-OH-Carbamazepine O-Desmethylvenlafaxine Aripiprazole Perazine Citalopram Quetiapine Lamotrigine Venlafaxine			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Psychotherapeutic Drugs 02

861

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen Deputy EQAS/PT Experts: Florian Ridders			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amisulpride Escitalopram Mirtazapine O-Desmethylvenlafaxine Quetiapine Venlafaxine			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22





Psychotherapeutic Drugs 03

862

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen Deputy EQAS/PT Experts: Florian Ridders		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 9-OH-Risperidone / Paliperidone Olanzapine Clozapine Quetiapine Duloxetine Risperidone Haloperidol Ziprasidone N-Desmethylozapine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22

Psychotherapeutic Drugs 04

863

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Dr. rer. nat. Dipl. Biochem. Ekkehard Haen Deputy EQAS/PT Experts: Florian Ridders		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amitriptyline Imipramine Clomipramine Maprotiline Clozapine N-Desmethylozapine Desipramine Norclomipramine Doxepin Nordoxepin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22



Respiratory Stimulants - Caffeine

870

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Caffeine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Therapeutic drugs - Antibiotics, Digitoxin, MTX

197

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider Dr. Patricia Kaiser (PhD)		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Digitoxin Vancomycin			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amicacin Methotrexate Gentamicin Tobramycin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29	26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-06-11 27-08-10 27-08-27





Therapeutic drugs - Antiepileptics, Digoxin, Lithium and others

195

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum				EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider Dr. Patricia Kaiser (PhD)		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Carbamacepine Phenytoin Lithium Theophylline Phenobarbital Valproic Acid				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Digoxin Ethosuximid Primidon		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Tri-/Tetracyclic Antidepressants 03 - Quantitative in Serum

202

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Desipramine		



Tricyclic Antidepressants 01 - Quantitative in Serum

199

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amitriptyline Norclomipramine Clomipramine Nortriptyline Tricyclic Antidepressants - Screen		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22

Tricyclic Antidepressants 02 - Quantitative in Serum

201

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Doxepin Nordoxepin Nortrimipramine Tricyclic Antidepressants - Screen Trimipramine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23	27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22	27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09	27-10-22





Tricyclic Antidepressants 04 - Qualitative in Serum

203

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Lyophilised serum Additional Information: - May contain the following substances: Amitriptyline, Clomipramine, Desipramine, Doxepin, Imipramine, Norclomipramine, Nordoxepin, Nortrimipramine, Nortriptyline, Trimipramine - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Tricyclic Antidepressants (qualitative)- Screening			Not subject to Rili-BÄK: Validity Certificate: 12 months Parameter / Analytes: Amitriptyline Clomipramine Desipramine Doxepin Imipramine Norclomipramine Nordoxepin Nortrimipramine Nortriptyline Trimipramine			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Photometry

Photometer Controls

181

EQAS/PT Properties Samples: 2 samples of 6 mL Sample Properties: Potassium picrate solution				EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Wavelengths 334, 340, 365, 405 and 436 nm		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22



Plasma Proteins

Cystatin C

242

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Liquid serum Max. number of sample sets: 1				EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Cystatin C		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

hsCRP

240

EQAS/PT Properties Samples: 2 samples of 0.4 mL Sample Properties: Liquid serum Max. number of sample sets: 1 Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: hsCRP			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22





Infection Serology - C-Reactive Protein

322

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: C-Reactive Protein (quantitative)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: C-Reactive Protein (qualitative)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May		Aug.	Oct.
Registration Deadline:	26-11-13		27-02-26		27-06-11	27-08-06
Sample Shipment:	27-01-12		27-04-27		27-08-10	27-10-05
Closing Date:	27-01-29		27-05-14		27-08-27	27-10-22

Plasmaproteins

241

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Liquid plasma			EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: C-Reactive Protein (quantitative) Ferritin IgA IgG IgM Transferrine			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: C3sTfR C4a1-Antitrypsine Coeruloplasmina1-Glycoprotein Haptoglobina2-Makroglobulin Hemopexin Quantitative determination of specific IgE against inhalant, food and insect venom allergens (4 samples) determination of total IgE (5 samples)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22



POCT

Blood Gas Analysis

161

EQAS/PT Properties Samples: 2 samples of 2.5 ml Sample Properties: Control solution Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. Peter B. Lupp Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Chloride Potassium pH Creatinine Sodium pO2 Glucose Urea Lactate ionized Calcium Magnesium pCO2			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Blood Gas Analysis - Haemoglobin

162

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Control solution Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. med. Benedikt Lohr Deputy EQAS/PT Experts: Dr. med. Thomas Nebe			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Haemoglobin			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Fraction CO-Hb Fraction Met-Hb Fraction O2-Hb			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22





Blood Gas Analysis OPTI Systems

163

EQAS/PT Properties Samples: 2 samples of 1.7 ml Sample Properties: Control solution Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. Peter B. Luppä Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Chloride Sodium pH Haemoglobin Urea pO2 Lactate ionized Calcium Potassium pCO2			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: sO2			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Dry Chemistry - POCT: Abaxis Piccolo System

810

EQAS/PT Properties Samples: 2 samples of 5 mL Sample Properties: Lyophilised serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. POCT EQAS/PT Experts: Dr. rer. nat. Manfred Falck Deputy EQAS/PT Experts: Prof. Dr. med. Matthias Nauck						
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: AP Albumin Bilirubin CK Calcium Chloride Cholesterol Creatinine GGT GOT (ASAT) GPT (ALAT) Glucose LDH Lactate Magnesium Phosphate Potassium Protein Sodium Triglycerides Urea Uric Acid			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Bilirubin conj. HDL-cholesterol LDL-cholesterol VLDL-cholesterol alpha-Amylase tCO2			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Kammel	Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22



Dry Chemistry - POCT: Glucose

800

EQAS/PT Properties Samples: 2 samples of 0.5 mL Sample Properties: Whole blood Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - For point-of-care testing (POCT) devices which work with unit-use reagents and preferably use whole blood as patient sample material.			 EQAS/PT Experts: Prof. Dr. med. Dipl.-Biol. Astrid Petersmann Deputy EQAS/PT Experts: Prof. Dr. med. Matthias Nauck			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Glucose			Not subject to Rili-BÄK: not applicable			
Shipping Information: - Shipping not cooled - Before registering for this EQAS/PT, please note that the samples have a limited stability of 72 hours!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Sep.	Oct.
Registration Deadline:	26-11-27	27-01-08	27-03-12	27-05-14	27-07-16	27-08-27
Sample Shipment:	27-01-26	27-03-02	27-05-11	27-07-13	27-09-14	27-10-26
Closing Date:	27-01-29	27-03-05	27-05-14	27-07-16	27-09-17	27-10-29

Trace Elements

Trace Elements - whole blood

208

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised whole blood				EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: 6 months Parameter / Analytes: Magnesium				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Antimony Arsenic Cadmium Chromium Cobalt Lead Manganese Mercury Nickel Selenium Zinc		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline:		26-12-18				27-08-06
Sample Shipment:		27-02-23				27-10-05
Closing Date:		27-03-19				27-10-29





Trace Elements Plasma

206

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aluminium Iodine Arsenic Iron Cadmium Manganese Chromium Nickel Cobalt Platinum Copper Selenium Fluoride Zinc Gold		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Oct.
Registration Deadline:		26-12-18			27-08-06
Sample Shipment:		27-02-23			27-10-05
Closing Date:		27-03-19			27-10-29

Trace Elements Serum

207

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Antimony Molybdenum Beryllium Tin Bismuth Vanadium		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.			Oct.
Registration Deadline:		26-12-18			27-08-06
Sample Shipment:		27-02-23			27-10-05
Closing Date:		27-03-19			27-10-29



Stool Diagnostics

Fecal Diagnostics - Calprotectin / Fecal Elastase

130

EQAS/PT Properties Samples: 2 samples of 0.75 ml Sample Properties: Lyophilised stool Max. number of sample sets: 1		EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Prof. Dr. med. Michael Spannagl			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Calprotectin Fecal elastase Calprotectin (qualitative) Fecal elastase (qualitative)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
		Mar.		July	Oct.
Registration Deadline:		26-12-18		27-04-23	27-08-06
Sample Shipment:		27-02-23		27-06-22	27-10-05
Closing Date:		27-03-12		27-07-09	27-10-22

Fecal Diagnostics - Hb, Hb-Hapto-complex

131

EQAS/PT Properties Samples: 2 samples of 0.75 ml Sample Properties: Lyophilised stool Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.		 EQAS/PT Experts: Prof. Dr. rer. nat. Dr. med. Jürgen Durner Deputy EQAS/PT Experts: Prof. Dr. med. Michael Spannagl			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Haemoglobin Haemoglobin (qualitative) Hemoglobin-Haptoglobin-complex Hemoglobin-Haptoglobin-complex (qualitative)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
		Mar.			Oct.
Registration Deadline:		26-12-18			27-08-06
Sample Shipment:		27-02-23			27-10-05
Closing Date:		27-03-12			27-10-22





Tumor Marker

Tumor Markers

292

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Liquid Serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. Stefan Holdenrieder Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: AFP CA 15-3 CEA			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: CA 125 CA 19-9 CA 72-4 CYFRA 21-1 HE4 HER2/new NSE PSA, free ROMA-Score S100 SCC TPA TPS Thyreoglobulin beta-2-Microglobulin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-06 27-10-05 27-10-22

Tumor Markers - Calcitonin, Pro-GRP, PIVKAI, AFP, AFP-L3

299

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Liquid Serum			EQAS/PT Experts: Prof. Dr. med. Stefan Holdenrieder Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: AFP AFP-L3 Calcitonin GAAD-Score GALAD-Score PIVKAI Progastrin-releasing Peptide		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.	Mar.	May	July	Aug.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27
					27-10-06 27-10-05 27-10-22



Tumor Markers - PSA and Testosterone

293

EQAS/PT Properties Samples: 2 samples of 2 mL Sample Properties: Liquid Serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.				 EQAS/PT Experts: Prof. Dr. med. Stefan Holdenrieder Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: PSA, total Testosterone				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PSA, free		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Urine Analysis

Drugs of Abuse in Human Urine 01 (Qualitative + Quantitative)

174

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.				 EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. med. Christoph Niederau		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Benzoyllecgonine (qualitative) Opiate / Morphin (qualitative)				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Amphetamine (qualitative) Amphetamine (quantitative) Barbiturate-Phenobarbital (qualitative) Barbiturate-Phenobarbital (quantitative) Benzoyllecgonine (quantitative) Opiate / Morphin (quantitative)		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22





Drugs of Abuse in Human Urine 02 (Qualitative + Quantitative)

176

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.					EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. med. Christoph Niederau	
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Methadone (qualitative)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: (d-)Methamphetamine (quantitative) (d-)Methamphetamine (qualitative) Buprenorphine (qualitative) Buprenorphine (quantitative) LSD (qualitative) LSD (quantitative) Methadone (quantitative)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Drugs of Abuse in Human Urine 03 (Qualitative + Quantitative)

177

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. med. Christoph Niederau			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: EDDP (qualitative) delta-9-THC-COOH (qualitative)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Benzodiazepine Lorazepam (qualitative) Benzodiazepine Lorazepam (quantitative) EDDP (quantitative) MDMA (qualitative) MDMA (quantitative) delta-9-THC-COOH (quantitative)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22



Markers of Ethanol Abuse - Ethylglucuronide

751

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised urine			EQAS/PT Experts: Prof. Dr. med. Peter B. Luppä Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Ethylglucuronide		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
					Oct.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27
					27-08-06 27-10-05 27-10-22

Systematic Toxicological Analysis (STA)

188

EQAS/PT Properties Samples: 2 samples of 10 ml Sample Properties: Lyophilised urine Max. number of sample sets: 1 Additional Information: - This EQAS/PT scheme is still in the planning stages, and we will announce details on the website and in the INSTAND e.V. newsletter. - From a list of 30 substances, the proof of 6 - 8 substances with chromatographic methods is required in both samples.			EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Chromatographic analysis with identification of the active substance (STA)			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
Registration Deadline: Sample Shipment: Closing Date:					





Trace Elements Urine

205

EQAS/PT Properties Samples: 2 samples of 10 ml Sample Properties: Lyophilised urine			EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aluminium Copper Manganese Arsenic Fluoride Mercury Cadmium Iodine Nickel Chromium Iron Selenium Cobalt Lead Zinc			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-19				27-08-06 27-10-05 27-10-29

Tricyclic Antidepressants 05 - Qualitative in Urine

204

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.				 EQAS/PT Experts: Prof. Dr. med. Werner Steimer Deputy EQAS/PT Experts: Dr. rer. nat Heike Schneider		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Tricyclic Antidepressants (qualitative)- Screening				Not subject to Rili-BÄK: Validity Certificate: 12 months Parameter / Analytes: Amitriptylin Imipramin Nortriptylin Clomipramin Norclomipramin Trimipramin Desipramin Nordoxepin Doxepin Nortrimipramin		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22



Urinary Stone Analyses

500

EQAS/PT Properties Samples: 2 samples Sample Properties: Urinary stone (powdered)			EQAS/PT Experts: Dr. rer. nat. Stefan Neubeck Deputy EQAS/PT Experts: Prof. Dr. med. Karl H. Reuner		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: urinary stone analysis (chemical) urinary stone analysis (physical)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Urine Chemistry Aminolaevulinic Acid / Porphobilinogen

180

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised urine			EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aminolaevulinic acid Porphobilinogen		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22





Urine Chemistry Biogene Amines

175

EQAS/PT Properties Samples: 2 samples of 8 ml Sample Properties: Lyophilised urine				EQAS/PT Experts: Dr. rer. nat Heike Schneider Deputy EQAS/PT Experts: Dr. med. Thomas Lutz		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 3-MethoxytyramineMetanephrine 5-Hydroxyindolea acidNorepinephrine DopamineNormetanephrine EpinephrineSerotonin Homovanillic acidVanillylmandelic acid		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
		Mar.	May		Aug.	Oct.
Registration Deadline:		26-12-18	27-02-26		27-06-11	27-08-06
Sample Shipment:		27-02-23	27-04-27		27-08-10	27-10-05
Closing Date:		27-03-12	27-05-14		27-08-27	27-10-22

Urine Chemistry Hormones

179

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aldosterone Cortisol free hCG intact			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			May			Oct.
Registration Deadline:			27-02-26			27-08-06
Sample Shipment:			27-04-27			27-10-05
Closing Date:			27-05-14			27-10-22



Urine Chemistry Porphyrins

178

EQAS/PT Properties Samples: 2 samples of 3 ml Sample Properties: Lyophilised urine			EQAS/PT Experts: Dr. Patricia Kaiser (PhD) Deputy EQAS/PT Experts: Udo Kramer, Dipl.-Ing. (FH)		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Coproporphyrin 1 Hexaporphyrin Coproporphyrin 3 Pentaporphyrin Coproporphyrin total Porphyrins total Heptaporphyrin Uroporphorin		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Urine Chemistry Qualitative

171

EQAS/PT Properties Samples: 2 samples of 10 ml Sample Properties: Liquid urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. Roman Fried Deputy EQAS/PT Experts: Dr. med. Christoph Niederau		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Albumin - Urine Nitrite Ascorbic acid Protein Bilirubin Urobilinogen Erythrocytes hCG Glucose pH Ketone bodies specific gravity Leucocytes		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-08-06 27-10-05 27-10-22





Urine Chemistry Quantitative

173

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised urine Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. Roman Fried Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck			
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Albumin - Urine Calcium Creatinine Glucose Phosphate Potassium Sodium Urea Uric Acid total Protein - Urine			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Chloride Magnesium Osmolality alpha-Amylase			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.	Mar.	May	July	Aug.	Oct.
Registration Deadline:	26-11-13	26-12-18	27-02-26	27-04-23	27-06-11	27-08-06
Sample Shipment:	27-01-12	27-02-23	27-04-27	27-06-22	27-08-10	27-10-05
Closing Date:	27-01-29	27-03-12	27-05-14	27-07-09	27-08-27	27-10-22

Urine Chemistry Sediment Pictures

172

EQAS/PT Properties Samples: Pictures Sample Properties: Digital slides Max. number of sample sets: 1 Additional Information: Available online in the virtual microscope! - No shipment!			EQAS/PT Experts: Dr. Roman Fried Deputy EQAS/PT Experts: Dr. med. Christoph Niederau			
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Urine sediment			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	27-01-08		27-04-23	27-06-18		27-10-01
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22



Urine Protein Differentiation

182

EQAS/PT Properties Samples: 2 samples of 1 mL Sample Properties: Liquid urine			EQAS/PT Experts: Dr. Roman Fried Deputy EQAS/PT Experts: Dr. rer. nat. Manfred Falck		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Albumin - Urine			Not subject to Rili-BÄK Validity Certificate: 6 months / 12 months Parameter / Analytes: Creatinine IgG Retinol binding protein Transferrine		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.		Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12		27-06-11 27-08-10 27-08-27	

Vitamins

Vitamins - Methylmalonic Acid

187

EQAS/PT Properties Samples: 2 samples of 1 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Methylmalonic acid		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		May	July	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-02-26 27-04-27 27-05-14	27-04-23 27-06-22 27-07-09	27-08-06 27-10-05 27-10-22





Vitamins - Serum

290

EQAS/PT Properties Samples: 2 samples of 5 ml Sample Properties: Lyophilised serum			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: 1,25-OH Cholecalciferol 25-OH CCF (Vitamin D) Biotin (Vitamin H) Cobalamin (Vitamin B12) Folic acid Holotranscobalamine Pantothenic acid (Vitamin B5) Pyridoxal-5-phosphate (Vitamin B6) Retinol (Vitamin A) Riboflavin (Vitamin B2) Thiamine total (Vitamin B1) Tocopherol (Vitamin E)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22

Vitamins - Vitamin C

296

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Lyophilised plasma				EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Ascorbic acid (Vitamin C)		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22



Vitamins - whole blood

291

EQAS/PT Properties Samples: 2 samples of 2 ml Sample Properties: Lyophilised whole blood			EQAS/PT Experts: Dr. med. Christoph Niederau Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Ingo Schellenberg			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Flavine Adenine Dinucleotide (FAD) Flavine mononucleotid (FMN) Pyridoxal-5-phosphate (Vitamin B6) Riboflavin (Vitamin B2) Thiamine total (Vitamin B1) Thiaminpyrophosphat (TPP)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
	Jan.		May	July		Oct.
Registration Deadline:	26-11-13		27-02-26	27-04-23		27-08-06
Sample Shipment:	27-01-12		27-04-27	27-06-22		27-10-05
Closing Date:	27-01-29		27-05-14	27-07-09		27-10-22





MICROBIOLOGY

Bacterial Genome Detection

Bacterial Genome Detection - Bordetella pertussis

532

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: not applicable Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of <i>Bordetella pertussis</i>			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Borrelia burgdorferi

535

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: Dr. med. Volker Fingerle		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of <i>Borrelia burgdorferi</i>			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05



Bacterial Genome Detection - Carbapenemase-Genes

544

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Carbapenemases		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Chlamydia pneumoniae

540

EQAS/PT Properties Samples: 4 samples of 1 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Chlamydia pneumoniae			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05





Bacterial Genome Detection - Chlamydia trachomatis

531

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: not applicable Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Chlamydia trachomatis			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Chlamydia trachomatis & Neisseria gonorrhoeae

530

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension Additional Information: Due to the limited amount of sample material, INSTAND e.V. reserves the right to close orders early.			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Chlamydia trachomatis and Neisseria gonorrhoeae			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05



Bacterial Genome Detection - Clostridium difficile (Toxin Gene)

545

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Clostridium difficile toxin-genes			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			June			Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Coxiella burnetii & Bacillus anthracis

542

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension		EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. med. Dimitrios Frangoulidis PD Dr. rer. nat. Gregor Grass			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Coxiella burnetii		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: and Bacillus anthracis			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05





Bacterial Genome Detection - EHEC / STEC

534

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of EHEC / STEC			Not subject to Rili-BÄK not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Francisella tularensis & Brucella spp.

543

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: Dr. med. vet. Heiner von Buttler Prof. Dr. rer. nat. Holger C. Scholz		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Francisella tularensis			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: and Brucella spp.		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - *Helicobacter pylori*

533

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of <i>Helicobacter pylori</i>			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - *Legionella pneumophila*

536

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of <i>Legionella pneumophila</i>			Not subject to Rili-BÄK Validity Certificate: 12 months		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05





Bacterial Genome Detection - Listeria spp.

538

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Listeria spp.			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-11		27-11-05

Bacterial Genome Detection - MRSA or cMRSA

539

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of MRSA / cMRSA			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-11		27-11-05



Bacterial Genome Detection - Mycoplasma pneumoniae

541

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Mycoplasma pneumoniae			Not subject to Rili-BÄK not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - PCR/NAT Multiplex Detection Method for Gastrointestinal Pathogens

548

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension Max. number of sample sets: 1 Additional Information: - In order to take into account the usually very different pathogen coverage of commercially available multiplex PCR/NAT concepts, each of the parameters listed above is certified separately as part of the evaluation. - Only results from multiplex PCR/NAT test systems with a precisely specified test/kit designation are accepted. - The parallel use of singleplex PCR/NAT detection methods for individual pathogens in the panel is not certified. The relatively broad spectrum of pathogen-specific EQA programmes for bacterial genome detection PCR/NAT is still available for this purpose. - Mixtures of 0 to 4 of the different pathogens specified in the panel are to be expected in the respective individual samples.			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: 12 months Parameter / Analytes: Clostridium difficile (toxin-producing) Enterohemorrhagic E. coli (EHEC / STEC)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Aeromonas spp. Campylobacter spp. Enterohemorrhagic E. coli (EHEC / STEC) Enterotoxigenic E. coli (ETEC) Enteropathogenic E. coli (EPEC) Enteraggregative E. coli (EAEC) Escherichia coli O157 Plesiomonas spp. Salmonella spp. Shigella/EIEC Vibrio spp. Yersinia enterocolitica		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05





Bacterial Genome Detection - Salmonella enterica

537

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of <i>Salmonella enterica</i>			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05

Bacterial Genome Detection - Urogenital Panel

547

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of specific DNA: Selection of <i>Mycoplasma hominis</i> , <i>Mycoplasma genitalium</i> , <i>Ureaplasma parvum</i> , <i>Ureaplasma urealyticum</i> , <i>Trichomonas vaginalis</i> , <i>Gardnerella vaginalis</i> , <i>Treponema pallidum</i>		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11		27-08-13 27-10-12 27-11-05



Bacterial Genome Detection - VRE (Vancomycin Resistant Enterococci)

546

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.							EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Vancomycin resistant enterococci (VRE)				
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material				
Dates	Q1		Q2	Q3		Q4	
			June			Nov.	
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-11			27-08-13 27-10-12 27-11-05	

Bacteriological Infection Serology

Infection Serology - Bartonella Antibodies

326

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.				EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: polyvalent (qualitative) IgA (semiquantitative) polyvalent (semiquantitative) IgM (qualitative) IgG (qualitative) IgM (semiquantitative) IgG (semiquantitative) diagnostic comment IgA (qualitative)			
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material			
Dates		Q1		Q2	Q3		Q4
					Aug.		
Registration Deadline: Sample Shipment: Closing Date:					27-06-11 27-08-10 27-08-27		





Infection Serology - Bordetella pertussis Antibodies

317

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.				EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: IgG (qualitative) IgG (semiquantitative) IgA (qualitative) IgM (qualitative) diagnostic comment			
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material			
Dates		Q1		Q2	Q3		Q4
							Oct.
Registration Deadline: Sample Shipment: Closing Date:							27-08-13 27-10-12 27-10-29

Infection Serology - Borrelia burgdorferi Antibodies

332

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: - For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. - A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.				EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: polyvalent (qualitative) IgM (semiquantitative) IgG (qualitative) IgG-Blot IgG (semiquantitative) IgM-Blot IgM (qualitative)				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: diagnostic comment			
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample materia			
Dates	Q1		Q2	Q3		Q4	
			June			Oct.	
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29	



Infection Serology - Brucella Antibodies

327

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.		EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: polyvalent (qualitative) IgM (qualitative) polyvalent (semiquantitative) IgM (semiquantitative) IgG (qualitative) diagnostic comment IgG (semiquantitative)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
			Aug.		
Registration Deadline: Sample Shipment: Closing Date:			27-06-11 27-08-10 27-08-27		

Infection Serology - Campylobacter Antibodies

319

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.		EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: IgG (qualitative) IgM (qualitative) IgG (semiquantitative) diagnostic comment			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
		June			
Registration Deadline: Sample Shipment: Closing Date:		27-03-19 27-05-18 27-06-04			





Infection Serology - Chlamydia pneumoniae (Chlamydophila) Antibodies

314

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: IgG (qualitative) IgM (qualitative) IgG (semiquantitative) IgM (semiquantitative) IgA (qualitative) diagnostic comment IgA (semiquantitative)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04		27-08-13 27-10-12 27-10-29

Infection Serology - Chlamydia trachomatis Antibodies

312

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: IgG (qualitative) IgM (qualitative) IgG (semiquantitativ) IgM (semiquantitative) IgA (qualitative) diagnostic comment IgA (semiquantitative)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04		27-08-13 27-10-12 27-10-29



Infection Serology - Chlamydia trachomatis Direct Detection (ELISA / PCR)

313

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Urine Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Direct detection of Chlamydia trachomatis antigen (ELISA, PCR)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: diagnostic comment		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-04		27-10-29



Infection Serology - Chlamydia trachomatis Direct Detection (Slide)

316

EQAS/PT Properties Samples: 2 slides Sample Properties: Slides Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Direct detection of Chlamydia trachomatis antigen (dir. IFA)			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: diagnostic comment		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-04		27-10-29





Infection Serology - Coxiella burnetii Antibodies

325

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: IgG - Phase I (qualitative) IgA (qualitative) IgG - Phase I (semiquantitative) IgM (qualitative) IgG - Phase II (qualitative) diagnostic comment IgG - Phase II (semiquantitative)				
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material				
Dates	Q1		Q2	Q3		Q4
						Oct.
Registration Deadline: Sample Shipment: Closing Date:						27-08-13 27-10-12 27-10-29

Infection Serology - Diphtheria Toxoid Antibodies

318

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative re- sults along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are suffi- ciently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: AB against Diphtherie toxoid (qualitative) AB against Diphtherie toxoid ((semi-)quantitative) diagnostic comment			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
			June			Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29



Infection Serology - Francisella tularensis Antibodies

328

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.				EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: polyvalent (qualitative) IgA (semiquantitative) polyvalent (semiquantitative) IgM (qualitative) IgG (qualitative) IgM (semiquantitative) IgG (semiquantitative) diagnostic comment IgA (qualitative)			
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material			
Dates		Q1		Q2	Q3		Q4
					Aug.		
Registration Deadline: Sample Shipment: Closing Date:					27-06-11 27-08-10 27-08-27		

Infection Serology - Helicobacter pylori Antibodies

334

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.				EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: IgG (qualitative) IgG (semiquantitative) IgA (qualitative) IgA (semiquantitative) diagnostic comment			
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material			
Dates		Q1		Q2	Q3		Q4
				June			Oct.
Registration Deadline: Sample Shipment: Closing Date:				27-03-19 27-05-18 27-06-04			27-08-13 27-10-12 27-10-29





Infection Serology - Leptospira Antibodies

329

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.		EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: polyvalent (qualitative) IgM (qualitative) polyvalent (semiquantitative) IgM (semiquantitative) IgG (qualitative) diagnostic comment IgG (semiquantitative)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
			Aug.		
Registration Deadline: Sample Shipment: Closing Date:			27-06-11 27-08-10 27-08-27		

Infection Serology - Mycoplasma pneumoniae Antibodies

324

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.		EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: IgG (qualitative) polyvalent (qualitative) IgG (semiquantitative) polyvalent (semiquantitative) IgA (qualitative) diagnostic comment IgM (qualitative)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
					Oct.
Registration Deadline: Sample Shipment: Closing Date:					27-08-13 27-10-12 27-10-29



Infection Serology - Procalcitonin

320

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Procalcitonin (qualitative) Procalcitonin (quantitative) Procalcitonin (semi-quantitative) Diagnostic comments		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04		27-08-13 27-10-12 27-10-29

Infection Serology - Rheumatoid Factor

323

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: quarterly Validity Certificate: 6 months Parameter / Analytes: Rheumatoid factor (RF) (qualitative) Rheumatoid factor (RF) (quantitative)			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Jan.		June	Aug.	Oct.
Registration Deadline: Sample Shipment: Closing Date:	26-11-13 27-01-12 27-01-29		27-03-19 27-05-18 27-06-04	27-06-11 27-08-10 27-08-27	27-08-13 27-10-12 27-10-29





EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.				EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf	
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: polyvalent (qualitative) IgM (qualitative) polyvalent (semiquantitative) IgM (semiquantitative) IgG (qualitative) diagnostic comment IgG (semiquantitative)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
			Aug.		
Registration Deadline: Sample Shipment: Closing Date:				27-06-11 27-08-10 27-08-27	



Infection Serology - Salmonella Antibodies

331

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.		EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: typhi, O-Antigen (qualitative) typhi, O-Antigen (semiquantitative) typhi, OH-Antigen (qualitative) typhi, OH-Antigen (semiquantitative) enteritidis, OH-Antigen (qualitative) enteritidis, OH-Antigen (semiquantitative) typhimurium, OH-Antigen (qualitative) typhimurium, OH-Antigen (semiquantitative) paratyphi B, OH-Antigen (qualitative) paratyphi B, OH-Antigen (semiquantitative) Group A, O-Antigen (qualitative) Group A, O-Antigen (semiquantitative) Group B, O-Antigen (qualitative) Group B, O-Antigen (semiquantitative) Group C, O-Antigen (qualitative) Group C, O-Antigen (semiquantitative) polyvalent (qualitative) IgA (qualitative) IgG (qualitative) IgM (qualitative) diagnostic comment			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-04		27-10-29





Infection Serology - Streptococcal AB

321

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: anti-streptolysin O (ASO) (qualitative) anti-streptolysin O (ASO) (quantitative) anti-streptodornase (aDNase) (qualitative) anti-streptodornase (aDNase) (quantitative)			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04		27-08-13 27-10-12 27-10-29

Infection Serology - Tetanus Toxoid Antibodies

310

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: AB against Tetanus toxoid (qualitative) AB against Tetanus toxoid ((semi-)quantitative) diagnostic comment		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-03-19 27-05-18 27-06-04		27-08-13 27-10-12 27-10-29



Infection Serology - Treponema pallidum Antibodies

311

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.		EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: TPHA (qualitative) IgG (semiquantitative) TPHA (semiquantitative) IgM (qualitative) TPPA (qualitative) IgG - Immunoblot TPPA (semiquantitative) IgM - Immunoblot polyvalent (qualitative) FTA-Abs IgG (qualitative) IgG (qualitative) FTA-Abs IgG (semiquantitative) FTA-Abs IgM (qualitative) FTA-Abs IgM (semiquantitative)		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: AB against Cardiolipin (qualitative) AB against Cardiolipin (semiquantitative) diagnostic comment			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
			June		Oct.
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-04		27-10-29





Infection Serology - Yersinia Antibodies

315

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Serum Max. number of sample sets: 1 Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. K.-P. Hunfeld Deputy EQAS/PT Experts: Ulyana Gräf		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: enterocolitica O3 (qualitative) IgG (semiquantitative) enterocolitica O3 (semiquantitative) IgA (qualitative) enterocolitica O9 (qualitative) IgM (qualitative) enterocolitica O9 (semiquantitative) diagnostic comment pseudotuberculosis (qualitative) pseudotuberculosis (semiquantitative) IgG (qualitative)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		
Registration Deadline:			27-03-19		
Sample Shipment:			27-05-18		
Closing Date:			27-06-04		

Human Microbiome

Bacterial Genome Detection - Molecular Genetic Analysis of the Human Microbiome

580

EQAS/PT Properties Samples: 4 samples of 0.5 mL Sample Properties: Stool suspension Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. Dr. rer. nat. André Gessner Deputy EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: NGS-Analysis (next generation sequencing)		
Shipping Information: - Cooled shipping - Delivered with dry ice! - Before registering for this EQAS/PT, please note that the samples have a limited stability of 5 Days!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			Aug.		
Registration Deadline:			27-04-16		
Sample Shipment:			27-06-15		
Closing Date:			27-08-20		



Conventional Bacteriology

Bacteriology (3 Samples)

411

EQAS/PT Properties**Samples:** 3 samples**Sample Properties:** Lyophilised strains + Bouillon**Additional Information:**

- Participants in the EQA schemes in bacteriology will get a certificate for Gram staining when successful in this part.
- Additional participation in EQA scheme No. 413 'Gram Stain' is not required.**
- Participants will be notified in advance in case the panel of tested antibiotics will be changed:

Ampicillin	Oxacillin
Ampicillin/Sulbactam	Trimethoprim/Sulfamethoxazol
Cefpodoximproxetil	Fosfomycintrometamol
Ceftazidim	Nitrofurantoin Pivmecillinam
Ciprofloxacin	Nitroxolin
Levofloxacin Penicillin	Gentamicin
Meropenem	

EQAS/PT Experts:

Prof. Dr. med. Dirk Schlüter

Deputy EQAS/PT Experts:

Dr. med. Marc Lindenberg

Dr. med. Stefan Ziesing

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual**Validity Certificate:** 12 months**Parameter / Analytes:**

Cultivation, identification and susceptibility testing of fast-growing bacteria and accompanying bacterial flora of the urogenital tract, incl. yeasts
Gram staining

Not subject to Rili-BÄK not applicable**Shipping Information:**

Shipping not cooled

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
	Jan.		Mar.	July		Nov.
Registration Deadline:	26-11-20		27-01-08	27-04-30		27-09-03
Sample Shipment:	27-01-19		27-03-02	27-06-29		27-11-02
Closing Date:	27-01-29		27-03-12	27-07-09		27-11-12





Bacteriology (5 Samples)

412

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Lyophilised strains Additional Information: - Participants in the EQA schemes in bacteriology will get a certificate for Gram staining when successful in this part. Additional participation in EQA scheme No. 413 ‘Gram Stain’ is not required. - Participants will be notified in advance in case the panel of tested antibiotics will be changed:<table><tr><td>Ampicillin</td><td>Levofloxacin Linezolid</td></tr><tr><td>Cefotaxim</td><td>Oxacillin</td></tr><tr><td>Ceftazidim Cefuroxim</td><td>Penicillin Piperacillin/Tazobactam</td></tr><tr><td>Ciprofloxacin</td><td>Trimethoprim/Sulfamethoxazol</td></tr><tr><td>Erythromycin Gentamicin High Level</td><td>Tobramycin Vancomycin</td></tr><tr><td>Meropenem</td><td></td></tr></table>			Ampicillin	Levofloxacin Linezolid	Cefotaxim	Oxacillin	Ceftazidim Cefuroxim	Penicillin Piperacillin/Tazobactam	Ciprofloxacin	Trimethoprim/Sulfamethoxazol	Erythromycin Gentamicin High Level	Tobramycin Vancomycin	Meropenem		EQAS/PT Experts: Prof. Dr. med. Dirk Schlüter Deputy EQAS/PT Experts: Dr. med. Marc Lindenberg Dr. med. Stefan Ziesing		
Ampicillin	Levofloxacin Linezolid																
Cefotaxim	Oxacillin																
Ceftazidim Cefuroxim	Penicillin Piperacillin/Tazobactam																
Ciprofloxacin	Trimethoprim/Sulfamethoxazol																
Erythromycin Gentamicin High Level	Tobramycin Vancomycin																
Meropenem																	
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Cultivation, identification and susceptibility testing of bacteria Gram staining		Not subject to Rili-BÄK not applicable															
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.															
Dates	Q1		Q2	Q3		Q4											
	Feb.				Sep.												
Registration Deadline:	26-12-04				27-07-02												
Sample Shipment:	27-02-02				27-08-31												
Closing Date:	27-02-12				27-09-10												



Bacteriology - Gram Stain

413

EQAS/PT Properties Samples: 3 samples Sample Properties: Slides Additional Information: Participants of the EQA schemes in bacteriology No. 411 or 412 will get a certificate for gram staining if they are successful in this part.				EQAS/PT Experts: Prof. Dr. med. Dirk Schlüter Deputy EQAS/PT Experts: Dr. med. Marc Lindenberg Dr. med. Stefan Ziesing		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Gram staining			Not subject to Rili-BÄK not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.				Oct.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-19				27-08-06 27-10-05 27-10-15



Mycobacteriology

Mycobacterial Diagnostics - Cultivation

422

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Artificial sputum, mixed with accompanying flora and possibly Mycobacterium tuberculosis complex or Non tuberculous Mycobacteria Max. number of sample sets: 1			EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Cultivation of Mycobacteria Differentiation of Tuberculosis Bacteria			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		May		Nov.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-05-28		27-07-09 27-09-07 27-11-19	



Mycobacterial Diagnostics - Drug Susceptibility Testing of Mycobacterium tuberculosis

425

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Mycobacterium tuberculosis complex suspensions for phenotypic resistance testing (incl. second-line drugs) Max. number of sample sets: 1 Additional Information: - Note: EQA scheme containing infectious substances according to UN2814, infectious substances category A. - Each registration for this group must confirm that the test is performed in a laboratory with security level S3 and with appropriately qualified personnel.			EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N.		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Susceptibility Testing of Tuberculosis Bacteria			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		May		Nov.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-05-28		27-07-09 27-09-07 27-11-19	





Mycobacterial Diagnostics - Drug Susceptibility Testing of Nontuberculous Mycobacteria

427

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Suspensions of Nontuberculous Mycobacteria Max. number of sample sets: 1				EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Susceptibility Testing of Nontuberculous Mycobacteria		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3		Q4
		May			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-05-07			27-07-09 27-09-07 27-10-29	



Mycobacterial Diagnostics - Identification

423

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Mycobacterial suspensions (non-tuberculous mycobacteria or Mycobacterium bovis BCG) Max. number of sample sets: 1			EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Identification of Mycobacteria			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		May			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-05-07			27-07-09 27-09-07 27-10-29	





Mycobacterial Diagnostics - Microscopy

421

EQAS/PT Properties Samples: 6 samples Sample Properties: Slides Max. number of sample sets: 1			EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Microscopic Detection of Mycobacteria			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Apr.			Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-04-02			27-07-09 27-09-07 27-09-24	



Mycobacterial Diagnostics - Molecular Drug Susceptibility Testing of tuberculosis bacteria

426

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Suspensions of inactivated Mycobacterium tuberculosis complex strains for molecular resistance testing Max. number of sample sets: 1			EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Susceptibility Testing of Tuberculosis Bacteria			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Apr.			Oct.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-15 27-03-16 27-04-23			27-07-09 27-09-07 27-10-15	





Mycobacterial Diagnostics - NAT Mycobacterium tuberculosis

424

EQAS/PT Properties Samples: 5 samples of 1 mL Sample Properties: Artificial sputum, with accompanying flora and in individual cases mixed with Mycobacterium tuberculosis Complex Max. number of sample sets: 1			EQAS/PT Experts: Dr. Sönke Andres Deputy EQAS/PT Experts: N.N		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Nucleic Acid Amplification of Tuberculosis Bacteria			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Apr.			Sep.
Registration Deadline:		27-01-15			27-07-09
Sample Shipment:		27-03-16			27-09-07
Closing Date:		27-04-02			27-09-24



Mycology

Fungal Genome Detection - Pneumocystis jirovecii

560

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Lyophilised cell suspension			EQAS/PT Experts: Prof. Dr. rer. nat. Udo Reischl Deputy EQAS/PT Experts: PD Dr. Andreas Hiergeist		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: PCR or other procedures for nucleic acid amplification/detection of Pneumocystis jirovecii		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			June		Nov.
Registration Deadline:			27-03-19		27-08-13
Sample Shipment:			27-05-18		27-10-12
Closing Date:			27-06-11		27-11-05



Genome Detection of Dermatophytes

492

EQAS/PT Properties Samples: 4 samples of 0.05 ml Sample Properties: Lyophilised strains			EQAS/PT Experts: PD Dr. rer. nat. et med. habil Cornelia Wiegand Deputy EQAS/PT Experts: Dr. rer. med. Silke Uhrlaß Prof. Dr. med. Pietro Nenoff		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other procedures for Genome detection of dermatophytes			Not subject to Rili-BÄK not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Apr.			Oct.
Registration Deadline:		27-01-08			27-07-09
Sample Shipment:		27-03-09			27-09-07
Closing Date:		27-04-02			27-10-01



Mycology Dermatophytes, Yeasts, Mould Fungus

491

EQAS/PT Properties Samples: 4 samples Sample Properties: Strains Additional Information: Living strains of causative agents or contaminants will be sent, that had been isolated from patients with skin mycoses or mucosal fungal infections.			EQAS/PT Experts: PD Dr. rer. nat. et med. habil Cornelia Wiegand Deputy EQAS/PT Experts: Dr. rer. med. Silke Uhrlaß Prof. Dr. med. Pietro Nenoff Prof. Dr. med. Dipl.-Biol. Gerhard Haase		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Identification of dermatophytes, yeasts and moulds			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Apr.			Oct.
Registration Deadline:		27-01-08			27-07-09
Sample Shipment:		27-03-09			27-09-07
Closing Date:		27-04-23			27-10-22





Mycology Mucorales, Yeasts, Coelomycetes, Hyphomycetes, Basidiomycetes

490

EQAS/PT Properties Samples: 5 samples Sample Properties: Strains			EQAS/PT Experts: Prof. Dr. med. Dipl.-Biol. Gerhard Haase Deputy EQAS/PT Experts: Dr. rer. nat. Walter Geißdörfer		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Cultivation and species identification of fungi (Mucorales, ascomycetes, yeast-like species, coelomycetes, hyphomycetes, basidiomycetes) known to cause mucosal, organ, systemic, or traumatic mycoses in humans, as well as contaminants that may be present in human specimens. Furthermore, a preliminary medical commentary should be provided to evaluate the respective fungus in the specified context.			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
	Feb.			Oct.	
Registration Deadline: Sample Shipment: Closing Date:	26-11-20 27-01-19 27-02-12			27-07-16 27-09-14 27-10-08	



Mycoserology - Candida (Antigen and Antibodies)

480

EQAS/PT Properties Samples: 2 samples of 0.5 mL Sample Properties: Liquid serum Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. med. Michael S. Weig Deputy EQAS/PT Experts: PD Dr. rer. nat. Oliver Bader		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Candida IgA (qual) Candida IgG (qual) Candida IgM (qual) Candida antigen (qual) Candida total AB (qual)			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
	Feb.			Oct.	
Registration Deadline: Sample Shipment: Closing Date:	26-11-20 27-01-19 27-02-05			27-07-16 27-09-14 27-10-01	



Mycoserology - Cryptococcus neoformans/ - gattii Antigen

481

EQAS/PT Properties**Samples:** 2 samples of 0.4 mL**Sample Properties:** Liquid serum**Additional Information:**

For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.

**EQAS/PT Experts:**

PD Dr. med. Volker Rickerts

Deputy EQAS/PT Experts:

Ilka McCormick Smith

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual**Validity Certificate:** 12 months**Parameter / Analytes:**

Detection of *Cryptococcus neoformans* / *Cryptococcus gattii* Antigen

Not subject to Rili-BÄK**Validity Certificate:** 12 months**Shipping Information:**

Shipping not cooled

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
	Feb.				Oct.	
Registration Deadline:	26-11-20				27-07-16	
Sample Shipment:	27-01-19				27-09-14	
Closing Date:	27-02-05				27-10-01	

Parasite Diagnostics

Detection of Toxoplasma DNA (PCR)

457

EQAS/PT Properties**Samples:** 4 samples**Sample Properties:** Stabilized amniotic fluid (and/or EDTA blood or other fluids), buffer**EQAS/PT Experts:**

Prof. Dr. Marc Hübner

Deputy EQAS/PT Experts:

Prof. Dr. med. Achim Hörauf

Requirement for EQAS/PT according to Rili-BÄK: bi-annual**Validity Certificate:** 12 months**Parameter / Analytes:**

Toxoplasma gondii (DNA) - qualitative

Not subject to Rili-BÄK: not applicable**Shipping Information:**

Shipping not cooled

Safety Information:

Process as patient sample material

Dates	Q1		Q2	Q3		Q4
		Mar.			Aug.	
Registration Deadline:		26-12-18			27-06-11	
Sample Shipment:		27-02-23			27-08-10	
Closing Date:		27-03-12			27-08-27	





Molecular Genetic Detection of Protozoa in Stool

458

EQAS/PT Properties Samples: 2 samples of 0.5 mL Sample Properties: Lyophilisate Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Egbert Tannich Deputy EQAS/PT Experts: Prof. Dr. Iris Bruchhaus		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Cryptosporidium spp. (DNA) - qualitative Entamoeba histolytica (DNA) - qualitative Giardia duodenalis (DNA) - qualitative		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Parasite Microscopy (Blood)

456

EQAS/PT Properties Samples: 2 samples of thin or thick blood smear Sample Properties: Slides Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. Marc Hübner Deputy EQAS/PT Experts: Prof. Dr. med. Achim Hörauf		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Blood parasites - specification			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.		Aug.	
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12		27-06-11 27-08-10 27-08-27	



Parasite Serology - Amoebiasis and Echinococcosis

455

EQAS/PT Properties Samples: 2 samples variable volumes Sample Properties: Serum / Plasma			EQAS/PT Experts: Prof. Dr. Marc Hübner Deputy EQAS/PT Experts: Prof. Dr. med. Achim Hörauf		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Antibodies against Echinococcus Antibodies against Entamoeba histolytica			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: diagnostic comment of an echinococcus infection		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
					Oct.
Registration Deadline: Sample Shipment: Closing Date:					27-08-06 27-10-05 27-10-22

Parasite Serology - Malaria and Schistosomiasis

454

EQAS/PT Properties Samples: 2 samples variable volumes Sample Properties: Serum / Plasma Additional Information: For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. Marc Hübner Deputy EQAS/PT Experts: Prof. Dr. med. Achim Hörauf		
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Antibodies against Plasmodium Antibodies against Schistosoma			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Comprehensive Diagnostic Evaluation of a Plasmodium Infection Comprehensive Diagnostic Evaluation of a Schistosoma Infection		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		





Parasite Serology - Toxoplasmosis

452

EQAS/PT Properties Samples: 2 samples variable volumes Sample Properties: Serum / Plasma Additional Information: - For certificates to be issued, all participants are expected to report (semi-) quantitative results along with qualitative results on the evaluation sheets, where requested. - A certificate for (semi-)quantitative results, however, can only be issued if the reported results are sufficiently comparable and if an international standard has been established for diagnostics.			EQAS/PT Experts: Prof. Dr. Marc Hübner Deputy EQAS/PT Experts: Prof. Dr. med. Achim Hörauf		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Antibodies against <i>Toxoplasma gondii</i>			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Comprehensive diagnostic evaluation		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		Oct.
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22

Virtual Parasite Microscopy (Blood)

906

EQAS/PT Properties Samples: Images of at least 2 clinical cases Sample Properties: Digital slides Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Egbert Tannich Deputy EQAS/PT Experts: Prof. Dr. Iris Bruchhaus Prof. Dr. med. Achim Hörauf Prof. Dr. Marc Hübner		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Blood parasites - specification			Not subject to Rili-BÄK: not applicable		
Shipping Information: - Available online in digital microscopy! - No shipment! - In March and September: Prof. Hübner, Bonn; in May and October: Prof. Tannich, Hamburg			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
		Mar.	May		Aug.
Registration Deadline: Sample Shipment: Closing Date:		26-12-18 27-02-23 27-03-12	27-02-26 27-04-27 27-05-14		27-06-11 27-08-10 27-08-27
					27-08-06 27-10-05 27-10-22



Virtual Parasite Detection (Stool)

907

EQAS/PT Properties Samples: Images of slides with fecal smears of at least 2 clinical cases Sample Properties: Digital slides Max. number of sample sets: 1			EQAS/PT Experts: Prof. Dr. med. Egbert Tannich Deputy EQAS/PT Experts: Prof. Dr. Iris Bruchhaus		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Stool parasites - specification			Not subject to Rili-BÄK: not applicable		
Shipping Information: Available online in digital microscopy! - No shipment!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
			May		
Registration Deadline: Sample Shipment: Closing Date:			27-02-26 27-04-27 27-05-14		27-08-06 27-10-05 27-10-22





VIRUS DIAGNOSTICS

Virus Genome Detection

Virus Antigen Detection - Panel for the Detection of Influenza A/B Viruses, RSV, and SARS-CoV-2 (Ag)

410

EQAS/PT Properties Samples: 5 samples of 0.5 ml Sample Properties: Liquid cell culture material (inactivated) Additional Information: - Note: When performing tests using your own swab, please note that the provided sample volume of 0.5 ml is generally sufficient for performing one SARS-CoV-2 test, one influenza virus test, and one RSV test. However, depending on the absorbency of the swab used, a second tube may be necessary. - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin			 EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: entfällt			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: The samples are suitable to detect influenza A/B antigen, RSV A/B antigen, and SARS-CoV-2 antigen.			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material Information will be updated at the end of autumn.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19



Virus Detection (Genome/Antigen) - Influenza A and B Viruses incl. Avian Influenza A Viruses

370

EQAS/PT Properties

Samples: 6 samples of 1.5 ml**Sample Properties:** Lyophilised cell culture material or allantoic fluid**Additional Information:**

- For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.
Note for laboratories from non-EU countries:
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Referenzzentrum für Influenza, Robert Koch-Institut, Berlin; Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Nationales Referenzlabor für Aviäre Influenza, Insel Riems



EQAS/PT Experts:

Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:

Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual**Validity Certificate:** 12 months**Parameter / Analytes:**

- This program may be completed with currently circulating influenza viruses.
- Please note: these EQA samples are not suitable for virus propagation and immune fluorescence tests for antigen detection. Some of the samples can contain chemically inactivated avian influenza A viruses.
- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for influenza A and B viruses and antigen testing
- Option for typing of seasonal and avian influenza A viruses

Not subject to Rili-BÄK: not applicable**Shipping Information:**

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
		Mar.				Nov.
Registration Deadline:		27-01-08				27-09-03
Sample Shipment:		27-03-09				27-11-02
Closing Date:		27-03-26				27-11-19





Virus Detection (Genome/Antigen) - Respiratory Syncytial Virus

359

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Cooperation with: Institut für Virologie und Immunbiologie, Universität Würzburg; Institut für Virologie, Universitätsklinikum Düsseldorf; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin		 EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for RSV RNA and RSV antigen testing		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1	Q2	Q3		Q4
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19



Virus Genome Detection - Adenoviruses

371

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material				EQAS/PT Experts: PD Dr. med. Albert Heim Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: • Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for adenovirus DNA • Determination of species of adenovirus • Typing of adenovirus			Not subject to Rili-BÄK not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19





Virus Genome Detection - BK Polyomavirus (BKPyV / BKV)

364



EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma or suspension of urine Additional Information: Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln			EQAS/PT Experts: Dr. Steffi Silling Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for BK-Polyomavirus DNA			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			27-06-25 27-08-24 27-09-10	

Virus Genome Detection - Borna Viruses

404

EQAS/PT Properties Samples: 4 samples of 1.5 ml* or 0.5 ml** Sample Properties: *Lyophilised cell culture material (inactivated) or ** lyophilised RNA eluate Additional Information: Cooperation with: Friedrich-Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Institut für Virusdiagnostik, Insel Riems				EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Bornaviruses - RNA		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19





Virus Genome Detection - Chikungunya Virus

392

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma and cell culture material (inactivated) Additional Information: • INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter. • Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg			EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: Validity Certificate: not applicable Parameter / Analytes:			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CHIKV RNA			
Shipping Information: • Shipping not cooled • Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	

**EQAS/PT Properties****Samples:** 6 samples of 1.5 ml**Sample Properties:** Lyophilised cell culture material**Additional Information:**

- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main

EQAS/PT Experts:

Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:

Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** bi-annual**Validity Certificate:** 12 months**Parameter / Analytes:**

- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2-RNA, MERS-CoV-RNA and other human coronavirus RNA
- Option for differentiation between SARS-CoV-2, MERS-CoV and other human coronaviruses (samples which contain SARS-CoV-2 and MERS-CoV, respectively, are inactivated)

Not subject to Rili-BÄK: not applicable**Shipping Information:**

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19





Virus Genome Detection - Cytomegalovirus Program 1

365

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma or cell culture material			EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CMV DNA			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Cytomegalovirus Program 2 - additional Training Program
(can only be ordered with program 365)

368

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: • The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3. • The training program (368) can only be ordered together with the corresponding main EQA scheme (365) for March. • Separate certificates will be issued for the training program (368) and the main EQA scheme (365, subject to Rili-BÄK-B3). • Cooperation with: Nationale Konsiliarlabore für Cytomegalievirus (CMV): Institut für Virologie, Universitätsklinikum Ulm; Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen			EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for CMV DNA			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.				
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26				





Virus Genome Detection - Cytomegalovirus Resistance Determination

349



EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma or cell culture material Additional Information: Cooperation with: Nationale Konsiliarlabore für Cytomegalievirus (CMV): Institut für Virologie, Universitätsklinikum Ulm; Institut für Medizinische Virologie und Epidemiologie der Viruskrankheiten, Universitätsklinikum Tübingen		EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for CMV resistance determination			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	Q4
				Oct.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-25 27-08-24 27-10-01	

Virus Genome Detection - Dengue Viruses

369

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma or cell culture material (inactivated) Additional Information: Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg		EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for denguevirus RNA - Typing of denguevirus			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	Q4
		Mar.		Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-06-25 27-08-24 27-09-10	





Virus Genome Detection - Enteroviruses

372

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for enterovirus RNA - Typing of enterovirus			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19



Virus Genome Detection - Epstein Barr Virus

376

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material			EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for EBV DNA			Not subject to Rili-BÄK not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19





Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests

430

EQAS/PT Properties Samples: 3 samples of 1.5 ml Sample Properties: Lyophilised suspension of feces or cell culture material Additional Information: - The RiliBÄK requirements (Guidelines of the German Medical Association on quality assurance in medical laboratory testing / Bundesärztekammer) will be used to detect the pathogens listed below. This EQA scheme will include each of the pathogens mentioned below at least once a year. Participation in both EQA scheme terms is recommended. Please note: Only results of multiplex tests will be accepted for EQA scheme 430 - This multiplex EQA scheme is not suitable for (i) 'singleplex' PCRs, (ii) tests for antigen detection, (iii) testing of sensitivity and (iv) typing. For this purpose, we refer to the INSTAND EQA schemes for the corresponding viruses. - This program will be completed with currently circulating virus variants.			EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of gastrointestinal adeno, astro, entero , noro , parecho , rota and sapoviruses , respectively.			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of gastrointestinal adeno, astro, entero , noro , parecho , rota and sapoviruses , respectively.		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Genome Detection - Hepatitis A Virus

377

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HAV RNA			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10
					Nov.
					27-09-03 27-11-02 27-11-19





Virus Genome Detection - Hepatitis B Virus Genotyping

396

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: Cooperation with: WHO Collaborating Centre for Blood Products and IVD-Devices, Paul-Ehrlich-Institut, Langen		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) incl. sequencing for HBV genotyping			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
					Nov.
Registration Deadline: Sample Shipment: Closing Date:					27-09-03 27-11-02 27-11-19



Virus Genome Detection - Hepatitis B Virus Program 1

361

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HBV DNA		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10
					27-09-03 27-11-02 27-11-19





Virus Genome Detection - Hepatitis B Virus Program 2 - additional Training Program (can only be ordered with program 361)

378

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: - The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3. - The training program (378) can only be ordered together with the corresponding main EQA scheme (361) for March. - Separate certificates will be issued for the training program (378) and the main EQA scheme (361, subject to Rili-BÄK-B3).		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HBV DNA			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			



Virus Genome Detection - Hepatitis B Virus Resistance Determination

397

EQAS/PT Properties Samples: 4 samples à 0.1 ml* or à 1.5 ml** Sample Properties: *Plasmids in water or **lyophilised plasma		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HBV resistance determination			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				Oct.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-25 27-08-24 27-10-01	





Virus Genome Detection - Hepatitis C Virus Geno-/Subtyping

375

EQAS/PT Properties Samples: 3-4 samples of 1.5 ml Sample Properties: Lyophilised serum/plasma Additional Information: Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf; Medizinisches Infektiologiezentrum Berlin			EQAS/PT Experts: Prof. Dr. med. Jörg Timm Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: yearly Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV geno- and subtype differentiation			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
					Sep.	
Registration Deadline: Sample Shipment: Closing Date:					27-06-25 27-08-24 27-09-10	



Virus Genome Detection - Hepatitis C Virus Program 1

362

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Prof. Dr. med. Jörg Timm Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV RNA			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10	27-09-03 27-11-02 27-11-19





Virus Genome Detection - Hepatitis C Virus Program 2 - additional Training Program (can only be ordered with program 362)

379

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: - The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3. - The training program (379) can only be ordered together with the corresponding main EQA scheme (362) for March. - Separate certificates will be issued for the training program (379) and the main EQA scheme (362, subject to Rili-BÄK-B3). - Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf			EQAS/PT Experts: Prof. Dr. med. Jörg Timm Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HCV RNA		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			



Virus Genome Detection - Hepatitis C Virus Resistance Determination

399

EQAS/PT Properties Samples: 2-3 samples of 0.5 ml Sample Properties: Serum/plasma (non-lyophilised) Additional Information: - Please note: Only tests in the gene region NS5A will be offered in this EQA scheme. Resistance tests in the gene region NS3 will no longer be offered due to lack of clinical relevance. - Cooperation with: Nationales Referenzzentrum für Hepatitis-C-Viren, Institut für Virologie, Universitätsklinikum Düsseldorf, Medizinisches Infektiologiezentrum Berlin			EQAS/PT Experts: Prof. Dr. med. Jörg Timm Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HCV resistance determination		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
				Oct.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-25 27-08-24 27-10-01	





Virus Genome Detection - Hepatitis D Virus

400

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: Cooperation with: WHO Collaborating Centre for Blood Products and IVD-Devices, Paul-Ehrlich-Institut, Langen			EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HDV RNA		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.		Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-06-25 27-08-24 27-09-10	



Virus Genome Detection - Hepatitis E Virus

380

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised serum/plasma or suspension of feces Additional Information: Cooperation with: Nationales Konsiliarlabor für Hepatitis-A-Virus (HAV) und Hepatitis-E-Virus (HEV), Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg			EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HEV RNA			Not subject to Rili-BÄK not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10





Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2

363

EQAS/PT Properties Samples: 6 samples of 1.5 ml Sample Properties: Lyophilised plasma or cell culture material			EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for differentiation of HSV 1 and HSV 2 DNA			Not subject to Rili-BÄK not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Genome Detection - HIV-1 (RNA) Program 2 - additional Training Program (can only be ordered with program 360)

382

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: - The training samples will contain virus concentrations which fall outside the requirements of the specified Rili-BÄK section B3. - The training program (382) can only be ordered together with the corresponding main EQA scheme (360) for March. - Separate certificates will be issued for the training program (382) and the main EQA scheme (360, subject to Rili-BÄK-B3). - Cooperation with: Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main			EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-1 (RNA)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			





Virus Genome Detection - HIV-1 (RNA) Program 1

360

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-1 (RNA)			Not subject to Rili-BÄK not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
					Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25
Sample Shipment:		27-03-09		27-06-08	27-08-24
Closing Date:		27-03-26		27-06-25	27-09-10
					27-09-03
					27-11-02
					27-11-19



Virus Genome Detection - HIV-1 Drug Resistance Determination - Standard Program for Protease and Reverse Transcriptase Inhibitors

383

EQAS/PT Properties Samples: 4 samples of 1.5 ml* or 0.1 ml** Sample Properties: *Plasma or **Plasmids in water (non-lyophilised) Additional Information: Cooperation with IMD Labor Frankfurt; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: - Please note: The samples will contain plasmids and heat-inactivated cell culture supernatant viruses respectively! - Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of protease inhibitors and reverse transcriptase inhibitors		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
				Oct.	
Registration Deadline:					27-06-25
Sample Shipment:					27-08-24
Closing Date:					27-10-01



Virus Genome Detection - HIV-1 Drug Resistance Determination - additional Program for Integrase Inhibitors and Tropism Determination

384

EQAS/PT Properties Samples: 2 samples of 1.5 ml Sample Properties: Plasma (non-lyophilised) Additional Information: Cooperation with IMD Labor Frankfurt; Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main; Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen; Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln; Medizinisches Infektiologiezentrum Berlin		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: - Please note: The samples will contain heat-inactivated cell culture supernatant viruses! - Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and sequencing for HIV-1 drug resistance determination of integrase inhibitors and determination of tropism			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
				Oct.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-25 27-08-24 27-10-01	

Virus Genome Detection - HIV-2 (RNA)

395

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised serum/plasma Additional Information: Cooperation with: Institut für Medizinische Virologie, Uniklinikum Frankfurt am Main		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HIV-2 (RNA)			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	
					Nov.
					27-09-03 27-11-02 27-11-19





Virus Genome Detection - Human Herpesvirus 6 (HHV-6)

405

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf			EQAS/PT Experts: Prof. Dr. med. Jörg Timm Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human herpesvirus 6 (HHV-6) - DNA		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.		Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-06-25 27-08-24 27-09-10	



Virus Genome Detection - Human Herpesvirus 8 (HHV-8)

406

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Institut für Virologie, Medizinische Hochschule Hannover			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human herpesvirus 8 (HHV-8) - DNA		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.			
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			





Virus Genome Detection - Human Metapneumovirus

385

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin		EQAS/PT Experts: Dr. rer. nat. Kerstin Knies Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for human metapneumovirus RNA			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Genome Detection - Human Papillomaviruses (HPV)

373

EQAS/PT Properties Samples: 5 samples of 1.5 ml Sample Properties: Lyophilised cell culture material or biopsy material Additional Information: Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln		EQAS/PT Experts: Dr. Steffi Silling Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR), other nucleic acid amplification techniques (NAT) and hybridization for HPV DNA - Differentiation of 'high risk' and 'low risk' types, and typing of 'high risk' HPV and 'low risk' HPV		Not subject to Rili-BÄK not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19





Virus Genome Detection - Human Rhinoviruses

393

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin		EQAS/PT Experts: Dr. rer. nat. Kerstin Knies Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for HRV RNA - Typing of human rhinovirus			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline:				27-04-09	27-09-03
Sample Shipment:				27-06-08	27-11-02
Closing Date:				27-06-25	27-11-19



Virus Genome Detection - JC Polyomavirus (JCPyV / JCV)

394

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material or suspension of urine Additional Information: Cooperation with: Nationales Referenzzentrum für Papillom- und Polyomaviren, Institut für Virologie, Uniklinik Köln		EQAS/PT Experts: Dr. Steffi Silling Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for JC-Polyomavirus DNA			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
		Mar.		Sep.	
Registration Deadline:		27-01-08		27-06-25	
Sample Shipment:		27-03-09		27-08-24	
Closing Date:		27-03-26		27-09-10	





Virus Genome Detection - Measles Virus

386



EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin				EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: • Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for measles virus RNA • Typing of measles virus				Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3		Q4
				July		Dec.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-07-09		27-09-03 27-11-02 27-12-03



**EQAS/PT Properties****Samples:** 4 samples of 1.5 ml**Sample Properties:** Lyophilised cell culture material (MPXV inactivated)**Additional Information:**

- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- Cooperation with: Nationales Konsiliarlabor für Pockenviren, Robert Koch-Institut, Zentrum für Biologische Gefahren und Spezielle Pathogene, ZBS 1 - Hochpathogene Viren, Berlin

EQAS/PT Experts:

Dr. med. Martin Obermeier

Deputy EQAS/PT Experts:

Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK:** not applicable**Not subject to Rili-BÄK****Validity Certificate:** 12 months**Parameter / Analytes:**

MPXV (DNA) - quantitative
 MPXV (DNA) - qualitative
 MPXV (DNA) - clade identification
 Orthopoxviruses (DNA) – quantitative
 Orthopoxviruses (DNA) – qualitative
 Orthopoxviruses (DNA) – type identification

Shipping Information:

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates**Q1****Q2****Q3****Q4****Mar.****Sep.****Registration Deadline:****Sample Shipment:****Closing Date:**

27-01-08

27-03-09

27-03-26

27-06-25

27-08-24

27-09-10



Virus Genome Detection - Mumps Virus

387

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin			EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for mumps virus RNA - Typing of mumps virus			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
				July	Dec.
Registration Deadline:				27-04-09	27-09-03
Sample Shipment:				27-06-08	27-11-02
Closing Date:				27-07-09	27-12-03



Virus Genome Detection - Norovirus

381

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised suspension of feces Additional Information: Cooperation with: Nationales Konsiliarlabor für Noroviren, Robert Koch-Institut, Berlin; Nationales Konsiliarlabor für Hepatitis-A-Virus (HAV) und Hepatitis-E-Virus (HEV), Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensburg; Institut für Virologie, Medizinische Hochschule Hannover			EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for norovirus RNA with the option for differentiation in genogroup I and II			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.			Nov.
Registration Deadline:		27-01-08			27-09-03
Sample Shipment:		27-03-09			27-11-02
Closing Date:		27-03-26			27-11-19





Virus Genome Detection - Panel for the Detection of Tropical Infectious Pathogens

NEW!

435

EQAS/PT Properties Samples: 5 samples of 1.5 ml Sample Properties: Lyophilised cell culture material		EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: N.N.			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for qualitative detection of Zika-, Dengue-, Chikungunya-, Japanese encephalitis- and Oropouche virus-RNA and Plasmodium spp.			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1	Q2	Q3	Q4	
	Mar.			Sep.	Nov.
Registration Deadline:		27-01-08		27-06-25	27-09-03
Sample Shipment:		27-03-09		27-08-24	27-11-02
Closing Date:		27-03-26		27-09-10	27-11-19



Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests

433

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: - We will include the listed pathogens in this EQAS/PT program at least once a year. We therefore recommend participating in both rounds of the EQAS/PT program. - We will accept only results from multiplex tests for this proficiency testing program. - This multiplex proficiency testing program is not suitable for (i) "singleplex" PCRs, (ii) antigen detection tests, (iii) sensitivity assessments, and (iv) typing. For these purposes, please refer to the corresponding INSTAND proficiency testing programs for the respective viruses. - The program includes currently circulating virus variants.		EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: not applicable Parameter / Analytes: Polymerase Chain Reaction (PCR) and other nucleic acid amplification techniques (NAT) for the simultaneous qualitative detection of cytomegalovirus, enteroviruses, Epstein-Barr virus, herpes simplex virus type 1, herpes simplex virus type 2, and varicella-zoster virus.		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase Chain Reaction (PCR) and other nucleic acid amplification techniques (NAT) for the simultaneous qualitative detection of adenoviruses, human herpesvirus 6, and parechovirus.			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1	Q2	Q3	Q4	
			June		Nov.
Registration Deadline:			27-04-09		27-09-03
Sample Shipment:			27-06-08		27-11-02
Closing Date:			27-06-25		27-11-19





Virus Genome Detection - Parainfluenza Viruses

388

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Institut für Virologie, Universitätsklinikum Düsseldorf; Institut für Virologie und Immunbiologie, Universität Würzburg; Nationales Konsiliarlabor für respiratorische Syncytialviren (RSV), Parainfluenzaviren, Metapneumoviren, Robert Koch-Institut, Berlin			EQAS/PT Experts: Dr. rer. nat. Kerstin Knies Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for parainfluenza virus RNA - Typing of parainfluenza virus		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.			Sep.
Registration Deadline:		27-01-08			27-06-25
Sample Shipment:		27-03-09			27-08-24
Closing Date:		27-03-26			27-09-10



Virus Genome Detection - Parechovirus

407

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Nationales Referenzzentrum für Poliomyelitis und Enteroviren, Robert Koch-Institut, Berlin			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Parechovirus (RNA)		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.			Sep.
Registration Deadline:		27-01-08			27-06-25
Sample Shipment:		27-03-09			27-08-24
Closing Date:		27-03-26			27-09-10





Virus Genome Detection - Parvovirus B19

367

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma			EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for parvovirus B19 DNA			Not subject to Rili-BÄK: not applicable		
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline:		27-01-08		27-04-09	27-06-25
Sample Shipment:		27-03-09		27-06-08	27-08-24
Closing Date:		27-03-26		27-06-25	27-09-10
					27-09-03
					27-11-02
					27-11-19



Virus Genome Detection - Rabies Virus (Tollwutvirus)

390

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised samples (inactivated, vaccine) Additional Information: INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rabies virus RNA		
Shipping Information: - Shipping not cooled - Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!			Safety Information: Process as patient sample material		
Dates	Q1		Q2	Q3	
					Sep.
Registration Deadline:					27-06-25
Sample Shipment:					27-08-24
Closing Date:					27-09-10



Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests

431

EQAS/PT Properties**Samples:** 4 samples of 1.5 ml**Sample Properties:** Lyophilised cell culture material**Additional Information:**

- The pathogens listed will be included in this EQAS/PT at least once a year. We therefore recommend participating in both EQAS/PT rounds.
- For this EQAS/PT (No. 431), only results from multiplex tests will be accepted.**
- This multiplex EQA scheme is not suitable for (i) 'singleplex' PCRs, (ii) tests for antigen detection, (iii) testing of sensitivity and (iv) typing. For this purpose, we refer to the INSTAND EQA schemes for the corresponding viruses.
- The program is rounded out with virus variants currently in circulation
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.

EQAS/PT Experts:

Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:

Dr. rer. nat. Martin Kammel

**Requirement for EQAS/PT according to Rili-BÄK: bi-annual****Validity Certificate:** 12 months**Parameter / Analytes:**

- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of respiratory **adeno, entero, influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated), respectively.**
- Some of the samples can contain chemically inactivated avian influenza A viruses.

Not subject to Rili-BÄK**Validity Certificate:** 12 months**Parameter / Analytes:**

Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of respiratory **boca, corona, human metapneumo, human rhino, parecho, parainfluenza.**

Shipping Information:

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19



**EQAS/PT Properties****Samples:** 4 samples of 1.5 ml**Sample Properties:** Lyophilised cell culture material**Additional Information:**

- This EQAS/PT program is not suitable for (I) antigen detection tests, (II) sensitivity testing, and (III) typing. For these purposes, please refer to the corresponding INSTAND proficiency testing programs for the respective viruses.
- INSTAND e.V. can only process EQA scheme orders from non-EU countries if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import permit! If we do not receive these documents by the registration/withdrawal deadline, we will unfortunately have to cancel the registration. Please also refer to the shipping information regarding this matter.
- The program is rounded out with virus variants currently in circulation.

EQAS/PT Experts:

Dr. rer. nat. Rolf Kaiser, Dipl.-Biol.

Deputy EQAS/PT Experts:

Dr. rer. nat. Martin Kammel

Requirement for EQAS/PT according to Rili-BÄK: bi-annual**Validity Certificate:** 12 months**Parameter / Analytes:**

- Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for simultaneous qualitative detection of **influenza A and B viruses incl. avian influenza A viruses, respiratory syncytial viruses (groups A and B) and SARS-CoV-2 (inactivated)**.
- Some of the samples can contain chemically inactivated avian influenza A viruses.

Not subject to Rili-BÄK: not applicable**Shipping Information:**

- Shipping not cooled
- Note for laboratories in non-EU countries: Shipping sample materials for participation in this EQA scheme requires approval from the Federal Office for Economic Affairs and Export Control under the EU Dual-Use Regulation (Regulation (EU) 2021/821) for sample recipients outside the EU. Orders for EQA schemes from non-EU countries can only be processed by INSTAND e.V. if the ordering laboratories provide a fully completed end-use declaration, a company profile including contact information (e.g., an excerpt from the website), and, if applicable, an import license!

Safety Information:

Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.

Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline:				27-04-09		27-09-03
Sample Shipment:				27-06-08		27-11-02
Closing Date:				27-06-25		27-11-19



Virus Genome Detection - Rotaviruses

401

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised suspension of feces Additional Information: Cooperation with: Nationales Konsiliarlabor für Rotaviren, Robert Koch-Institut, Berlin		EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rotavirus RNA - Typing of rotavirus			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Genome Detection - Rubella Virus

389

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Nationales Referenzzentrum für Masern, Mumps, Röteln, Robert Koch-Institut, Berlin		EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: - Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for rubella virus RNA - Typing of rubella virus		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				July	Dec.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-07-09	27-09-03 27-11-02 27-12-03





Virus Genome Detection - SARS-CoV-2

409

EQAS/PT Properties Samples: 5 samples of 1.5 ml Sample Properties: Lyophilised cell culture material Additional Information: Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité - Universitätsmedizin Berlin			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for SARS-CoV-2			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material Information will be updated at the end of autumn.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10	27-09-03 27-11-02 27-11-19

Virus Genome Detection - SARS-CoV-2 sequence analysis

417

EQAS/PT Properties Samples: 3-5 samples of 1.5 ml Sample Properties: Lyophilised cell culture material (inactivated) Additional Information: Cooperation with: Nationales Konsiliarlabor für Coronaviren, Institut für Virologie, Charité – Universitätsmedizin Berlin; Medizinisches Infektiologiezentrum Berlin; Abt. Methodenentwicklung und Forschungsinfrastruktur, Robert Koch-Institut, Berlin			EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing Please note: - Submitted sequences are evaluated for sequence quality both in the S gene and separately in the whole genome.			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Apr.			Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-04-09			27-06-25 27-08-24 27-09-24	



Virus Genome Detection - Torque Teno Virus (TTV)

408

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma Additional Information: Cooperation with: Institut für Virologie, Uniklinik Köln		EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Torque teno virus (TTV) DNA			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1	Q2	Q3		Q4
			Sep.		
Registration Deadline: Sample Shipment: Closing Date:			27-06-25 27-08-24 27-09-10		



Virus Genome Detection - Varicella Zoster Virus

366

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma or cell culture material		EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for VZV DNA		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1	Q2	Q3		Q4
			June		Nov.
Registration Deadline: Sample Shipment: Closing Date:			27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19





Virus Genome Detection - West Nile Virus

391

EQAS/PT Properties Samples: 6 samples of 1.5 ml Sample Properties: Lyophilised plasma and cell culture material (inactivated) Additional Information: Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg			EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: • Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for West Nile virus RNA • Typing of West Nile virus (Lineage determination)			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material Information will be updated at the end of autumn.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19

Virus Genome Detection - Zika Virus

403

EQAS/PT Properties Samples: 4 samples of 1.5 ml Sample Properties: Lyophilised plasma or cell culture material (inactivated) Additional Information: Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg			EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: • Polymerase chain reaction (PCR) and other nucleic acid amplification techniques (NAT) for Zika virus RNA • Typing of Zika virus (Lineage determination)			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	



Virus Immunology

Virus Immunology - Borna Viruses (Ab)

415

EQAS/PT Properties Samples: 10 samples of 100 µl Sample Properties: Liquid serum/plasma Additional Information: Cooperation with WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg		EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Anti-borna virus IgG			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
			June		
Registration Deadline: Sample Shipment: Closing Date:			27-04-09 27-06-08 27-06-25		

Virus Immunology - Chikungunya Virus (Ab)

402

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Liquid serum (inactivated in case of chikungunya virus RNA positive samples) Additional Information: Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg		EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Anti-CHIKV IgG Anti-CHIKV IgG - avidity Anti-CHIKV IgM			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1	Q2	Q3		Q4
			Sep.		
Registration Deadline: Sample Shipment: Closing Date:			27-06-25 27-08-24 27-09-10		





Virus Immunology - Cytomegalovirus (Ab)

351

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum			EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-CMV IgG Anti-CMV IgG - avidity Anti-CMV IgM			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline:		27-01-08		27-04-09	27-06-25	27-09-03
Sample Shipment:		27-03-09		27-06-08	27-08-24	27-11-02
Closing Date:		27-03-26		27-06-25	27-09-10	27-11-19



Virus Immunology - Dengue Viruses (Ab and NS1 Antigen)

350

EQAS/PT Properties Samples: 4 samples of 0.3 ml Sample Properties: Liquid serum (inactivated in case of dengue virus RNA positive ples) Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg			 EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-dengue virus IgG Anti-dengue virus IgM dengue virus-NS1 Ag clinical interpretation			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline:		27-01-08			27-06-25	
Sample Shipment:		27-03-09			27-08-24	
Closing Date:		27-03-26			27-09-10	





Virus Immunology - Epstein Barr Virus (Ab)

352

EQAS/PT Properties Samples: 2 samples of 0.6 ml Sample Properties: Liquid serum Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - The following parameters are not considered for the ‘certificate’ (only stated in the ‘certificate of participation’): anti-EA IgG, anti-EA IgA, anti-EA IgM, anti-EA, anti-VCA IgA, anti-EBV IgA and strip-immunoblot anti-EBV IgA		 EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel				
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Antibodies against EBV with and without differentiation of antigen specificity (incl. avidity) and heterophilic antibodies clinical interpretation				
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.				
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19



Virus Immunology - Hantaviruses (Ab)

355

EQAS/PT Properties Samples: 4 samples of 0.5 ml Sample Properties: Liquid serum (inactivated in case of Hantavirus RNA positive samples) Additional Information: - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device. - Cooperation with: Labor Berlin, Charite-Vivantes GmbH			 EQAS/PT Experts: Prof. Dr. Jörg Hofmann Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable			Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: - Antibodies against hantaviruses (IgG and IgM) and differentiation of serotype specific antibodies - Status of hantavirus infection			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3		Q4
		Mar.			Sep.	
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26			27-06-25 27-08-24 27-09-10	





Virus Immunology - Hepatitis A Virus (Ab)

343

EQAS/PT Properties Samples: 4 samples of 0.5 ml Sample Properties: Liquid serum			EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Anti-HAV IgG / Anti-HAV total Anti-HAV IgM			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10	27-09-03 27-11-02 27-11-19



Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc, HBeAg, Anti-HBe)

344

EQAS/PT Properties Samples: 5 samples of 1.5 mL Sample Properties: Liquid serum Additional Information: - Please note: Note: The EQA schemes for hepatitis B virus immunology have been restructured to incorporate diagnostic scenarios. Instead of individual samples for each parameter, samples with simulated diagnostic scenarios will be sent out in the future. Since only a few laboratories perform testing for anti-HBc-IgM, this parameter has been moved to the separate Program 345. All other parameters of HBV serology are grouped together in this Program 344. - For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: HBsAg Anti-HBc Confirmation test HBsAg HBeAg Anti-HBs Anti-HBe		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Diagnostic interpretation				
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.				
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10	27-09-03 27-11-02 27-11-19





Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM)

345

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Anti-HBc IgM		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08		27-04-09	27-06-25
		27-03-09		27-06-08	27-08-24
		27-03-26		27-06-25	27-09-10
					Nov.
					27-09-03
					27-11-02
					27-11-19



Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen)

346

EQAS/PT Properties Samples: 4 samples of 0.5 ml Sample Properties: Liquid serum/plasma Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.		 EQAS/PT Experts: Prof. Dr. med. Jörg Timm Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Screening test anti-HCV and combined detection anti-HCV and HCV antigen HCV antigen Complementary test (blot) anti-HCV		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08		27-04-09	27-06-25
		27-03-09		27-06-08	27-08-24
		27-03-26		27-06-25	27-09-10
					Nov.
					27-09-03
					27-11-02
					27-11-19





Virus Immunology - Hepatitis D Virus (Ab)

347

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum/plasma		EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-HDV IgG / Anti-HDV total Anti-HDV IgM			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09	27-09-03
				27-06-08	27-11-02
				27-06-25	27-11-19



Virus Immunology - Hepatitis E Virus (Ab)

348

EQAS/PT Properties Samples: 2 samples of 0.4 ml Sample Properties: Liquid serum		EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-HEV IgG Anti-HEV IgM			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09	27-09-03
				27-06-08	27-11-02
				27-06-25	27-11-19





Virus Immunology - Herpes Simplex Viruses (Ab)

354

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum				EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-HSV 1/2 IgG Anti-HSV 2 IgG - avidity Anti-HSV 1/2 IgG - avidity Anti-HSV 1/2 IgM Anti-HSV 1 IgG Anti-HSV 1 IgM Anti-HSV 1 IgG - avidity Anti-HSV 2 IgM Anti-HSV 2 IgG		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19



Virus Immunology - HIV-1 p24 Antigen

337

EQAS/PT Properties Samples: 2 samples of 0.75 ml Sample Properties: Liquid serum Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: HIV-1 p24 Ag HIV-1 p24 Ag Confirmation test			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10	27-09-03 27-11-02 27-11-19





Virus Immunology - HIV-1/HIV-2 (Ab)

335

EQAS/PT Properties Samples: 4 samples of 0.75 ml Sample Properties: Liquid serum/plasma Additional Information: For POCT systems: Please ensure that the sample matrix used in the EQA scheme is suitable for your test system. In case of uncertainty, we recommend contacting the manufacturer or supplier of your device.			 EQAS/PT Experts: Dr. rer. nat. Rolf Kaiser, Dipl.-Biol. Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Screening test anti-HIV-1 / anti-HIV-2 (3rd and 4th Generation) Confirmation test (blot and other confirmatory test) anti-HIV-1 / anti-HIV-2 Confirmation test (blot and other confirmatory test) anti-HIV-1 Confirmation test (blot and other confirmatory test) anti-HIV-2			Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled			Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3		Q4
		Mar.		June	Sep.	Nov.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10	27-09-03 27-11-02 27-11-19



Virus Immunology - HTLV-1/HTLV-2 (Ab)

339

EQAS/PT Properties Samples: 4 samples of 0.5 ml Sample Properties: Liquid serum/plasma Additional Information: Cooperation with: Institut für Klinische und Molekulare Virologie, Uniklinikum Erlangen				EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel		
Requirement for EQAS/PT according to Rili-BÄK: not applicable				Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Screening test anti-HTLV-1 / anti-HTLV-2 Confirmation test (Blot and other confirmation test) anti-HTLV-1 / anti-HTLV-2		
Shipping Information: Shipping not cooled				Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.		
Dates	Q1		Q2	Q3		Q4
				June		Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25		27-09-03 27-11-02 27-11-19





Virus Immunology - Measles Virus (Ab)

357

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum		EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Anti-measles virus IgG Anti-measles virus IgG - avidity Anti-measles virus IgM		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Immunology - Mumps Virus (Ab)

356

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum		EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Anti-mumps virus IgG Anti-mumps virus IgG - avidity Anti-mumps virus IgM		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19





Virus Immunology - Parvovirus B19 (Ab)

342

EQAS/PT Properties Samples: 4 samples of 0.5 ml Sample Properties: Liquid serum/plasma		EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-parvovirus B19 IgG Anti-parvovirus B19 IgG - avidity Anti-parvovirus B19 IgM			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Immunology - Rabies Virus (Tollwutvirus) (Ab)

336

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum/plasma (vaccinee)		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Anti-rabies Virus			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
				Sep.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-25 27-08-24 27-09-10	



Virus Immunology - Rubella Virus (Ab)

341

EQAS/PT Properties Samples: 2 samples of 0.8 ml Sample Properties: Liquid serum		EQAS/PT Experts: Prof. Dr. med. Martin Enders Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Anti-rubella virus IgG Anti-rubella virus IgG - avidity Anti-rubella virus IgM		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Immunology - SARS-CoV-2 (Ab)

416

EQAS/PT Properties Samples: 4 samples of 0.5 ml Sample Properties: Liquid serum/plasma		EQAS/PT Experts: Dr. med. Martin Obermeier Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-SARS-CoV-2 total (without differentiation of IgG, IgA and IgM) Anti-SARS-CoV-2 IgG Anti-SARS-CoV-2 IgG avidity (not certified) Anti-SARS-CoV-2 IgA (not certified) Anti-SARS-CoV-2 IgM (not certified) Anti-SARS-CoV-2 Surrogate neutralizing antibodies			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
		Mar.		June	Sep.
Registration Deadline: Sample Shipment: Closing Date:		27-01-08 27-03-09 27-03-26		27-04-09 27-06-08 27-06-25	27-06-25 27-08-24 27-09-10





Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab)

358

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum		EQAS/PT Experts: Dr. Axel Schubert Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 12 months Parameter / Analytes: Anti-TBE/FSME virus IgG Anti-TBE/FSME virus IgG - avidity Anti-TBE/FSME virus IgM			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19



Virus Immunology - Varicella Zoster Virus (Ab)

353

EQAS/PT Properties Samples: 2 samples of 0.5 ml Sample Properties: Liquid serum		EQAS/PT Experts: Prof. Dr. Holger F. Rabenau Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: bi-annual Validity Certificate: 12 months Parameter / Analytes: Anti-VZV IgG Anti-VZV IgG - avidity Anti-VZV IgM		Not subject to Rili-BÄK: not applicable			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material. The participating laboratory must be authorized to perform direct and/or indirect detection of pathogens.			
Dates	Q1		Q2	Q3	
				June	Nov.
Registration Deadline: Sample Shipment: Closing Date:				27-04-09 27-06-08 27-06-25	27-09-03 27-11-02 27-11-19





EQAS/PT Properties Samples: 2 samples of 0.3 ml Sample Properties: Liquid serum (inactivated in case of Zika virus RNA positive samples) Additional Information: Cooperation with: WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Nationales Referenzzentrum für tropische Infektionserreger, Bernhard-Nocht-Institut für Tropenmedizin, Hamburg		EQAS/PT Experts: Prof. Dr. med. Jonas Schmidt-Chanasit Deputy EQAS/PT Experts: Dr. rer. nat. Martin Kammel			
Requirement for EQAS/PT according to Rili-BÄK: not applicable		Not subject to Rili-BÄK Validity Certificate: 24 months Parameter / Analytes: Anti-ZIKV IgG Anti-ZIKV IgG - avidity Anti-ZIKV IgM			
Shipping Information: Shipping not cooled		Safety Information: Process as patient sample material			
Dates	Q1		Q2	Q3	
				Sep.	
Registration Deadline: Sample Shipment: Closing Date:				27-06-25 27-08-24 27-09-10	



Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. med. Nicolas Ahsen, von

Zentrallaboratorien der Kliniken Bremen-Mitte, Bremen-Nord, Bremen-Ost und Links der Weser
Gesundheit Nord Klinikverbund Bremen gGmbH
Klinikum Links der Weser
Senator-Weßling-Straße 1, Bremen

T +49 421 879 4557
E nicolas.vonahsen@gesundheitnord.de

Herr Dr. Sönke Andres

Forschungszentrum Borstel
Nationales Referenzzentrum für Mykobakterien
Parkallee 38, Borstel

T +49 4537 188 6480
E sandres@fz-borstel.de

Herr Dr. med. Harald Bartsch

Gemeinschaftspraxis für Pathologie Traunstein
Cuno-Niggel-Str. 3, Traunstein

T +49 211-1592 13 0
E harald.bartsch@instand-ringversuch.de

Herr Dr. rer. nat. Martin Blüthner

MVZ Labor PD Dr. Volkmann und Kollegen SE & Co.
eGbR

Gerwigstrasse 67, Karlsruhe

T +49 721 85000 225
E bluethner@laborvolkmann.de

Frau Prof. Dr. Iris Bruchhaus

Bernhard-Nocht-Institut für Tropenmedizin
Bernhard-Nocht-Straße 74, Hamburg

T +49 40 285380-472
E bruchhaus@bniitm.de

Frau MSc. Simone Ahting

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig

T +49 341 97 20596
E simone.ahting@medizin.uni-leipzig.de

Herr PD Dr. rer. nat. Oliver Bader

Institut für Medizinische Mikrobiologie und Virologie
Universitätsmedizin Göttingen
Kreuzberggring 57, Göttingen

T +49 551 3965403
E obader@gwdg.de

Herr Prof. Dr. med. Hannsjörg Baum

IN STAND e.V.

Ubierrstraße 20, Düsseldorf

T +49 211-1592 13 0
E hannsjoerg.baum@instand-ringversuch.de

Herr Dr. Gernot Brauers

Uniklinikum Düsseldorf

Moorenstr. 5, Düsseldorf

T +49 211-1592 13 0
E gernot.brauers@med.uni-duesseldorf.de

Herr Dr. med. vet. Heiner Buttler, von

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

T +49 992692 3894
E heinervonbuttlar@bundeswehr.org

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. rer. nat. Morten O. Christensen

Gerinnungszentrum Rhein-Ruhr
Ambulanz und Fachlaboratorium für
Gerinnungserkrankungen/Hämophilie
Königstraße 13, Duisburg

T +49 203 348 336 24
E morten.christensen@gzrr.de

Frau Dr. rer. biol. hum. Andrea Dick

LMU Klinikum
Abteilung für Transfusionsmedizin, Zelltherapeutika und
Hämostaseologie
Elisabeth-Winterhalter-Weg 15, München

T +49 89 44007 7403
E andrea.dick@med.uni-muenchen.de

Herr Prof. Dr. rer. nat. Dr. med. Jürgen Durner

Labor Becker MVZ GbR
Führichstr. 70, München

T +49 89 450 917 349
E j.durner@labor-becker.de

Herr Prof. Dr. med. Martin Enders

Labor Prof. G. Enders & Kollegen, MVZ
Medizinische Diagnostik
Rosenbergstr. 85, Stuttgart

T +49 711-6357 120
E martin.enders@instand-ringversuch.de

Frau Dr. ssa Rosanna Falbo

University Department of Laboratory Medicine
University Milano Bicocca
Piazza dell'Ateneo Nuovo, 1, Milano
Italien
T +39 362-385312
E rosanna.falbo@asst-brianza.it

Herr Dr. rer. nat. Manfred Falck

IN STAND e.V.
Udierstraße 20, Düsseldorf
T +49 211 178 355 20
E manfred.falck@instand-ringversuch.de

Herr Dr. med. Volker Fingerle

Nationales Referenzzentrum für Borrelien
Bayerisches Landesamt für Gesundheit und
Lebensmittelsicherheit (LGL)
Veterinärstraße 2, Oberschleißheim

T +49 9131 6808 5870
E volker.fingerle@lgl.bayern.de

Herr Prof. Dr. med. Willy A. Flegel

Chief, Laboratory Services Section
DTM/CC/NIH
, Bethesda MD 20892-1184
USA
T +1 301 5947 401
E willy.flegel@instand-ringversuch.de

Herr Dr. rer. nat. Ralf-Rüdiger Flörke

Am Lindenbruch 48, Essen

T +49 160 2131 052
E ralf.florke@instand-ringversuch.de

Herr PD Dr. med. Dimitrios Frangoulidis

Institut für Mikrobiologie der Bundeswehr

Neuherbergstraße 11, München

T +49 89 992692 3869
E dimitriosfrangoulidis@bundeswehr.org

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. Roman Fried

MQ Zürich, Universitätsspital Zürich
Institut für Klinische Chemie
Rämistrasse 100, Zürich
Schweiz
T +41 44 255 3518
E roman.fried@usz.ch

Frau Dr. med. Claudia Frömmel

MDI Limbach Berlin GmbH
Aroser Allee 84, Berlin
T +49 30 443364 535
E claudia.froemmel@instand-ringversuch.de

Herr Prof. Dr. med. Winfried Gassmann

St. Marienkrankenhaus
Medizinische Klinik III
Kampenstr. 51, Siegen
T +49 271 231 1300
E w.gassmann@mariengesellschaft.de

Herr Dr. rer. nat. Walter Geißdörfer

Mikrobiologisches Institut - Klinische Mikrobiologie,
Immunologie und Hygiene
Universitätsklinikum Erlangen
Wasserturmstraße 3-5, Erlangen
T +49 9131 85 22668
E walter.geissdoerfer@uk-erlangen.de

Herr Prof. Dr. Dr. med. André Gessner

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg
T +49 941 944 6400
E andre.gessner@ukr.de

Frau Ulyana Gräf

Krankenhaus Nordwest
Zentralinstitut für Labormedizin, Mikrobiologie &
Krankenhaushygiene
Steinbacher Hohl 2-26, Frankfurt
T +49 69-7601 3646
E graef.ulyana@khnw.de

Herr PD Dr. rer. nat. Gregor Grass

Institut für Mikrobiologie der Bundeswehr
Neuherbergstraße 11, München
T +49 992692 2806
E gregorgrass@bundeswehr.org

Herr Prof. Dr. med. Kai Gutensohn

IN STAND e.V.
Ublerstraße 20, Düsseldorf
T +49 160 1549548
E kai.gutensohn@instand-ringversuch.de

Herr Prof. Dr. med. Gerhard Haase

Labordiagnostisches Zentrum - Bereich Mikrobiologie
Universitätsklinikum RWTH Aachen
Pauwelsstraße 30, Aachen
T +49 241 8089 515/510
E ghaase@ukaachen.de

Herr Prof. Dr. med. Dr. rer. nat. Ekkehard Haen

Klinische Pharmakologie am Lehrstuhl für Psychiatrie
und Psychotherapie
und am Lehrstuhl für Pharmakologie und Toxikologie der
Universität und am Institut AGATE gGmbH
Nelkenweg 10, Pentling
T +49 178 204 3288
E ekkehard.haen@klinik.uni-regensburg.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. med. Dr. phil. Torsten Haferlach

MLL Münchner Leukämielabor GmbH

Max-Lebsche-Platz 31, München

T +49 89 99017 100

E torsten.haferlach@mll.com

Herr Dr. Gerulf Hänel

Klinikum der Universität München

Labor für Leukämiediagnostik

Marchioninstr. 15, München

T +49 89 - 2180 76835

E haenel@genzentrum.lmu.de

Herr Prof. Dr. Dr. med. Fabian Hauck

LMU Klinikum

Dr. von Haunersches Kinderspital

Lindwurmstr. 4, München

T +49 89 4400-53931

E fabian.hauck@med.uni-muenchen.de

Herr PD Dr. med. Albert Heim

Institut für Virologie

Medizinische Hochschule Hannover

, Hannover

T +49 511-5324311

E adenovirus@gmx.de

Frau PD Dr. rer.nat. Julia Hentschel

Institut für Humangenetik

Universitätsklinikum Leipzig AöR

Philipp-Rosenthal-Str. 55, Leipzig

T +49 341 97 11349

E julia.hentschel@instand-ringversuch.de

Herr PD Dr. Andreas Hiergeist

Institut für Klinische Mikrobiologie und Hygiene

Universitätsklinikum Regensburg

Franz-Josef-Strauß-Allee 11, Regensburg

T +49 941 944 16465

E andreas.hiergeist@ukr.de

Frau Dr. med. Britta Höchsmann

Institut für Klinische Transfusionsmedizin und

Immungenetik Ulm (IKT)

Helmholtzstraße 10, Ulm

T +49 731 150 560

E b.hoechsmann@blutspende.de

Herr Prof. Dr. Jörg Hofmann

IN STAND e.V.

Urbierstraße 20, Düsseldorf

T +49 30 8105 4300

E joerg.hofmann@instand-ringversuch.de

Herr Prof. Dr. med. Stefan Holdenrieder

Institut für Laboratoriumsmedizin

TUM Universitätsklinikum - Deutsches Herzzentrum

München

Lazarettstraße 36, München

T +49 89 1218 1011

E stefan.holdenrieder@instand-ringversuch.de

Herr Prof. Dr. med. Achim Hörauf

Institut für Medizinische Mikrobiologie, Immunologie und

Parasitologie

Universitätsklinikum Bonn

Sigmund-Freud-Straße 25, Bonn

T +49 228 287 15675

E immip.office@ukbonn.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. Marc Hübner

Universitätsklinikum Bonn
Institut für Medizinische Mikrobiologie, Immunologie und
Parasitologie (IMMIP)
Venusberg-Campus 1, Bonn

T +49-228-287-19177
E huebner@uni-bonn.de

Herr Prof. Dr. med. Andreas Humpe

Klinikum der Universität München, Campus Großhadern
Abteilung für Transfusionsmedizin, Zelltherapeutika und
Hämostaseologie
Marchioninistraße 15, München

T +49 89 4400 7 3701
E andreas.humpe@med.uni-muenchen.de

Herr Prof. Dr. med. Klaus-Peter Hunfeld

Zentralinstitut für Labormedizin, Mikrobiologie &
Krankenhaushygiene
Krankenhaus Nordwest
Steinbacher Hohl 2-26, Frankfurt am Main

T +49 69 7601 4349
E hunfeld.klaus-peter@khnw.de

Frau Dr. rer. nat. Eva-Maria Jacobsen

Diagnostische Laboratorien der Universitätsklinik für
Kinder- und Jugendmedizin Ulm

Eythstr. 24, Ulm

T +49 731 500 57202
E eva-maria.jacobsen@uniklinik-ulm.de

Frau Dr. Patricia KaiserP

IN STAND e.V.

Udierstraße 20, Düsseldorf

T +49 211-1592 13 210
E kaiser@instand-ev.de

Herr Dr. rer. nat. Rolf KaiserR

Institut für Virologie
Universität und Universitätsklinikum zu Köln
Fürst-Pückler-Straße 56, Köln

T +49 221 478-85808
E rolf.kaiser@uk-koeln.de

Herr Dr. rer. nat. Martin Kammel

Institut für Qualitätssicherung in der Virusdiagnostik -
IQVD

Potsdamer Chaussee 80, Berlin

T +49 30 8105 4300
E m.kammel@iqvd.de

Herr Dr. med. Günther Kappert

Gerinnungszentrum Rhein-Ruhr

Königstraße 13, Duisburg

T +49 203 348 336 0
E guenther.kappert@gzrr.de

Herr Prof. Dr. med. Wolfgang Kern

MLL Münchner Leukämie Labor GmbH

Max-Lebsche-Platz 31, München

T +49 89 99017 200
E wolfgang.kern@mll.com

Frau Irina Keßel

MVZ Düsseldorf-Centrum GbR

Immermannstraße 65A, Düsseldorf

T +49 162 211 4792
E irina.kessel@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. Michael Kirschfink

INSTAND e.V.

Udierstraße 20, Düsseldorf

T +49 211-1592 13 0

E kirschfink@uni-hd.de

Frau Dr. rer. nat. Kerstin Knies

Universität Würzburg - Institut für Virologie und Immunbiologie

c/o INSTAND e.V.

Udierstr. 20, Düsseldorf

T +49 211-1592 13 0

E kerstin.knies@uni-wuerzburg.de

Herr Dr. Uwe Kölsch

IMD Institut für Medizinische Diagnostik Berlin-Potsdam GbR

Nicolaistraße 22, Berlin-Steglitz

T +49 30 77001322

E u.koelsch@imd-berlin.de

Herr Dipl.-Ing. (FH) Udo Kramer

INSTAND e.V.

Udierstraße 20, Düsseldorf

T +49 211-1592 13 220

E kramer@instand-ev.de

Herr Prof. Dr. med. Karl-Anton Kreuzer

Universitätsklinikum Köln

Innere Medizin I

Kerpener Straße 62, Köln

T +49 221 478 97626

E karl-anton.kreuzer@uni-koeln.de

Herr Dr. med. Hartmut Kroll

Institut für Transfusionsmedizin Dessau

DRK-Blutspendedienst NSTOB

Altener Damm 50, Dessau

T +49 340 54141 110

E hartmut.kroll@bsd-nstob.de

Herr Dr.-Ing. Nils Lachmann

Charité-Universitätsmedizin Berlin, ZTB-Zentrum für Transfusionsmedizin und Zelltherapie Berlin gGmbH, Gewebetypisierung am Campus Virchow-Klinikum Augustenburger Platz 1, Berlin

T +49 30 450 665 098

E nils.lachmann@instand-ringversuch.de

Herr Dr. med. Marc Lindenberg

Medizinische Hochschule Hannover

Institut für Medizinische Mikrobiologie und

Krankenhaushygiene

Carl-Neuberg-Straße 1, Hannover

T +49 511 532 19521

E lindenberg.marc@mh-hannover.de

Herr Dr. med. Benedikt Lohr

St. Vincenz-Krankenhaus Limburg

Auf dem Schafsberg, Limburg

T +49 6431-292 7620

E benedikt.lohr@instand-ringversuch.de

Frau Dr. rer. nat. Eva Lorsy

Universitätsklinikum Köln

Kerpener Straße 62, Köln

T +49 221 478 98828

E eva.lorsy@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Prof. Dr. med. Peter B. Lupp

Institut für Laboratoriumsmedizin
TUM Universitätsklinikum Rechts der Isar
Ismaninger Straße 22, München

T +49 211-1592 13 0
E p.lupp@tum.de

Herr Dr. med. Thomas Lutz

MVZ Düsseldorf-Centrum GbR
Immermannstraße 65A, Düsseldorf

T +49 211 27101 1326
E lutz@zotzklimas.de

Frau Dr. Marie Mayrhofer

MVZ Labor PD Dr. Volkmann und Kollegen SE & Co.
eGbR

Gerwigstrasse 67, Karlsruhe

T +49 721 85000 226
E m.mayrhofer@laborvolkmann.de

Frau Ilka McCormick Smith

Robert Koch-Institut
FG 16 Erreger von Pilz- und Parasiteninfektionen und
Mykobakterien
Seestraße 10, Berlin

T +49 30 18754 2184
E mccormick-smithl@rki.de

Frau Dr. med. Adriana Méndez

Kantonsspital Baden AG

, Baden
Schweiz

T +41 56 486 26 41
E adriana.mendez@ksb.ch

Herr Prof. Dr. med. Matthias Nauck

Institut für Klinische Chemie und Laboratoriumsmedizin
Universitätsmedizin Greifswald
Körperschaft des öffentlichen Rechts
Ferdinand-Sauerbruch-Straße, Greifswald

T +49 3834 86 5500
E matthias.nauck@med.uni-greifswald.de

Herr Dr. med. Thomas Nebe

INSTAND e.V.

Ubierstraße 20, Düsseldorf

T +49 621 4373 2991
E instand@instand-ev.de

Herr Prof. Dr. med. Pietro Nenoff

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof.
Dr. P. Nenoff, T. Löwe, E. von Rein
Mölbiser Hauptstraße 8, Rötha/OT Mölbis

T +49 34347 6191-0
E p.nenoff@labopart.de

Herr Dr. rer. nat. Stefan Neubeck

Medizinische Universität Lausitz □ Carl Thiem
Institut für Laboratoriumsmedizin
Thiemstraße 111, Cottbus

T +49 355 46 3304
E s.neubeck@mul-ct.de

Herr Dr. med. Christoph Niederau

MVZ Labor Dortmund Leopoldstraße GmbH
Leopoldstraße 10, Dortmund

T +49 231 860 27 0
E christoph.niederau@labor-dortmund.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. med. Martin Obermeier

MVZ medizinisches Infektiologiezentrum Berlin AG

Oudenarder Strasse 16, Berlin

T +49 30-34409104-66

E obermeier@mvz-mib.de

Frau Dr. Michaela Patz

Universitätsklinikum Köln

Kerpener Straße 62, Köln

T +49 221 478 32569

E michaela.patz@uk-koeln.de

Frau Prof. Dr. med. Dipl.-Biol. Astrid Petersmann

Universitätsmedizin Oldenburg, Klinikum Oldenburg AöR
Universitätsinstitut für Klinische Chemie und
Laboratoriumsmedizin
Rahel-Straus-Str. 10, Oldenburg

T +49 441-403-2601

E astrid.petersmann@instand-ringversuch.de

Herr Prof. Dr. Zoltan Prohaszka

Semmelweis University
Department of Internal Medicine and Hematology
Szentkirályi st. 46, Budapest
Ungarn

T +361 3251379

E prohaszka.zoltan@semmelweis.hu

Herr Prof. Dr. Holger F. Rabenau

Institut für Medizinische Virologie
Universitätsklinikum Frankfurt
Paul-Ehrlich-Str. 40, Frankfurt

T +49 211-1592 13 0

E holger.rabenau@instand-ringversuch.de

Herr Dr. med. Roland Reibke

Klinik Bad Trissl GmbH
Abteilung für Innere Medizin I und Palliativmedizin
Bad-Trissl-Straße 73, Bad Trissl

T +49 80 33 20-285

E roland.reibke@klinik-bad-trissl.de

Herr Prof. Dr. rer. nat. Udo Reischl

Institut für Klinische Mikrobiologie und Hygiene
Universitätsklinikum Regensburg
Franz-Josef-Strauß-Allee 11, Regensburg

T +49 941 944 6450

E udo.reischl@instand-ringversuch.de

Herr Prof. Dr. med. Karl H. Reuner

Medizinische Universität Lausitz □ Carl Thiem
Institut für Laboratoriumsmedizin
Thiemstraße 111, Cottbus

T +49 355 46-2480

E k.reuner@mul-ct.de

Herr PD Dr. med. Volker Rickerts

Robert Koch-Institut
FG 16 Erreger von Pilz- und Parasiteninfektionen und
Mykobakterien
Seestraße 10, Berlin

T +49 30 18754 2208

E rickertsv@rki.de

Herr Florian Ridders

Klinische Pharmakologie am Lehrstuhl für
Pharmakologie und Toxikologie der Universität

Universitätsstr. 31, Regensburg

T +49 941 943 4766

E florian.ridders@klinik.uni-regensburg.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. med Martin Roskos

MVZ SYNLAB Leverkusen GmbH
Paracelsus Straße 13, Leverkusen
T +49 214 374 - 24892
E martin.roskos@synlab.com

Herr Prof. Dr. med. Ulrich Sachs

Justus-Liebig-Universität Gießen
Institut für Klinische Immunologie und
Transfusionsmedizin
Langhansstraße 7, Gießen
T +49 641 985 41514
E ulrich.sachs@instand-ringversuch.de

Herr Prof. Dr. med. Ulrich Sack

Universitätsklinikum Leipzig AöR
Institut für Klinische Immunologie
Johannisallee 30, Leipzig
T +49 341 972 5500
E ulrich.sack@instand-ringversuch.de

Herr Dr. med. Richard Schabath

Praxis für Hämatologie und Onkologie Berlin Mitte
Friedrichstraße 113A, Berlin
T
E richard@schabath.de

Herr Prof. Dr. rer. nat. Ingo Schellenberg

IN STAND e.V.
Udierstraße 20, Düsseldorf
T +49 211-1592 13 120
E schellenberg@instand-ev.de

Herr Prof. Dr. med. Dirk Schlüter

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und
Krankenhausthygiene
Carl-Neuberg-Straße 1, Hannover
T +49 511 532 0
E dirk.schluter@instand-ringversuch.de

Herr Prof. Dr. med. Jonas Schmidt-Chanasit

Bernhard-Nocht-Institut für Tropenmedizin
Nationales Referenzzentrum für tropische
Infektionserreger Kooperationszentrum der WHO für
Arboviren
Bernhard-Nocht-Strasse 74, Hamburg
T +49 40 285380 271
E schmidt-chanasit@bniitn.de

Frau Dr. rer. nat. Heike Schneider

Institut für Klinische Chemie und Pathobiochemie
TUM-Klinikum Rechts der Isar AöR
Ismaninger Straße 22, München
T +49 89 4140 5252
E heike.schneider@instand-ringversuch.de

Herr Prof. Dr. rer. nat. Holger C. Scholz

Robert Koch-Institut
Abteilung ZBS 2
Nordufer 20, Berlin
T +49 211-1592 13 0
E scholz@rki.de

Frau Dr. rer. nat. Susanna Schubert

Institut für Humangenetik
Universitätsklinikum Leipzig AöR
Philipp-Rosenthal-Str. 55, Leipzig
T
E susanna.schubert@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. Axel Schubert

IN STAND e.V.

UdierstraÙe 20, Düsseldorf

T +49 211-15 92 13 720

E schubert@instand-ev.de

Herr Dr. Torsten J. Schulze

Institut Springe

Eldagsener StraÙe 38, Springe

T +49 5041 772 □ 533

E torsten.schulze@bsd-nstob.de

Frau Dr. Steffi Silling

Nationales Referenzzentrum für Papillom- und Polyomaviren

Institut für Virologie Uniklinik Köln

Fürst-Pückler-StraÙe 56, Köln

T +49 221-47885811

E steffi.silling@instand-ringversuch.de

Herr Prof. Dr. med. Michael Spannagl

IN STAND e.V.

UdierstraÙe 20, Düsseldorf

T +49 211-1592 13 125

E m.spannagl@instand-ev.de

Herr Prof. Dr. med. Werner Steimer

Institut für Laboratoriumsmedizin

TUM Klinikum Rechts der Isar

IsmaningerstraÙe 22, München

T +49 89 30659957

E werner.steimer@instand-ringversuch.de

Frau Prof. Dr. Marion Subklewe

Ludwig-Maximilians-Universität München

Gene Center Laboratory for Translational Cancer

Immunology

Feodor-Lynen-StraÙe 25, München

T +49 89 - 4400 73133

E marion.subklewe@med.uni-muenchen.de

Herr Prof. Dr. med. Egbert Tannich

IN STAND e.V.

UdierstraÙe 20, Düsseldorf

T +49 211-1592 13 0

E egbert.tannich@hamburg.de

Herr Prof. Dr. med. Jörg Timm

Universitätsklinikum Düsseldorf

Heinrich-Heine-Universität

Moorenstr. 5, Düsseldorf

T +49 211-81-12225

E joerg.timm@med.uni-duesseldorf.de

Frau M.Sc. Luisa Toll

IN STAND e.V.

UdierstraÙe 20, Düsseldorf

T +49 211-1592 13 380

E toll@instand-ev.de

Herr Prof. Dr. med. Dr. rer. nat. Manfred Uhr

Max-Planck-Institut für Psychiatrie

KraepelinstraÙe 2-10, München

T +49 89 30622 8035

E manfred.uhr@instand-ringversuch.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Frau Dr. rer. med. Silke Uhrlaß

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof.
Dr. P. Nenoff, T. Löwe, E. von Rein
Mölbiser Hauptstraße 8, Rötha/OT Mölbis

T +49 34347 6191-259
E s.uhrlaß@labopart.de

Herr PD Dr. med. Franz F. Wagner

DRK-Blutspendedienst NSTOB
Eldagsener Straße 38, Springe

T +49 5041 772 172
E fwagner@bsd-nstob.de

Herr Prof. Dr. med. Michael S. Weig

Institut für Medizinische Mikrobiologie
Universitätsmedizin Göttingen
Kreuzberggring 57, Göttingen

T +49 551 39 67099
E mweig@gwdg.de

Herr Dr. med. Christof Weinstock

DRK-Blutspendedienst Baden-Württemberg
Hessen gemeinnützige GmbH
Helmholtzstraße 10, Ulm

T +49 731 150 600
E c.weinstock@blutspende.de

Frau Dr. Nathalie Weiss

IN STAND e.V.
Ubierstraße 20, Düsseldorf

T +49 211-1592 13 430
E weiss@instand-ev.de

Herr Prof. Dr. med. Folker Wenzel

Fakultät Medical and Life Sciences
Campus Villingen-Schwenningen
Jakob-Kienzle-Str. 17, Villingen-Schwenningen

T +49 7720 307 4358
E wenzel@instand-ev.de

Frau PD Dr. rer. nat. et med. habil Cornelia Wiegand

Klinik für Hautkrankheiten Universitätsklinikum Jena
Dermatologisches Forschungslabor
Am Klinikum 1, Jena

T +49 3641 9328878
E c.wiegand@med.uni-jena.de

Herr Dr. med. Georg Wittmann

Labor Becker MVZ eGmbH
Führichstr. 70, München

T +49 89 450917-395
E g.wittmann@labor-becker.de

Frau Sükran Zaralioglu

Charité-Universitätsmedizin Berlin, ZTB-Zentrum für
Transfusionsmedizin
und Zelltherapie Berlin gGmbH, Gewebetypisierung am
Campus Virchow-Klinikum
Augustenburger Platz 1, Berlin

T +49 30 450 665 098
E suekran.zaralioglu@charite.de

Frau Prof. Dr. med. Inga Zerr

Nationales Referenzzentrum für TSE
Klinik für Neurologie Universitätsmedizin Göttingen
Robert-Koch-Straße 40, Göttingen

T +49 551 39 61805
E ingazerr@med.uni-goettingen.de

Addresses EQAS/PT Experts and Deputy EQAS/PT Experts

Herr Dr. med. Stefan Ziesing

Medizinische Hochschule Hannover
Institut für Medizinische Mikrobiologie und
Krankenhaushygiene
Carl-Neuberg-Straße 1, Hannover

T +49 511 532 4344

E ziesing.stefan@mh-hannover.de

Herr Dr. rer. nat. Thomas Zimmermann

labopart - Medizinische Laboratorien
Partnerschaft Dr. M. Gerber, Prof. Dr. F. Bühling, Prof.
Dr. P. Nenoff, T. Löwe, E. von Rein
Wurzener Straße 5, Dresden

T +49 351 210799 211

E th.zimmermann@labopart.de

INDEX

SYMBOL

(d-)Methamphetamine (urine) (176) 151

1

1,25 dihydroxy vitamin D (290) 159
 1,25-OH Cholecalciferol (serum) (290) 159
 1-39 ACTH (298) 105
 1-84 PTH (301) 106
 10-OH-Carbamazepine (192, 860) 128, 136
 17-beta-Estradiol (302) 109
 17-Hydroxyprogesterone (dried blood spots) (785) 125
 17-Hydroxyprogesterone (serum / plasma) (309) 111

2

21-hydroxylase deficiency (DNA) (773) 33
 25-Hydroxy-Cholecalciferol (290) 159
 25-Hydroxy-Vitamin-D (290) 159
 25-OH CCF (Vitamin D) (290) 159

3

3-Methoxytyramine (175) 155

4

4-Hydroxyproline (710) 113

5

5-HIAA (175) 155
 5-Hydroxyindolea acid (175) 155

9

9-OH-Risperidone (862) 137

A

A - Subtyping (Machine-based, whole blood) (237, 83, 83
 A - Subtyping (serum / erythrocytes suspension) (231, 232) 81, 81
 A B 0 - system (DNA) (235) 26
 A B 0 characteristics, Rhesus type (Machine-based, whole blood) (237, 238) 83, 83
 A B 0 characteristics, Rhesus type (serum / erythrocytes suspension) (231, 232) 81, 81
 a1-Antitrypsine (241) 143
 a1-AT S-Locus (743) 28
 a1-AT Z-Locus (743) 28
 a1-Globulins (141) 120
 a1-Globulins (electrophoresis, Serum) (102) 115

a1-Glycoprotein (241) 143
 A1298C (DNA) (747) 42
 A1298C (whole blood, Dna) (732) 42
 A149P (793) 27
 A174D (793) 27
 a1PI (743) 28
 a2-Globulins (141) 120
 a2-Globulins (electrophoresis, Serum) (102) 115
 a2-Makroglobulin (241) 143
 A20 (plasma) (509) 103
 AAT (743) 28
 ACE (630) 113
 ACE INS/DEL (DNA) (763) 28
 acetaminophen (194) 135
 Acid phosphatase (100) 115
 Acid-fast bacilli (Slide) (421) 188
 ACT (286) 102
 activated clotting time (286) 102
 Activated partial thromboplastin time (221, 230, 280, 94, 95, 102,
 Acute myeloid leukemia (798) 57
 Adenoviruses (cell culture lysate) (371, 431, 433) 199, 221, 224
 Adenoviruses (suspensions of feces) (430) 206
 ADHS-Treatment (879) 135
 aDNase (321) 181
 Adrenal Gland (298) 105
 Aeromonas spp (548) 168
 AFP (Pregnancy) (306) 107
 AFP (tumor marker) (292) 149
 Alanine (710) 113
 ALAT (100, 810) 115, 145
 Albumin (CSF) (460) 124
 Albumin (electrophoresis, Serum) (102) 115
 Albumin (POCT: Abaxis Piccolo) (810) 145
 Albumin (serum) (100, 141) 115, 120
 Albumin (urine) (171, 182) 156, 158
 Albumin quotient (CSF / serum) (460) 124
 Alcohol (750, 751) 119, 152
 ALDOB (793) 27
 Aldolase (serum) (100) 115
 Aldolase B (A149P, A174D, N334K) (DNA) (793) 27
 Aldolase B (DNA) (793) 27
 Aldosterone (serum) (304) 105
 Aldosterone (urine) (179) 155
 Alkaline Phosphatase (100, 810) 115, 145
 Allergy Diagnostic (basophils, EDTA-whole blood) (653) 70
 Allergy Diagnostic (IgE, serum) (720) 62
 allo-Isoleucine (710) 113
 alpha-1-Microglobulin (urine) (182) 158
 alpha-2-macroglobulin (urine) (182) 158
 alpha-Aminoadipic acid (710) 113
 alpha-Amylase (POCT: Abaxis Piccolo) (810) 145
 alpha-Amylase (serum) (100) 115
 alpha-Amylase (urine) (173) 157
 Alpha-Fetoprotein (306) 107

INDEX

alpha-Globin (DNA) (794)	27	Anti - ds-DNA (251)	64
alpha1-Antitrypsin (743)	28	Anti - Endomysium (271)	65
alpha1-proteinase-Inhibitor (743)	28	Anti - Glia Cell Nuclear Antibody (AGNA) (265)	67
Alprazolam (876)	133	Anti - Gliadin (271)	65
ALT (100, 810)	115, 145	Anti - glomerular basement membrane (GBM) (serum) (257)	69
Alternative pathway (246)	80	Anti - Glutamic Acid Decarboxylase (GAD) (261)	65
Aluminium (plasma) (206)	147	Anti - H+/K+-ATPase (253)	66
Aluminium (urine) (205)	153	Anti - HAV (serum) (343)	233
AMH (297)	106	Anti - HBc (serum) (344)	233
Amicacin (197)	138	Anti - HBc-IgM (serum) (345)	234
Amino Acid Analysis (710)	113	Anti - HBe (serum) (345)	234
Aminolaevulinic acid (urine) (180)	154	Anti - HBs (serum) (344)	233
Amiodarone (190)	126	Anti - HCV (serum) (346)	234
Amisulpride (861, 873)	131, 136	Anti - HDV (serum) (347)	235
Amitriptyline (serum) (199, 203, 863)	137, 140, 141	Anti - Hemidesmosomes (259)	63
Amitriptyline (urine) (204)	153	Anti - HEV (serum) (348)	235
AML-Panel (NGS) (798)	57	Anti - HIV-1 (serum) (335)	237
Ammonia (118)	114	Anti - HIV-2 (serum) (335)	237
Amoebiasis (455)	194	Anti - HSV (serum) (354)	236
Amphetamine (urine) (174)	150	Anti - HTLV-1 (serum) (339)	237
Ampicillin (890)	127	Anti - HTLV-2 (serum) (339)	237
AMR (544)	162	Anti - HuD (serum) (265)	67
Amyloid β Peptid 40 (A β 40) (466)	121	Anti - Insulin (IAA) (261)	65
Amyloid β Peptid 42 (A β 42) (466)	121	Anti - Islet Cells (ICA) (261)	65
Amyloid β Peptid Ratio (A β 42/40) (466)	121	Anti - Jo 1 (Histidyl-tRNA-Synthetase) (255)	64
ANA (251)	64	Anti - MCV (mutated citrullinated Vimentin) (273)	69
ANCR (DNA) (786)	45	Anti - measles virus (serum) (357)	238
Androstendion (309)	111	Anti - Microsomes (LKM 1) (253)	66
Angelman syndrome (AS) (DNA) (786)	45	Anti - Mikrosomen (295)	110
Angiotensin Converting Enzym Apolipoprotein (DNA) (763)	28	Anti - Mitochondria (253)	66
Angiotensin-Converting-Enzyme (630)	113	Anti - Monosialoganglioside (GM1) (267)	68
Anthrax (542)	164	Anti - Monosialoganglioside (GM2) (267)	68
Anti - P450 C17 -Hydroxylase (263)	63	Anti - Monosialoganglioside (GM3) (267)	68
Anti - Acetylcholin Receptors (269)	66	Anti - MPO (257)	69
Anti - Actin (253)	66	Anti - Mullerian hormone (297)	106
Anti - Adrenal Cortex (263)	63	Anti - mumps virus (serum) (358)	241
Anti - Amphiphsin 1 (265)	67	Anti - Musclespecific Receptor Tyrosinkinase (MuSK) (269)	66
Anti - Asialoganglioside (AGA1) (267)	68	Anti - Myelin-associated Glycoprotein (MAG) (267)	68
Anti - Borna virus (415)	230	Anti - Neuronal Nuclei (265)	67
Anti - BPAg-1 (259)	63	Anti - P450 C21 -Hydroxylase (263)	63
Anti - BPAg-2 (259)	63	Anti - P450 ssc -Hydroxylase (263)	63
Anti - C1 inhibitor (250)	77	Anti - Parietal Cells (253)	66
Anti - Cardiolipin (IgG) (275)	62	Anti - parvovirus B19 (serum) (342)	239
Anti - Cardiolipin (IgM) (275)	62	Anti - PM / Scl (255)	64
Anti - CCP (cyclic citrulline peptide) (273)	69	Anti - PR3 (257)	69
Anti - CHIKV (cell culture lysate) (402)	230	Anti - Purkinje Cells (265)	67
Anti - CMV (serum) (351)	231	Anti - Quadrosialoganglioside (GQ1b) (267)	68
Anti - deamidated Gliadin (271)	65	Anti - rabies Virus (serum) (336)	239
Anti - dengue virus (serum) (350)	231	Anti - Ri / Nova 1 (265)	67
Anti - Desmoglein-1 (259)	63	Anti - rubella virus (serum) (341)	240
Anti - Desmoglein-3 (259)	63	Anti - Skeletal Muscle (269)	66
Anti - Desmoplakin I/II (259)	63	Anti - Sm (255)	64
Anti - Desmosomes (serum) (259)	63	Anti - Sm (D) (255)	64
Anti - DFS70/LEDGF (251)	64	Anti - Smooth Muscle (253)	66
Anti - Disialoganglioside (GD1a) (267)	68	Anti - SOX1 (265)	67
Anti - Disialoganglioside (GD1b) (267)	68	Anti - SSA / Ro (255)	64
		Anti - SSA / Ro (52kD - Proteins) (255)	64



INDEX

Anti - SSA / Ro (60kD - Proteins) (255)	64	Antibodies against Treponema pallidum (serum) (311)	182
Anti - SSB / La (255)	64	Antibodies against Yersinia (serum) (315)	183
Anti - streptodornase (serum) (321)	181	Antibody ID (Machine-based, whole blood) (237, 238)	83, 83
Anti - streptolysin O (serum) (321)	181	Antibody ID (serum / erythrocytes suspension) (232)	81
Anti - Ta (Ma 2) (265)	67	Antibody Identification (232, 237, 238)	81, 83, 83
Anti - TBE/FSME (serum) (358)	241	Antibody quantitation (Machine-based, whole blood) (238)	83
Anti - Titin (269)	66	Antibody quantitation (serum / erythrocytes suspension) (232)	81
Anti - Topoisomerase-1 (Scl 70) (255)	64	Antibody Screening (Machine-based, whole blood) (237, 238)	83, 83
Anti - TPO (295)	110	Antibody Screening (serum / erythrocytes suspension) (231, 232)	81, 81
Anti - Transglutaminase IgA (271)	65	Antibody titer (232)	81
Anti - Trisialoganglioside (GT1b) (267)	68	anticoagulant (230, 282, 501, 502, 503, 504, 505)	94, 94, 96, 97,
Anti - Tyreoglobulin (295)	110	Anticonvulsants (191, 192, 871, 872)	127, 128, 128,
Anti - Tyrosine Phosphatase (IA2) (261)	65	Antifungals (198, 602)	129, 130
Anti - U1 -snRNP (Anti - U1 -70K) (255)	64	Antimon (lyophilized whole blood) (208)	146
Anti - VZV (serum) (353)	241	Antimon (serum) (207)	147
Anti - Yo (CDR62) (265)	67	Antiphospholipid Syndrome (275)	62
Anti - ZIKV (serum) (338)	242	Antipsychotic Drugs (200, 200, 873, 873, 874, 874, 875, 875)	130, 130, 131, 131, 131, 131, 132, 132
Anti - Zinc Transporter 8 (ZnT8A) (261)	65	Antithrombin (225, 285)	95, 95
Anti - β 2-Glycoprotein (IgG) (275)	62	Antithrombin (DNA) (792)	29
Anti - β 2-Glycoprotein (IgM) (275)	62	Antivirals (850)	132
anti nuclear antibodies (251)	64	AP (100)	115
Anti- DNA double stranded (251)	64	AP (POCT: Abaxis Piccolo) (810)	145
Anti-DGP (271)	65	APC resistance (288)	100
anti-Microsome (295)	110	Apixaban (504)	94
anti-Thyroglobulin (295)	110	Apo B (DNA) (771)	30
anti-TPO (295)	110	Apo E (Genotyp 2, 3, 4) (DNA) (744)	30
Antiarrhythmics (190)	126	Apo-E (734)	29
Antibacterials (193, 890)	126, 127	ApoB (151, 771)	30, 119
antibiotic resistance (544)	162	ApoB (DNA) (771)	30
Antibiotics (193)	126	ApoE (151)	119
Antibodies (452)	195	ApoE (genotype 2, 3, 4) (DNA) (744)	30
Antibodies against Bartonella henselae (serum) (326)	170	ApoE (genotype 2, 3, 4) (whole blood) (734)	29
Antibodies against Bordetella pertussis (serum) (317)	171	Apolipoprotein A1 (151)	119
Antibodies against Borrelia (serum) (332)	171	Apolipoprotein B (151)	119
Antibodies against Brucella (serum) (327)	172	Apolipoprotein E (744)	30
Antibodies against campylobacter (serum) (319)	172	Apolipoprotein E (serum / plasma) (151)	119
Antibodies against Chlamydia pneumoniae (serum) (314)	173	Apolipoprotein E (whole blood) (734)	29
Antibodies against Chlamydia trachomatis (serum) (312)	173	Apolipoprotein E (whole blood, Dna) (734)	29
Antibodies against Coxiella burnetii (serum) (325)	175	APS (275)	62
Antibodies against diphtheria toxoid (serum) (318)	175	aPTT (Argatroban) (230)	94
Antibodies against EBV (serum) (352)	232	aPTT (Plasma) (221, 280, 285)	95, 102, 104
Antibodies against Echinococcus (455)	194	aPTT (whole blood) (286)	102
Antibodies against Entamoeba histolytica (455)	194	Argatroban (Argatroban) (230)	94
Antibodies against Francisella (serum) (328)	176	Arginine (710)	113
Antibodies against hantaviruses (serum) (355)	232	Argininosuccinic acid (710)	113
Antibodies against Helicobacter pylori (serum) (334)	176	Aripiprazole (860)	136
Antibodies against Leptospira (serum) (329)	177	Arsenic (lyophilized whole blood) (208)	146
Antibodies against mycoplasma pneumoniae (serum) (324)	177	Arsenic (plasma) (206)	147
Antibodies against Plasmodium (454)	194	Arsenic (urine) (205)	153
Antibodies against Rickettsia (serum) (330)	179	ASAT (100, 810)	115, 145
Antibodies against salmonella (serum) (331)	180	Ascorbic acid (urine) (171)	156
Antibodies against Schistosoma (454)	194		
Antibodies against tetanus toxoid (serum) (310)	181		
Antibodies against Toxoplasma gondii (452)	195		

INDEX

Ascorbic acid (Vitamin C) (plasma) (296)	159
Asialotransferrin (750)	119
ASO (serum) (321)	181
Asparagine (710)	113
Aspartic acid (710)	113
AST (100, 810)	115, 145
Astroviruses (suspensions of feces) (430)	206
ASXL1 Nomenclature (798)	57
AT (plasma) (225)	95
AT3 (DNA) (792)	29
Atazanavir (850)	132
Atomoxetine (879)	135
ATP 7 B: H 1069 Q (DNA) (745)	34
Auto-anti C1q (245)	78
Auto-anti FH (249)	78
auto-anti-C1 inhibitor (250)	77
Autoantibodies against nuclei (251, 251)	64, 64
Autoimmune Dermatitis (259)	63
Autoimmune Diseases 01 - Connective Tissue Diseases (ANA) (251)	64
Autoimmune Diseases 02 - Hepatic Syndromes (253)	66
Autoimmune Diseases 03 - Connective Tissue Diseases (ENA) (255)	64
Autoimmune Diseases 04 - Vasculitis/Glomerulopathies (257)	69
Autoimmune Diseases 05 - Autoimmune Dermatitis (259)	63
Autoimmune Diseases 06 - Diabetes mellitus (261)	65
Autoimmune Diseases 07 - Autoimmune Endocrinopathies (263)	63
Autoimmune Diseases 08 - Paraneoplastic Neuropathies (265)	67
Autoimmune Diseases 09 - Peripheral Neuropathies (267)	68
Autoimmune Diseases 10 - Myasthenia gravis (269)	66
Autoimmune Diseases 11 - Gluten-Sensitive Enteropathies (271)	65
Autoimmune Diseases 12 - Rheumatoid Arthritis (273)	69
Autoimmune Diseases 13 - Antiphospholipid Syndrome (275)	62
Autoimmune Endocrinopathies (263)	63
autoprothrombin IIA (788)	31
Avian Influenza (cell culture lysate) (370)	198
Avidity - Anti-CHIKV IgG (cell culture lysate) (402)	230
Avidity - Anti-CMV IgG (serum) (351)	231
Avidity - Anti-HSV IgG (serum) (354)	236
Avidity - Anti-measles virus IgG (serum) (357)	238
Avidity - Anti-mumps virus IgG (serum) (356)	238
Avidity - Anti-parvovirus B19 IgG (serum) (342)	239
Avidity - Anti-rubella virus IgG (serum) (341)	240
Avidity - Anti-TBE/FSME virus IgG (serum) (358)	241
Avidity - Anti-VZV IgG (serum) (353)	241
Avidity - Anti-ZIKV IgG (serum) (338)	242
AZF (DNA) (788)	31
Azoospermia factor (788)	31

B

b-Alanine (710)	113
B-cells (cellular products) (617)	93
B-Cells (EDTA-Vollblut) (651)	74
B-Lymphocytes (213)	90
Bacillary angiomatosis (326)	170
Bacillus anthracis (Bacterial genome) (542)	164
Bacterial Genome Detection (548)	168
Bacterial identification (412)	185
Bacteriology (411, 412)	184, 185
Bacteriology (Slide (fixed)) (413)	185
Bacteriology - Gram Stain (Slide (fixed)) (413)	185
Barbiturate-phenobarbiturate (urine) (174)	150
Bartonella henselae (antibody, serum) (326)	170
Basidiomycetes (living cultures) (490)	191
Basophil Activation Test (653)	70
Basophilic Granulocytes (whole blood) (612)	88
Bb (247)	79
Becker muscular dystrophy (BMD) (DNA) (780)	37
Benzodiazepine Lorazepam (urine) (177)	151
Benzodiazepines (serum) (876, 877, 878)	133, 133, 134
Benzoylcegonine (urine) (174)	150
Beryllium (serum) (207)	147
beta-2-Microglobulin (serum) (292)	149
beta-2-Microglobulin (urine) (182)	158
beta-Globin (DNA) (794)	27
beta-Globulins (electrophoresis, Serum) (102)	115
beta-Globulins (Serum) (141)	120
Bilirubin (newborn, serum) (110)	125
Bilirubin (POCT: Abaxis Piccolo) (810)	145
Bilirubin (serum) (100)	115
Bilirubin (urine) (171)	156
Biochemistry (100)	115
Biogene Amines (plasma) (185)	114
Biogene Amines (urine) (175)	155
Biotin (Vitamin H) (290)	159
Bismuth (207)	147
BK polyomavirus (BKPyV or BKV) (plasma / urine) (364)	200
BK Virus (plasma / urine) (364)	200
BK virus-associated nephropathy (364)	200
bleeding tendency (670, 671, 672, 673, 674, 675, 676, 677, 678)	49, 49, 50, 50, 51, 51, 52, 52, 54
Blood Cell Count (QBC systems) (209)	87
Blood Cell Count (stabilized control blood) (211)	86
blood coagulation factor XIV (788)	31
Blood Gas Analysis (POCT OPTI Systems) (163)	145
Blood Gas Analysis (POCT) (161, 162)	144, 144
blood grouping (231, 232, 237)	81, 81, 83
Blood parasites (blood smear) (456)	193
Blood parasites (pictures) (906)	195
Blood Smear Analysis (blood smear) (212)	87
BNP (761)	112
Bocaviruses (cell culture lysate) (431)	224
BoDV (404, 415)	200, 230

INDEX

Bone Marrow Cytology (bone marrow aspirate (digital image)) (218)	88	Cadmium (plasma) (206)	147
Bordetella pertussis (antibody, serum) (317)	171	Cadmium (urine) (205)	153
Bordetella pertussis (Bacterial genome) (532)	161	Caffeine (870)	138
Borna Viruses (cell culture lysate) (404)	200	CAH (DNA) (773)	33
Borna Viruses (serum) (415)	230	Calcitonin (Calcium metabolism) (301)	106
Borrelia burgdorferi (Ab) (antibody, serum) (332)	171	Calcitonin (Tumor marker) (299)	149
Borrelia burgdorferi (Bacterial genome) (535)	161	Calcium (POCT: Abaxis Piccolo) (810)	145
Borrelia IgG Antibody Index (AI) calculation (CSF) (465)	123	Calcium (serum) (100)	115
Borrelia IgG Antibody Index (CSF) (465)	123	Calcium (urine) (173)	157
Borrelia specific quotient (CSF) (465)	123	Calcium Metabolism (301)	106
BRAF (795)	57	Calprotectin (130)	148
BRAF Nomenclature (795)	57	CALR (DNA) (768)	59
BRAF p.V600 (795, 795)	57, 57	Campylobacter (548)	168
BRAF V600 (liquid biopsy) (752)	35	Campylobacter (antibody, serum) (319)	172
BRCA1 (DNA) (779)	31	Candida antibodies (480)	191
BRCA2 (DNA) (779)	31	Candida antigen (serum) (480)	191
breast and ovarian cancer (DNA) (779)	31	Candidiasis (480)	191
Brivaracetam (871)	128	Capillary Zone Electrophoresis (102)	115
Bromazepam (878)	134	CAR-T-Cells (822)	85
Brucella (antibody, serum) (327)	172	Carbamacepine (195)	139
Brucella spp. (Bacterial genome) (543)	165	Carbamazepine-epoxide (192)	128
Brucellosis (543)	165	carbamazepine (195)	139
Bruton tyrosine kinase (796)	58	Carbapenemase genes (microbiological samples) (544)	162
BTK (796)	58	Carbapenemase-Genes (Bacterial genome) (544)	162
BTK Nomenclature (796)	58	Cardiac markers (760)	112
BTK p.C481 (796)	58	Cariprazine (875)	132
Buprenorphine (urine) (176)	151	Cat-scratch disease (326)	170
C		CCR5-Gene (DNA) (764)	32
c-ANCA (serum) (257)	69	CD107a expression (NK and T cell blasts) (657)	76
C-Peptide (serum / plasma) (300)	108	CD16+ (651)	74
C-Reactive Protein (241)	143	CD19+ (651)	74
C-Reactive Protein (antibody, serum) (322)	143	CD21low/CD38low B cells (651)	74
C. difficile (545)	164	CD3+ (651)	74
C1 inhibitor: activity (246)	80	CD34 (whole blood) (217, 660)	92, 93
C1 inhibitor: proteine (246)	80	CD34+ events (whole blood) (217)	92
C1-Inhibitor (plasma) (225)	95	CD4 (213)	90
C1q proteine (246)	80	CD4+ (651)	74
C282Y (DNA) (741)	39	CD45+ (cellular products) (617)	93
C282Y (whole blood, Dna) (733)	40	CD45+ events (whole blood) (217)	92
C3 - nephritic factor (248)	79	CD56+ (651)	74
C3-Complement (246)	80	CD8 (213)	90
C3-Complement (plasma) (241)	143	CDI (545)	164
C3a (247)	79	CEA (292)	149
C3d (247)	79	CEBPA (CDS) Mutation(s) (798)	57
C4-Complement (246)	80	CEBPA Nomenclature (798)	57
C4-Complement (plasma) (241)	143	Cefepime (890)	127
CA 125 (292)	149	Ceftazidime (890)	127
CA 15-3 (292)	149	Celiac disease (271)	65
CA 19-9 (292)	149	Cellular Immunodeficiency Diagnostic (EDTA-whole blood) (651)	74
CA 72-4 (292)	149	Cerebrospinal Fluid Analysis (467, 468)	121, 122
Cadmium (lyophilized whole blood) (208)	146	Cerebrospinal Fluid Analysis (CSF + serum) (460, 462, 463)	123, 124, 124
		Cerebrospinal Fluid Analysis (CSF) (464, 465, 466)	121, 122, 123
		Cerebrospinal Fluid Analysis 01 - Protein Analysis (CSF + serum) (460)	124

INDEX

Cerebrospinal Fluid Analysis 02 - Oligoclonal IgG (CSF + serum) (462)	124	clotting factor (670, 671, 672, 673, 674, 675, 676, 677, 678, 790, 791, 792)	29, 45, 46, 49, 49, 50, 50, 51, 51, 52, 52, 54
Cerebrospinal Fluid Analysis 03 - MRZ Reaction (CSF + serum) (463)	123	Clozapine (200, 862, 863)	130, 137, 137
Cerebrospinal Fluid Analysis 04 - Lactate/ Glucose (CSF) (464)	122	cMRSA (Bacterial genome) (539)	167
Cerebrospinal Fluid Analysis 05 - Neuroborreliosis (CSF + serum) (465)	123	CMV (349, 351)	204, 231
Cerebrospinal Fluid Analysis 06 - Dementia Markers (CSF) (466)	121	CMV (cell culture lysate) (433)	221
CFTR Common Mutations (DNA) (778)	32	CMV (plasma) (349, 365, 368)	203, 203, 204
CFTR gene (DNA) (778)	32	coagulation (223, 224, 225, 226, 227, 670, 671, 672, 673, 674, 675, 676, 677, 678)	49, 49, 50, 50, 51, 51, 52, 52, 54, 95, 96, 98, 98, 99
CGG-Repeat (DNA) (781)	39	coagulation (DNA) (790, 791)	45, 46
CHE (100)	115	Cobalamin (Vitamin B12) (290)	159
chemokine receptor (764)	32	Cobalt (lyophilized whole blood) (208)	146
Chikungunya Virus (cell culture lysate) (402)	230	Cobalt (plasma) (206)	147
Chikungunya Virus (plasma) (392)	201	Cobalt (urine) (205)	153
Chimerism Diagnostics (618)	26	Coeliac Disease (772)	73
Chlamydia (312, 313, 314, 316, 530, 531)	163, 163, 173, 173, 174, 174	Coeliac disease diagnostics (serum) (271)	65
Chlamydia pneumoniae (antibody, serum) (314)	173	Coelomycetes (living cultures) (490)	191
Chlamydia pneumoniae (Bacterial genome) (540)	162	Coeruloplasmin (241)	143
Chlamydia trachomatis (antibody, serum) (312, 313)	173, 174	Collagen Receptor C807T (739)	33
Chlamydia trachomatis (Bacterial genome) (530, 531)	163, 163	Collagen receptor C807T (DNA) (739)	33
Chlamydia trachomatis (Slide (fixed)) (316)	174	Collagen receptor GP Ia/IIa (C 807 T) (739)	33
Chloramphenicol (198)	130	Collagen receptor GP Ia/IIa (DNA) (739)	33
Chlordiazepoxide (876)	133	Collagenosis Screening (ANA) (serum) (251)	64
Chloride (POCT OPTI Systems) (163)	145	Colton system [CO] (DNA) (235)	26
Chloride (POCT) (161)	144	Complement activation products (247)	79
Chloride (POCT: Abaxis Piccolo) (810)	145	Complement Analysis (245, 246, 247, 248, 249, 250)	77, 78, 78, 79, 79, 80
Chloride (serum) (100)	115	Complement Analysis 01 (Auto-anti-C1q) (245)	78
Chloride (urine) (173)	157	Complement Analysis 02 (Functions and proteins) (246)	80
Chlorpromazine (875)	132	Complement Analysis 03 (Complement activation products) (247)	79
Cholesterol (100, 151)	115, 119	Complement Analysis 04 (C3 - nephritic factor) (248)	79
Cholesterol (POCT: Abaxis Piccolo) (810)	145	Complement Analysis 05 (Auto-anti FH) (249)	78
Cholinesterase (100)	115	Complement Analysis 06 (anti - C1 inhibitor) (250)	77
Chromatographic analysis (188)	152	Complement factor H (246)	80
Chromium (lyophilized whole blood) (208)	146	Complement factor I (246)	80
Chromium (plasma) (206)	147	Concentration of Hb in reticulocytes (216)	91
Chromium (urine) (205)	153	congenital adrenal hyperplasia (DNA) (773)	33
Chromium release assay (657)	76	Connective Tissue Diseases (ANA) (serum) (251)	64
chronic lymphocytic leukemia (820)	86	Connective Tissue Diseases (ENA) (255)	64
Citalopram (860)	136	Connexin 26 (DNA) (782)	34
Citrulline (710)	113	Copper (plasma) (206)	147
CK (100)	115	Copper (serum) (100)	115
CK (POCT: Abaxis Piccolo) (810)	145	Copper (urine) (205)	153
CK-MB (760)	112	Coproporphyrin (178)	156
Classical pathway (246)	80	Coronaviruses (409)	227
CLL-MRD Immunophenotyping (820)	86	Coronaviruses (cell culture lysate) (340, 417, 431, 432)	202, 224, 225, 227
Clobazam (878)	134	Coronaviruses (cell culture supernatants) (410, 410)	197, 197
Clobazepam (878)	134	Coronaviruses (serum) (416)	240
Clomipramine (serum) (199, 203, 863)	137, 140, 141	Cortisol (serum) (302)	109
Clomipramine (urine) (204)	153	Cortisol free (urine) (179)	155
Clonazepam (877)	133	COVID (409, 410, 416)	197, 227, 240
Clostridium difficile (Bacterial genome) (545)	164		
Clostridium difficile (microbiological samples) (545)	164		
Clostridium difficile (toxigen) (548)	168		



INDEX

Coxiella burnetii (antibody, serum) (325)	175
Coxiella burnetii (Bacterial genome) (542)	164
Creatine Kinase (100)	115
Creatinine (POCT) (161)	144
Creatinine (POCT: Abaxis Piccolo) (810)	145
Creatinine (serum) (100)	115
Creatinine (urine) (173, 182)	157, 158
Creatinine kinase (810)	145
CRP (810)	145
Cryptococcosis (481)	192
Cryptococcus gattii (serum or liquor) (481)	192
Cryptococcus neoformans (serum or liquor) (481)	192
Cryptosporidium spp. (458)	193
CSF (460, 462, 463, 464, 465, 466, 467, 468)	121, 121, 122, 122, 123, 123, 124, 124
ctDNA (liquid biopsy) (752)	35
Cultivation of mycobacteria (sputum) (422)	186
Cultivation, identification and sensitivity testing of bacteria (3 Samples) (411)	184
Cultivation, identification and sensitivity testing of bacteria (5 Samples) (412)	185
Cx26 (782)	34
Cyclosporine A (601)	134
CYFRA 21-1 (292)	149
Cyp21A2 (DNA) (773)	33
CYP21A2 gene (DNA) (773)	33
CYP2C19 (DNA) (775)	35
CYP2C9 (DNA) (775)	35
CYP2D6 (DNA) (777)	36
Cystathionine (710)	113
Cystatin-C (242)	142
Cysteine-Homocysteine-disulfide (710)	113
Cystic fibrosis (778)	32
Cystine (710)	113
Cytomegalovirus (cell culture lysate) (433)	221
Cytomegalovirus (plasma) (349, 365, 368)	203, 203, 204
Cytomegalovirus (serum) (351)	231

D

D-Dimer (226, 285)	95, 96
Dabigatran (502)	96
Darunavir (850)	132
DAT (231, 232, 237, 238)	81, 81, 83, 83
delta-9-THC-COOH (urine) (177)	151
Dementia Markers (CSF) (466)	121
Dengue fever (350, 369)	204, 231
Dengue Viruses (plasma) (369)	204
Dengue Viruses (serum) (350)	231
Dermatophytes (living cultures) (491)	190
Dermatophytes Genome Detection (Lyophilized spore suspension) (492)	190
Desalkylflurazepam (876)	133
Desethylamiodarone (190)	126
Desipramine (863)	137

Desipramine (serum) (202, 203)	139, 141
Desipramine (urine) (204)	153
Desmethyl fluoxetine (874)	131
Desmethyl olanzapine (875)	132
Desmethyl sertraline (873)	131
Desmethyldiazepam (876)	133
DFNB1 (DNA) (782)	34
DHEA (298)	105
DHEA sulfate (298)	105
DHEA-S (298)	105
Diabetes mellitus (261)	65
Diazepam (876)	133
Diego system [DI] (DNA) (235)	26
Differential Blood Count (whole blood) (612)	88
Differentiation of tuberculosis bacteria (sputum) (422)	186
Digitoxin (197)	138
Digoxin (195)	139
Dihydropyrimidin Dehydrogenase (DNA) (762)	36
Diphtheria Toxoid (antibody, serum) (318)	175
Dipstick (171)	156
Direct Antiglobulin Test (Machine-based, whole blood) (237, 238)	83, 83
Direct Antiglobulin Test (serum / erythrocytes suspension) (231, 232)	81, 81
Direct detection of Chlamydia trachomatis antigen (antigen, serum) (313)	174
Direct detection of Chlamydia trachomatis antigen (Slide (fixed)) (316)	174
Disialotransferrin (serum) (750)	119
DMD (DNA) (780)	37
Dolutegravir (serum) (850)	132
Dombrock system [DO] (DNA) (235)	26
Dopamine (plasma) (185)	114
Dopamine (urine) (175)	155
Doxepin (serum) (201, 203, 863)	137, 140, 141
Doxepin (urine) (204)	153
DPA1 (444)	70
DPB1 (444)	70
DPD (777)	36
DPYD (DNA) (762)	36
DQA1 (444)	70
DQB1 (444)	70
DRB1 (444)	70
DRB3 (444)	70
DRB4 (444)	70
DRB5 (444)	70
Drug Resistance Determination (plasma) (349, 383, 384, 397, 399)	204, 208, 210, 213, 214
Drugs of Abuse (174, 176, 177)	150, 151, 151
Duchenne muscular dystrophy (DMD) (DNA) (780)	37
Duffy system [FY] (DNA) (235)	26
Duloxetine (862)	137
Dysfibrinogenemia (676)	52
Dystrophin (DNA) (780)	37

INDEX

E

E. coli (534)	165
EBV (352, 376, 433)	205, 221, 232
Echinococcosis (serum/plasma) (455)	194
EDDP (urine) (177)	151
Edoxaban (505)	97
educational program (378, 379, 382)	208, 210, 212
Efavirenz (850)	132
Effector memory T cells (651)	74
Effector T cells (651)	74
EGFR T790M (liquid biopsy) (752)	35
EHEC (Bacterial genome) (534)	165
Elvitegravir (850)	132
Emicizumab (plasma) (506)	97
ENA (255)	64
Endocrinopathies (263)	63
Engraftment Diagnostics (618)	26
Entamoeba histolytica (458)	193
Enterohemorrhagic E. coli (EHEC / STEC) (548)	168
Enteroinvasive E. coli (EIEC) (548)	168
Enteropathogenic E. coli (EPEC) (548)	168
Enterotoxigenic E. coli (ETEC) (548)	168
Enteroviruses (cell culture lysate) (372, 431, 433)	205, 221, 224
Enteroviruses (suspensions of feces) (430)	206
Eosinophilic Granulocytes (whole blood) (612)	88
Epinephrine (175)	155
Epinephrine (plasma) (185)	114
Epinephrine (urine) (175)	155
Epstein Barr Virus (cell culture lysate) (433)	221
Epstein Barr Virus (plasma) (376)	205
Epstein Barr Virus (serum) (352)	232
Erythrocyte - alleles (DNA) (235)	26
Erythrocytes (stabilized control blood) (211)	86
Erythrocytes (urine) (171)	156
Erythrocytes (whole blood) (612)	88
Erythropoiesis (bone marrow aspirate (digital image)) (218)	88
Erythropoietin (626)	108
Escherichia coli (534)	165
Escherichia coli O157 (548)	168
Escitalopram (861)	136
Eslicarbazepine (871)	128
ESR1 (liquid biopsy) (752)	35
ESR1 (DNA) (590)	55
Ethanol (700)	116
Ethosuximid (195)	139
Ethylglucuronid (751)	152
Etravirine (850)	132
Everolimus (601)	134
Expansion of trinucleotide CAG repeats (DNA) (784)	40

F

F10 (DNA) (674)	51
F11 (DNA) (675)	51
F13A1 (DNA) (677)	52
F13B (DNA) (677)	52

F5 (DNA) (670)	49
F7 (DNA) (671)	50
F8 (DNA) (672)	50
F9 (DNA) (673)	49
Factor II (223)	98
Factor IX (224)	98
Factor IX (DNA) (673)	49
Factor V (223)	98
Factor V (DNA) (670)	49
Factor V-Leiden (DNA) (740)	37
Factor V-Leiden (DNA) (740)	37
Factor V-Leiden (whole blood) (730)	38
Factor VII (223)	98
Factor VII (DNA) (671)	50
Factor VIII (227)	99
Factor VIII (DNA) (672)	50
Factor X (223)	98
Factor X (DNA) (674)	51
Factor XI (224)	98
Factor XI (DNA) (675)	51
Factor XII (224)	98
Factor XIII (224)	98
Factor XIII (DNA) (677)	52
FDP screening (222)	99
Fecal Diagnostics (130, 131)	148, 148
Fecal elastase (130)	148
Felbamate (871)	128
Ferritin (241)	143
Ferritin (CSF) (467)	121
Fertility (297)	106
fetal haemoglobin (210)	89
Fetoprotein (306)	107
FGA (DNA) (676)	52
FGB (DNA) (676)	52
FGG (DNA) (676)	52
Fibrinogen (222, 285)	95, 99
Fibrinogen (DNA) (676)	52
Fibrinogen degradation products (222)	99
Fibrinogen Receptor (749)	38
Fifth disease (342, 367)	223, 239
Flavine Adenine Dinucleotide (FAD) (291)	160
Flavine mononucleotide (FMN) (291)	160
Flowcytometry (217, 617)	92, 93
FLT3 (internal tandem duplication) (DNA) (701)	53
FLT3 (TKD) Mutation(s) (798)	57
FLT3 Nomenclature (798)	57
FLT3-ITD (DNA) (701)	53
Fluconazole (198)	130
Flucytosine (198)	130
Flunitrazepam (877)	133
Fluoride (plasma) (206)	147
Fluoride (urine) (205)	153
Fluoxetine (874)	131
Flurazepam (877)	133
Fluvoxamine (873)	131
FMR1 (DNA) (781)	39
Folate (290)	159



INDEX

Folic acid (serum) (290)	159
Follicle-stimulating hormone (297)	106
Fondaparinux (plasma) (501)	100
Food allergens (IgE against) (720)	62
Fraction CO-Hb (POCT) (162)	144
Fraction Met-Hb (POCT) (162)	144
Fraction O2-Hb (POCT) (162)	144
Fragile X (DNA) (781)	39
Fragile X syndrom (DNA) (781)	39
Francisella (antibody, serum) (328)	176
Francisella tularensis (Bacterial genome) (543)	165
Free beta-chain hCG (serum / plasma) (305)	107
Free Haemoglobin (236)	89
Free Hemoglobin (236)	89
Free light chains (243)	117
Fructosamine (146)	116
FSH (297)	106
Fungal Genome Detection (Fungal genome) (560)	189
fungal infection (480, 481)	191, 192
FXPOI (DNA) (781)	39
FXS (DNA) (781)	39
FXTAS (DNA) (781)	39

G

G6PDH (279)	117
Gabapentin (872)	129
gamma-Globulins (100, 141)	115, 120
gamma-Globulins (electrophoresis, Serum) (102)	115
Gammopathies (243)	117
Gap junction beta-2 protein (782)	34
Gardnerella (547)	169
Gastrin (300)	108
Gastrointestinal disease (381, 430)	206, 220
Gastrointestinal Virus Panel (suspensions of feces) (430)	206
Gastrointestinale Pathogene (548)	168
genome detection (424)	189
Gentamicin (197)	138
GGT (POCT: Abaxis Piccolo) (810)	145
GGT (serum) (100)	115
Giardia duodenalis (458)	193
GJB2 (782)	34
GJB2 (DNA) (782)	34
GJB2 gene (DNA) (782)	34
GJB6 (DNA) (782)	34
GJB6 gene (DNA) (782)	34
Glandular fever (352, 376)	205, 232
GLDH (100)	115
Glomerulopathies (serum) (257)	69
Glucagon (300)	108
Glucose (CSF) (464)	122
Glucose (POCT) (161, 800)	144, 146
Glucose (POCT: Abaxis Piccolo) (810)	145
Glucose (serum) (100, 111)	115, 118

Glucose (urine) (171, 173)	156, 157
Glucose quotient (CSF/Serum) (CSF) (464)	122
Glucose-6 Phosphat-Dehydrogenase (279)	117
Glutamic acid (710)	113
Glutamine (710)	113
Gluten-Sensitive Enteropathies (serum) (271)	65
Glycine (710)	113
Gold (plasma) (206)	147
GOT (POCT: Abaxis Piccolo) (810)	145
GOT (serum) (100)	115
GP Ia/Ia (DNA) (739)	33
GPI deficient cells (616)	91
GPT (POCT: Abaxis Piccolo) (810)	145
GPT (serum) (100)	115
Gram Stain (Lyophilisate) (411, 412)	184, 185
Gram Stain (Slide (fixed)) (413)	185
Granulocyte (neutrophil) antigens (234)	82
Granulocyte - alleles (DNA) (235)	26
Granulocyte antibodies (234)	82
Granulocyte Function (Oxidative Burst) (654)	77
Granulocyte Function (Phagocytosis Test) (655)	68
Granulocyte Immunology (234)	82
Granulopoiesis (bone marrow aspirate (digital image)) (218)	88
Growth Hormone (GH) (298)	105

H

H. pylori (334, 533)	166, 176
H63D (741)	39
Haematocrit (QBC systems) (209)	87
Haematocrit (stabilized control blood) (211)	86
Haematocrit (whole blood) (612)	88
Haematology 07 - Blood Smear Analysis (blood smear) (212)	87
Haematology 09 - Bone Marrow Cytology (bone marrow aspirate (digital image)) (218)	88
Haemoglobin (POCT OPTI Systems) (163)	145
Haemoglobin (POCT) (162)	144
Haemoglobin (QBC systems) (209)	87
Haemoglobin (stabilized control blood) (211)	86
Haemoglobin (whole blood) (612)	88
Haemoglobin-Haptoglobin-Complex (stool) (131)	148
Haemoglobinopathies (whole blood) (210)	89
Haloperidol (862)	137
Hantaviruses (serum) (355)	232
Haptoglobin (plasma) (241)	143
Haptoglobin (stool) (131)	148
HAV (344, 377)	206, 233
Hb-A (210)	89
Hb-A2 (210)	89
Hb-F (210)	89
Hb-S (210)	89
HBA (794)	27
HbA1c (EDTA Vollblut) (145)	118

INDEX

HBB (794)	27	Hexaporphyrin (178)	156
HBDH (100)	115	HFE (741)	39
HBeAg (serum) (345)	234	HFE (C282Y, H63D, S65C) (DNA) (741)	39
HBOC (DNA) (779)	31	HFE (C282Y, H63D, S65C) (whole blood) (733)	40
HBsAg (serum) (344)	233	HFE: C 282 Y (733)	40
HBV (345, 361, 378, 396, 397)	207, 207, 208, 208, 234	HFE: H 63 D (733)	40
hCG (urine) (171)	156	HFE: S 65 C (733)	40
hCG intact (Pregnancy) (306)	107	HGH (298)	105
hCG intact (Tumor marker) (292)	149	HHV-6 (cell culture lysate) (405)	215
hCG intact (urine) (179)	155	HHV-8 (cell culture lysate) (406)	215
HCT (209, 211, 612)	86, 87, 88	high resolution (444)	70
HCV (346, 362, 375, 379, 399)	209, 209, 210, 210, 234	Histidine (710)	113
HCV Antigen (serum) (346)	234	HIV (850)	132
HD (784)	40	HIV-1 (plasma) (360, 382, 383, 384)	212, 213, 213, 214
HDL-cholesterol (151)	119	HIV-1 (serum) (335)	237
HDL-cholesterol (POCT: Abaxis Piccolo) (810)	145	HIV-1 Drug Susceptibility Determination (plasma) (384)	214
HDV (347, 400)	211, 235	HIV-1 p24 Antigen (serum) (337)	236
HE4 (292)	149	HIV-2 (plasma) (395)	214
Helicobacter pylori (antibody, serum) (334)	176	HIV-2 (serum) (335)	237
Helicobacter pylori (Bacterial genome) (533)	166	HLA A (441, 442, 444)	70, 72, 73
hematocrit (209, 211, 612)	86, 87, 88	HLA Antibody Screening and Specification (445)	71
Hematopoietic Growth Factors (626)	108	HLA B (441, 442, 444)	70, 72, 73
Hemoglobin (162, 163, 209, 211, 612)	86, 87, 88, 144, 145	HLA B 57 (444)	70
Hemoglobin-Haptoglobin-Complex (131)	148	HLA C (442, 444)	70, 73
Hemoglobinopathies (210)	89	HLA Crossmatching (443)	71
hemolytic anemia (279)	117	HLA Typing (blood samples) (441, 442)	72, 73
Hemopexin (241)	143	HLA Typing (buffy coat) (444)	70
Hemophilia A (672)	50	HLA-B27 Determination (440)	72
Hemophilia B (673)	49	HLA-DQ (441, 772)	72, 73
Hemophilia C (675)	51	HLA-DR (441)	72
hemostasis (670, 671, 672, 673, 674, 675, 676, 677, 678, 790, 791, 792)	29, 45, 46, 49, 49, 50, 50, 51, 51, 52, 52, 54	HMPV (385)	216
Hepatic Syndromes (serum) (253)	66	HNA (234)	82
Hepatitis A Virus (plasma) (377)	206	HNA - system (DNA) (235)	26
Hepatitis A Virus (serum) (343)	233	HNPCC (DNA) (783)	41
Hepatitis B Virus (plasma) (361, 378, 396, 397)	207, 207, 208, 208	Holotranscobalamine (290)	159
Hepatitis B Virus (serum) (344, 345)	233, 234	Homocystein (151)	119
Hepatitis C Virus (plasma) (362, 375, 379, 399)	209, 209, 210, 210	Homovanillic acid (175)	155
Hepatitis C Virus (serum) (346)	234	HPA (749)	38
Hepatitis D Virus (plasma) (400)	211	HPA - system (DNA) (235)	26
Hepatitis D Virus (serum) (347)	235	HPA 1a/1b (DNA) (749)	38
Hepatitis E Virus (plasma) (380)	211	HPV (373)	216
Hepatitis E Virus (serum) (348)	235	HPV (cell culture lysate) (373)	216
Heptaporphyrin (178)	156	hsCRP (240)	142
HER2/new (292)	149	HSV (354, 363, 433, 463)	123, 212, 221, 236
hereditary hemochromatosis (733, 741)	39, 40	HTLV-1 (serum) (339)	237
Hereditary nonpolyposis colorectal cancer (783)	41	HTLV-2 (serum) (339)	237
Herpes simplex specific quotient (CSF / serum) (463)	123	HTT (DNA) (784)	40
Herpes simplex virus IgG Antibody Index (CSF / serum) (463)	123	HTT gene (DNA) (784)	40
Herpes Simplex Viruses (cell culture lysate) (433)	221	HTT Huntingtin (DNA) (784)	40
Herpes Simplex Viruses (plasma) (363)	212	Human brucellosis (327)	172
Herpes Simplex Viruses (serum) (354)	236	Human Herpesvirus (cell culture lysate) (405, 406)	215, 215
HEV (348, 380)	211, 235	Human immunodeficiency virus (360, 382, 383, 384, 850)	132, 212, 213, 213, 214
		Human immunodeficiency virus 2 (395)	214
		Human immunodeficiency viruses (335, 337)	236, 237



INDEX

L

Lacosamide (871)	128
Lactase gene (DNA) (770)	41
Lactase-gene (DNA) (770)	41
Lactate (CSF) (464)	122
Lactate (POCT OPTI Systems) (163)	145
Lactate (POCT) (161)	144
Lactate (POCT: Abaxis Piccolo) (810)	145
Lactate (serum) (100)	115
Lactate Dehydrogenase (100, 810)	115, 145
Lactose (DNA) (770)	41
lactose intolerance (770)	41
Lactose intolerance (DNA) (770)	41
lambda (243)	117
Lamotrigine (191, 860)	127, 136
Landsteiner Wiener system [LW] (DNA) (235)	26
LCT (DNA) (770)	41
LDH (100)	115
LDH (POCT: Abaxis Piccolo) (810)	145
LDL-cholesterol (151)	119
LDL-cholesterol (POCT: Abaxis Piccolo) (810)	145
Lead (lyophilized whole blood) (208)	146
Lead (urine) (205)	153
Lectin pathway (246)	80
Legionella pneumophila (Bacterial genome) (536)	166
Legionellosis (536)	166
Legionnaires disease (536)	166
Leptospira (329)	177
Leptospira (antibody, serum) (329)	177
Leptospirosis (329)	177
Leucine (710)	113
Leucocytes (cellular products) (617)	93
Leucocytes (QBC systems) (209)	87
Leucocytes (stabilized control blood) (211)	86
Leucocytes (urine) (171)	156
Leucocytes (whole blood) (213, 217, 612)	88, 90, 92
leukozyte antigen (440, 441, 442, 443, 444, 445)	70, 71, 71, 72, 72, 73
Levetiracetam (191)	127
Levomopromazine (873)	131
LH (297)	106
Lime borreliosis (535)	161
Linezolid (890)	127
Lipase (100)	115
Lipids (151)	119
Lipoproteins (151)	119
Liquid Biopsy (752)	35
Listeria (538)	167
Listeria spp. (Bacterial genome) (538)	167
Listeriosis (538)	167
Lithium (100, 195)	115, 139
Liver disease (253)	66
LMW Heparin (281)	101
Lopinavir (850)	132
Lorazepam (878)	134

low molecular weight heparin (281)	101
low resolution (442)	73
Lp (a) (151)	119
LSD (urine) (176)	151
Luteinizing hormone (297)	106
Lutheran system [Lu] (DNA) (235)	26
Lyme disease (332, 535)	161, 171
Lymphocyte Proliferation Assay (656)	76
lymphocytes (651)	74
Lymphocytes (whole blood) (213, 612)	88, 90
Lymphocyte Transformation Test (LTT) (656)	76
Lynch syndrome (783)	41
Lysine (710)	113

M

Magnesium (lyophilized whole blood) (208)	146
Magnesium (POCT) (161)	144
Magnesium (POCT: Abaxis Piccolo) (810)	145
Magnesium (serum) (100)	115
Magnesium (urine) (173)	157
Malaria (serum/plasma) (454)	194
Manganese (lyophilized whole blood) (208)	146
Manganese (plasma) (206)	147
Manganese (urine) (205)	153
Maprotiline (202, 863)	137, 139
Maraviroc (850)	132
Markers of Ethanol Abuse (serum) (750)	119
Markers of Ethanol Abuse (urine) (751)	152
MCV (stabilized control blood) (211)	86
MCV (whole blood) (612)	88
MDMA (urine) (177)	151
mean cell volume (211, 612)	86, 88
mean corpuscular volume (211, 612)	86, 88
Measles specific quotient (CSF + serum) (463)	123
Measles Virus (cell culture lysate) (386)	218
Measles Virus (serum) (357)	238
Measles virus IgG Antibody Index (CSF + serum) (463)	123
mecA (539)	167
Megakaryopoiesis (bone marrow aspirate (digital image)) (218)	88
Memory T cells (651)	74
MEN2 Syndrome (DNA) (738)	56
MEN2A (DNA) (738)	56
Mercury (lyophilized whole blood) (208)	146
Mercury (urine) (205)	153
Meropenem (890)	127
MERS (cell culture lysate) (340)	202
Metanephries (175)	155
Methadone (urine) (176)	151
Methicillin-resistant Staphylococcus aureus (539)	167
Methionine (710)	113
Methotrexate (197)	138
Methylmalonic Acid (187)	158
Methylphenidate (879)	135



INDEX

Mianserine (874)	131
Microalbumin (173)	157
Microbiome (stool) (580)	183
Microscopic detection of mycobacteria (Slide) (421)	188
Minimal residual disease (820, 821)	86, 120
Mirtazapine (861)	136
MLH1 (DNA) (783)	41
MMF (602)	129
MNS - system (DNA) (235)	26
MNS system [GYP] (DNA) (235)	26
molecular susceptibility testing of tuberculosis bac- teria (suspensions of mycobacterial strains) (426)	188
Molybdaen (207)	147
Molybdenum (207)	147
Monkeypox virus / Orthopoxviruses (418)	219
Monocytes (whole blood) (612)	88
Morphology (Slide (fixed)) (413)	185
Morphology of erythrocytes (blood smear) (212)	87
Morphology of leukocytes (blood smear) (212)	87
Morphology of platelets (blood smear) (212)	87
Mould Fungus (living cultures) (491)	190
MPA (602)	129
MPL (768)	59
MPN (768)	59
MPOX (418)	219
MPXV (418)	219
MRSA (Bacterial genome) (539)	167
MSH2 (DNA) (783)	41
MSH6 (DNA) (783)	41
MTHFR (C677T, A1298C) (DNA) (747)	42
MTHFR (C677T, A1298C) (whole blood) (732)	42
MTHFR (whole blood, Dna) (732)	42
MTHFR C677T (DNA) (747)	42
MTHFR C677T (whole blood, Dna) (732)	42
Mucorales (living cultures) (490)	191
Multiple Endocrine Neoplasia Type 2A (DNA) (738)	56
Multiplex Test (cell culture lysate) (431, 432, 433)	221, 224, 225
Multiplex Test (suspensions of feces) (430)	206
Mumps Virus (cell culture lysate) (387)	220
Mumps Virus (serum) (356)	238
muscular dystrophy (780)	37
Myasthenia gravis (serum) (269)	66
Mycobacteria (Slide) (421)	188
Mycobacteria (sputum) (422, 424)	186, 189
Mycobacteria (suspensions of mycobacterial	186, 187, 187,
	188
Mycobacterial diagnostics - Cultivation (sputum) (422)	186
Mycobacterial diagnostics - Drug Susceptibility Testing of nontuberculous mycobacteria (suspen- sions of non-mycobacterial strains) (427)	187
Mycobacterial diagnostics - Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) (425)	186
Mycobacterial diagnostics - Identification (suspen- sions of mycobacterial strains) (423)	187
Mycobacterial diagnostics - Microscopy (Slide) (421)	188
Mycobacterial diagnostics - Molecular Drug Sus- ceptibility Testing of tuberculosis bacteria (suspen- sions of mycobacterial strains) (426)	188

Mycobacterial diagnostics - NAT tuberculosis bacteria (sputum) ⁽⁴²⁴⁾	189
Mycobacterial diagnostics 01 - Microscopy (Slide) ⁽⁴²¹⁾	188
Mycobacterial diagnostics 02 - Cultivation (sputum) ⁽⁴²²⁾	186
Mycobacterial diagnostics 03 - Identification (suspensions of mycobacterial strains) ⁽⁴²³⁾	187
Mycobacterial diagnostics 05 - Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) ⁽⁴²⁶⁾	186
Mycobacterial diagnostics 06 - Molecular Drug Susceptibility Testing of tuberculosis bacteria (suspensions of mycobacterial strains) ⁽⁴²⁶⁾	188
Mycobacterial diagnostics 07 - Drug Susceptibility Testing of nontuberculous mycobacteria (suspensions of non-mycobacterial strains) ⁽⁴²⁷⁾	187
Mycology (living cultures) ^(490, 490, 491)	190, 191, 191
Mycophenolic acid ⁽⁶⁰²⁾	129
Mycoplasma ⁽⁵⁴⁷⁾	169
Mycoplasma pneumoniae (antibody, serum) ⁽³²⁴⁾	177
Mycoplasma pneumoniae (Bacterial genome) ⁽⁵⁴¹⁾	168
Mycoserology (serum or liquor) ⁽⁴⁸¹⁾	192
Mycoserology (serum) ⁽⁴⁸⁰⁾	191
MYD88 ⁽⁷⁶⁶⁾	59
Myeloproliferative Neoplasia ⁽⁷⁶⁸⁾	59
Myocardial Markers ^(760, 761)	112, 112
Myoglobin ⁽⁷⁶⁰⁾	112

N

N-Desmethyleclozapine (200, 862, 863)	130, 137, 137
N-Desmethylethylmethsuximide (192)	128
N334K (793)	27
Naive B cells (651)	74
Naive T cells (651)	74
Neisseria gonorrhoeae (Bacterial genome) (530)	163
Neonatal Bilirubin (110)	125
Neuroborreliosis (CSF) (465)	123
Neutrophilic Granulocytes (whole blood) (612)	88
Nevirapine (850)	132
Newborn screening (785, 785)	125, 125
Next Generation Sequencing (798)	57
Next Generation Sequencing (stool) (580)	183
NGS-Analysis (stool) (580)	183
Nickel (lyophilized whole blood) (208)	146
Nickel (plasma) (206)	147
Nickel (urine) (205)	153
Nitrazepam (877)	133
Nitrite (urine) (171)	156
NK and cytotoxic T cells function (657)	76
NK cell activation assay (CD107a) (657)	76
NK cell subpopulations (651)	74
NK cytotoxicity assay (CD107a or lysis) (657)	76
NK-cells (cellular products) (617)	93
NK-Cells (EDTA-whole blood) (651)	74
NK-cells (whole blood) (213)	90
Non-switched B cells (651)	74
non-syndromic hearing impairment (DNA) (782)	34
Nontuberculous mycobacteria (suspensions of mycobacterial strains) (427)	187

INDEX

Norclomipramine (serum) (199, 203, 863)	137, 140, 141	Parasites (serum/plasma) (452, 454, 455)	194, 194, 195
Norclomipramine (urine) (204)	153	Parasites (stool) (451)	145
Norclozapine (862, 863)	137, 137	Parechovirus (cell culture lysate) (407, 431, 433)	221, 222, 224
Nordiazepam (876)	133	Parechovirus (suspensions of feces) (430)	206
Nordoxepin (serum) (201, 203, 863)	137, 140, 141	Paroxetine (875)	132
Nordoxepin (urine) (204)	153	Paroxysmal Nocturnal Hemoglobinuria (616)	91
Norepinephrine (plasma) (185)	114	Parvovirus B19 (plasma) (367)	223
Norepinephrine (urine) (175)	155	Parvovirus B19 (serum) (342)	239
Normaproptiline (202)	139	pCO ₂ (POCT OPTI Systems) (163)	145
Normetanephine (175)	155	pCO ₂ (POCT) (161)	144
Noroviruses (suspensions of feces) (381, 430)	206, 220	PCR/NAT Multiplex (548)	168
Nortrimipramine (serum) (201, 203)	140, 141	Peliosis hepatis (326)	170
Nortrimipramine (urine) (204)	153	Pentaporphyrin (178)	156
Nortriptyline (serum) (199, 203, 863)	137, 140, 141	Perampanel (871)	128
Nortriptyline (urine) (204)	153	Perazine (860, 874)	131, 136
NPM1 Exon 11 Mutation(s) (798)	57	Peripheral Neuropathies (serum) (267)	68
NPM1 Nomenclature (798)	57	pH (POCT OPTI Systems) (163)	145
NSAIDs (194)	135	pH (POCT) (161)	144
NSE (292)	149	pH (urine) (171)	156
NT-pro BNP (760)	112	Pharmacogenetics (775)	35
O		Phenobarbital (195)	139
O-Desmethylvenlafaxine (860, 861)	136, 136	Phenylalanine (710)	113
Olanzapine (862, 875)	132, 137	Phenytoin (195)	139
Oligoclonal IgG (CSF / serum) (462)	124	Phosphate (POCT: Abaxis Piccolo) (810)	145
Opiate (urine) (174)	150	Phosphate (serum) (100)	115
Orgaran (282)	101	Phosphate (urine) (173)	157
Ornithine (710)	113	Phosphoethanolamine (710)	113
Osmolality (serum) (100)	115	Phospholipids (151)	119
Osmolality (urine) (173)	157	PhosphoTau Protein (pTau) (CSF) (466)	121
Oxazepam (876)	133	Photometer Controls (181)	141
P		PIGF (625)	109
p-ANCA (serum) (257)	69	PIK3CA (liquid biopsy) (752)	35
P. jirovecii (560)	189	PIK3CA (DNA) (752, 590)	35, 55
p.D816V (767)	58	Pipamperone (873)	131
p.L265P (766)	59	Piperacilline (890)	127
PAI-1 (4G/5G) (DNA) (748)	44	Pituitary (298)	105
PAI-1 (4G/5G) (whole blood) (735)	44	Placental growth factor (625)	109
PAI-1 (4G/5G) (whole blood, Dna) (735)	44	Plasma Cell Neoplasia-MRD Immunophenotyping (821)	120
Paliperidone (862)	137	Plasmaprotein (240, 241, 242)	142, 142, 143
Pancreas (300)	108	Plasminogenactivator inhibitor (PAI): 4G, 5G (whole blood) (735)	44
Pancreas amylase (serum) (100)	115	Plasminogenactivator-Inhibitor (PAI): 4G, 5G (DNA) (748)	44
Panel for Viral Meningitis (cell culture lysate) (433)	221	Plasminogenactivator-Inhibitor (PAI): 4G, 5G (whole blood, Dna) (735)	44
Pantothenic acid (Vitamin B5) (290)	159	Plasmodia (454)	194
PAP (785)	125	Platelet antibodies (233)	82
PAPP-A (serum / plasma) (305)	107	Platelet antigens (233)	82
Paracetamol (194)	135	Platelet Immunology (233)	82
Parainfluenza Viruses (cell culture lysate) (388, 431)	222, 224	Platelets (209, 211, 612)	86, 87, 88
Paraneoplastic Neuropathies (serum) (265)	67	Platin (206)	147
Parasite Microscopy (blood smear) (456)	193	PLGF (625)	109
Parasite Microscopy (stool) (451)	145	PML::RARA gene fusion (cDNA) (702)	54
Parasites (blood smear) (456)	193	PML::RARA qualitative (cDNA) (702)	54
Parasites (pictures) (906, 907)	195, 196	PMS2 (DNA) (783)	41
		Pneumocystis jirovecii (Fungal genome) (560)	189
		PNH (EDTA-whole blood) (616)	91



INDEX

pO2 (POCT OPTI Systems) (163)	145
pO2 (POCT) (161)	144
POCT (100, 131, 145, 151, 171, 173, 174, 176, 177, 179, 203, 204, 209, 211, 226, 240, 286, 292, 293, 311, 321, 322, 324, 334, 337, 344, 346, 350, 352, 355, 359, 370, 410, 481, 539, 545, 546, 612, 760, 761, 800, 810)	86, 87, 88, 96, 102, 112, 112, 115, 118, 119, 141, 142, 143, 145, 146, 148, 149, 150, 150, 151, 151, 153, 155, 156, 157, 164, 167, 170, 176, 177, 181, 182, 192, 197, 198, 199, 231, 232, 232, 233, 234, 236
Porphobilinogen (urine) (180)	154
Porphyrins (178)	156
Posaconazole (198)	130
Potassium (POCT OPTI Systems) (163)	145
Potassium (POCT) (161)	144
Potassium (POCT: Abaxis Piccolo) (810)	145
Potassium (serum) (100)	115
Potassium (urine) (173)	157
Prader-Willi syndrome (PWS) (DNA) (786)	45
Prader-Willi-Fanconi syndrome (786)	45
Preeclampsia Marker (625)	109
Pregabalin (872)	129
Pregnancy (305, 306)	107, 107
Primidon (195)	139
Pro-Gastrin-Releasing Peptide (299)	149
Pro-insuline (300)	108
PROC (DNA) (790, 791)	45, 46
PROC gene (DNA) (790)	45
Procalcitonin (serum) (320)	178
Progenitor Cells (whole blood) (217)	92
Progesterone (302)	109
Prolactin (298)	105
Proline (710)	113
PROS (791)	46
PROS1 gene (DNA) (791)	46
Prostatic acid Phosphatase (100)	115
Protease Inhibitors (plasma) (384)	214
Protein (CSF) (460)	124
Protein (POCT: Abaxis Piccolo) (810)	145
Protein (serum) (100, 141)	115, 120
Protein (urine) (171, 173)	156, 157
Protein Analysis (CSF + serum) (460)	124
Protein C (DNA) (790)	45
Protein C (plasma) (225)	95
Protein S (DNA) (791)	46
Protein S (plasma) (225)	95
Prothrombin G20210A (DNA) (746)	46
Prothrombin G20210A (whole blood) (731)	47
Prothrombin G20210A (whole blood, Dna) (731)	47
Prothrombin Time (221)	102
PSA (292, 293)	149, 150
Psychostimulants (879)	135
Psychotherapeutic Drugs (860, 861, 862, 863)	136, 136, 137, 137

Pyridoxal-5-phosphate (Vitamin B6) (lyophilized whole blood) (291)	160
Pyridoxal-5-phosphate (Vitamin B6) (serum) (290)	159

Q

Q fever (325, 542)	164, 175
Query fever (325, 542)	164, 175
Quetiapine (860, 861, 862)	136, 136, 137
Quick (plasma) (221, 285)	95, 102
Quick (whole blood) (286)	102

R

RA (273)	69
Rabies Virus (lyophilised) (390)	223
Rabies Virus (serum) (336)	239
Raltegravir (850)	132
rare erythrocyte blood group systems (DNA) (235)	26
Reboxetine (873)	131
red blood cell (RBC) morphology (212)	87
red blood cells (RBC) (171, 211, 612)	86, 88, 156
Respiratory burst (granulocytes) (654)	77
respiratory diseases (431, 432)	224, 225
respiratory infection (314)	173
Respiratory Stimulants (870, 870)	138, 138
Respiratory Syncytial Virus (cell culture lysate) (359, 432)	199, 225
Respiratory Virus Panel (cell culture lysate) (431, 432)	224, 225
RET (DNA) (738)	56
Ret Proto-Oncogene (DNA) (738)	56
Reticulated Platelets (216)	91
Reticulocyte (blood smears) (215)	92
Reticulocyte production Index (RPI) (216)	91
Reticulocytes (blood smears) (215)	92
Reticulocytes (whole blood) (216)	91
Retinol (Vitamin A) (290)	159
Retinol binding protein (urine) (182)	158
Reverse Transcriptase Inhibitors (plasma) (384)	214
RF (273, 323)	69, 178
Rh (D) Factor (Machine-based, whole blood) (237, 238)	83, 83
Rh (D) Factor (serum / erythrocytes suspension) (231, 232)	81, 81
Rh - Subtyping (Machine-based, whole blood) (237)	83
Rh - Subtyping (serum / erythrocytes suspension) (231, 232)	81, 81
Rh - Subtyping (without Cw) (Machine-based, whole blood) (238)	83
RHCE (DNA) (235)	26
RHD (DNA) (235)	26
RHD - Deletion (DNA) (235)	26
Rheumatoid Arthritis (serum) (273)	69
Rheumatoid Factor (IgA) (serum) (273)	69
Rheumatoid Factor (IgG) (serum) (273)	69
Rheumatoid Factor (IgM) (serum) (273)	69
Rheumatoid Factor (serum) (273, 323)	69, 178

INDEX

Ribavirine (850)	132	sexually transmitted disease (STI) (311, 312, 313, 316, 530, 531, 547)	163, 163, 169, 173, 174, 174, 182
Riboflavin (Vitamin B2) (lyophilized whole blood) (291)	160	sexually transmitted diseases (STI) (373)	216
Riboflavin (Vitamin B2) (serum) (290)	159	sexuell übertragbare Krankheiten (STI) (480)	191
Rickettsia (antibody, serum) (330)	179	SF3B1 (DNA) (797)	60
rickettsioses (330)	179	SF3B1 Exon 14-15 (DNA) (797)	60
Rilpivirin (850)	132	SF3B1 Nomenclature (DNA) (797)	60
Risperidone (862)	137	sFLT-1 (soluble fms-like tyrosine kinase-1) (625)	109
Ritalinic acid (879)	135	Shiga toxin-producing Escherichia coli (534)	165
Ritonavir (850)	132	Shigella spp (548)	168
Rivaroxaban (503)	103	sickle cells (210)	89
ROMA-Score (292)	149	Sipple syndrome (738)	56
Rotaviruses (suspensions of feces) (401, 430, 430)	206, 206, 226	Sirolimus (601)	134
ROTEM Sigma (plasma) (509)	103	Skin antibodies (259)	63
RSV (359)	199	SMA (DNA) (787)	47
Rubella specific quotient (CSF + serum) (463)	123	SMN (DNA) (787)	47
Rubella Virus (cell culture lysate) (389)	226	SMN1 (DNA) (787)	47
Rubella Virus (serum) (341)	240	SMN1 and SMN2 genes (DNA) (787)	47
Rubella virus IgG Antibody Index (CSF + serum) (463)	123	SMN2 (DNA) (787)	47
Rufinamide (871)	128	SNRPN (DNA) (786)	45
RUNX1 (CDS) Mutation(s) (798)	57	sO2 (POCT OPTI Systems) (163)	145
RUNX1 Nomenclature (798)	57	Sodium (POCT OPTI Systems) (163)	145
S		Sodium (POCT) (161)	144
S100 (292)	149	Sodium (POCT: Abaxis Piccolo) (810)	145
S65C (741)	39	Sodium (serum) (100)	115
Salicylate (194)	135	Sodium (urine) (173)	157
Salicylic acid (194)	135	soluble transferrin receptor (241)	143
Salmonella (537)	169	specific gravity (urine) (171)	156
Salmonella (antibody, serum) (331)	180	spinal muscular atrophy (DNA) (787)	47
Salmonella enterica (Bacterial genome) (537)	169	Staining characteristics (411)	184
Salmonellosis (331, 537)	169, 180	Staining characteristics (Slide (fixed)) (413)	185
Sapoviruses (suspensions of feces) (430, 430)	206, 206	STAT3 (DNA) (769)	60
Sarcosine (710)	113	Status of hantavirus infection (serum) (355)	232
SARS-CoV-2 (Ag) (cell culture supernatants) (410)	197	STEC (Bacterial genome) (534)	165
SARS-CoV-2 (cell culture lysate) (340, 409, 417, 431)	202, 224, 227, 227	Stem Cells (whole blood) (217)	92
SARS-CoV-2 (cell culture supernatants) (410)	197	Steroid Hormones (302)	109
SARS-CoV-2 (RNA) (cell culture lysate) (409)	227	sTfR (241)	143
SARS-CoV-2 (serum) (416)	240	Stool parasites (pictures) (907)	196
sC5b-9 (247)	79	Stool parasites (stool) (451)	145
SCC (292)	149	Streptococcal AB (antibody, serum) (321)	181
Schistosomiasis (serum/plasma) (454)	194	Sulbactam (890)	127
Sediment Pictures (pictures) (172)	157	Sulthiame (191)	127
Selenium (lyophilized whole blood) (208)	146	Survival of motor neuron (787)	47
Selenium (plasma) (206)	147	Susceptibility Testing of nontuberculous mycobacteria (427)	187
Selenium (urine) (205)	153	Susceptibility Testing of tuberculosis bacteria (425)	186
Sepsis (320, 322)	143, 178	Susceptibility tests (3 Samples) (drying process) (411)	184
Serine (710)	113	Susceptibility tests (5 samples) (Lyophilisate) (412)	185
Serotonin (plasma) (185)	114	Switched B cells (651)	74
Serotonin (urine) (175)	155	Syphilis (311)	182
SERPINC1 (792)	29	Systematic Toxicological Analysis (STA) (188)	152
SERPINC1 gene (DNA) (792)	29		
Sertraline (serum) (873)	131		
Serum Proteins (141)	120		



INDEX

T

T cell subpopulations (651)	74	Total Tau Protein (Tau) (CSF) (466)	121
T cytotoxicity assay (CD107a or lysis) (657)	76	Toxin Gene (Bacterial genome) (545)	164
T-cells (cellular products) (617)	93	Toxin genes (microbiological samples) (545)	164
T-Cells (EDTA-whole blood) (651)	74	Toxoplasma gondii (EDTA whole blood) (457)	192
T-Helper Cells (EDTA-whole blood) (651)	74	toxoplasmosis (457)	192
T-lymphocytes (whole blood) (213)	90	Toxoplasmosis (serum/plasma) (452)	195
T3 (294, 302)	109, 110	TP53 (CDS) Mutation(s) (798)	57
T4 (294, 302)	109, 110	TP53 (DNA) (765)	61
Tacrolimus (601)	134	TP53 Nomenclature (798)	57
Taurine (710)	113	TPA (292)	149
Tazobactam (890)	127	TPMT (775)	35
tCO ₂ (POCT: Abaxis Piccolo) (810)	145	TPS (292)	149
TEG/ROTEM (283)	104	TPT (221)	102
Teicoplanin (193)	126	TPZ (plasma) (221, 285)	95, 102
Temazepam (877)	133	TPZ (whole blood) (286)	102
Testosterone (293, 302)	109, 150	TRAb (295)	110
Tetanus Toxoid (antibody, serum) (310)	181	Trace Elements (lyophilized whole blood) (208)	146
Tetracyclic Antidepressants (202)	139	Trace Elements (plasma) (206)	147
TgAB (295)	110	Trace Elements (serum) (207)	147
thalassemia (210)	89	Trace Elements (urine) (205)	153
Theophylline (195)	139	Training Program (plasma) (368, 378, 379, 382)	203, 208, 210, 212
Thiamine total (Vitamin B1) (291)	160	TRAK/THYBIA (295)	110
Thiaminpyrophosphat (TPP) (291)	160	transcription factor (769)	60
Threonine (710)	113	Transferrine (plasma) (241)	143
Thrombin time (222, 280, 285)	95, 99, 104	Transferrine (serum) (100)	115
Thrombin time (Argatroban) (230)	94	Transferrine (urine) (182)	158
Thrombocyte - alleles (DNA) (235)	26	Trazodone (876)	133
Thrombocytes (QBC systems) (209)	87	Treponema (547)	169
Thrombocytes (stabilized control blood) (211)	86	Treponema pallidum (antibody, serum) (311)	182
Thrombocytes (whole blood) (612)	88	Trichomonas (547)	169
thromboembolism (501)	100	Tricyclic Antidepressants (serum) (199, 201, 202, 203)	139, 140, 140, 141
thrombophilia (275, 730, 731, 740, 746)	37, 38, 46, 47, 62	Tricyclic Antidepressants (urine) (204)	153
thrombophilia (DNA) (790, 791, 792)	29, 45, 46	Triglycerides (100, 151)	115, 119
Thromboplastin time (221)	102	Triglycerides (POCT: Abaxis Piccolo) (810)	145
Thrombopoietin (626)	108	Triiodothyronine (294)	110
thrombosis (730, 731, 740, 746)	37, 38, 46, 47	Trijodthyronin (294, 302)	109, 110
thrombosis (DNA) (790, 791, 792)	29, 45, 46	Trimipramine (serum) (201, 203, 863)	137, 140, 141
Thyreoglobulin (Special Thyroid) (301)	106	Trimipramine (urine) (204)	153
Thyreoglobulin (Tumor marker) (292)	149	Trockenchemie (POCT) (800)	146
Thyroglobulin (301)	106	Trockenchemie (POCT: Abaxis Piccolo) (810)	145
Thyroid Gland Antibodies (295)	110	Tropism Determination (plasma) (384)	214
Thyroid Hormones (294, 301, 302)	106, 109, 110	Troponin I (760)	112
thyroid-stimulating hormone (294)	110	Troponin T (760)	112
Thyroxine (294, 302)	109, 110	Tryptophan (710)	113
Tiagabine (872)	129	TSH (dried blood spots) (785)	125
TIBC (100)	115	TSH (serum / plasma) (294)	110
Tick-Borne Encephalitis (serum) (358)	241	TSH (serum) (302)	109
Tin (serum) (207)	147	Tuberculosis (Slide) (421)	188
Tobramycin (197)	138	Tuberculosis (sputum) (422)	186
Tocopherol (Vitamin E) (290)	159	Tuberculosis (suspensions of mycobacterial strains) (423, 425, 426, 427)	186, 187, 187, 188
Topiramate (872)	129	Tuberculosis bacteria (sputum) (424)	189
Torque Teno Virus (TTV) (plasma) (408)	228	Tuberculosis bacteria, genome detection (sputum) (424)	189
Total Protein C (plasma) (225, 225)	95, 95		

INDEX

Tularemia (328, 543)	165, 176
Tumor Markers (292, 293, 299)	149, 149, 150
Tumor Panel (liquid biopsy) (752)	35
tumor suppressor (765)	61
Typing of adenovirus (cell culture lysate) (371)	199
Typing of Dengue Viruses (plasma) (369)	204
Typing of enterovirus (cell culture lysate) (372)	205
Typing of human rhinovirus (cell culture lysate) (393)	217
Typing of measles virus (cell culture lysate) (386)	218
Typing of mumps virus (cell culture lysate) (387)	220
Typing of parainfluenza virus (cell culture lysate) (388)	222
Typing of rotavirus (suspensions of feces) (401)	226
Typing of rubella virus (cell culture lysate) (389)	226
Typing of seasonal and avian influenza A viruses (cell culture lysate) (370)	198
Typing of West Nile virus (cell culture lysate) (391)	229
Typing of Zika virus (cell culture lysate) (403)	229
Tyrosine (710)	113
tyrosine kinase (767)	58

U

UDP-glucuronyltransferase 1 (*28, *6) (DNA) (742)	48
UDP-glucuronyltransferase 1 (*28, *6) (whole blood) (726)	48
UDP-Glucuronyltransferase 1 (DNA) (742)	48
UDP-GT1 (742)	48
UDPG1 (*28, *6) (DNA) (742)	48
UDPG1 (*28, *6) (whole blood) (726)	48
UF Heparin (280)	104
unfractionated heparin (280)	104
Unit-Use (800)	146
Urate (100, 810)	115, 145
Urea (POCT OPTI Systems) (163)	145
Urea (POCT) (161)	144
Urea (POCT: Abaxis Piccolo) (810)	145
Urea (serum) (100)	115
Urea (urine) (173)	157
Ureaplasma (547)	169
Uric Acid (POCT: Abaxis Piccolo) (810)	145
Uric Acid (serum) (100)	115
Uric Acid (urine) (173)	157
Urinary Stone (500)	154
Urinary Stone Analyses (500)	154
Urine Chemistry (171, 173, 175, 178, 182)	155, 156, 156, 157, 158
Urine Chemistry (pictures) (172)	157
Urine Chemistry (urine) (179)	155
Urine Chemistry 06 (urine) (180)	154
Urine Protein Differentiation (171)	156
Urine Sediment Pictures (pictures) (172)	157
Urobilinogen (171)	156
Urogenital Panel (Bacterial genome) (547)	169
Uroporphorin (178)	156

V

Valine (710)	113
Valproic Acid (195)	139
Vanadium (207)	147
Vancomycin (197)	138
Vancomycin Resistant Enterococci (Bacterial genome) (546)	170
Vanillylmandelic acid (175)	155
Varicella Zoster Virus (cell culture lysate) (433)	221
Varicella Zoster Virus (plasma) (366)	228
Varicella Zoster Virus (serum) (353)	241
Varizella zoster specific quotient (CSF + serum) (463)	123
Varizella zoster virus IgG Antibody Index (CSF + serum) (463)	123
Vasculitis (serum) (257)	69
Vel system [VEL] (DNA) (235)	26
Venlafaxine (860, 861)	136, 136
Viable CD34+ events (whole blood) (217)	92
Viable CD45+ events (whole blood) (217)	92
Vibrio spp. (548)	168
Vigabatrin (872)	129
viral hemorrhagic fever (350, 355, 369, 392, 402)	201, 204, 230, 231, 232
Virilization (serum / plasma) (309)	111
virtual (172, 218, 906, 907)	88, 157, 195, 196
Virtual Parasite Microscopy (Blood) (pictures) (906)	195
Virtual Parasite Microscopy (Stool) (pictures) (907)	196
Virus Antigen Detection □ SARS-CoV-2 (Ag) (cell culture supernatants) (410)	197
Virus Detection (cell culture lysate) (370)	198
Virus Detection (Genome/Antigen) - Influenza Viruses (cell culture lysate) (370)	198
Virus Genome Detection - Adenoviruses (cell culture lysate) (371)	199
Virus Genome Detection - BK Virus (plasma / urine) (364)	200
Virus Genome Detection - Borna Viruses (cell culture lysate) (404)	200
Virus Genome Detection - Chikungunya Virus (plasma) (392)	201
Virus Genome Detection - Coronaviruses (cell culture lysate) (340)	202
Virus Genome Detection - Cytomegalovirus - additional Training Program (plasma) (368)	203
Virus Genome Detection - Cytomegalovirus Program 1 (plasma) (365)	203
Virus Genome Detection - Cytomegalovirus Susceptibility Determination (plasma) (349)	204
Virus Genome Detection - Dengue Viruses (plasma) (369)	204
Virus Genome Detection - Enteroviruses (cell culture lysate) (372)	205
Virus Genome Detection - Epstein Barr Virus (plasma) (376)	205
Virus Genome Detection - Gastrointestinal Virus Panel for Multiplex Tests (suspensions of feces) (430)	206

INDEX

Virus Genome Detection - Hepatitis A Virus (plasma) ⁽³⁷⁷⁾	206	Virus Genome Detection - Respiratory Virus Panel 2 for Multiplex Tests (cell culture lysate) ⁽⁴³²⁾	225
Virus Genome Detection - Hepatitis B Virus - additional Training Program (plasma) ⁽³⁷⁸⁾	208	Virus Genome Detection - Rotaviruses (suspensions of feces) ⁽⁴⁰¹⁾	226
Virus Genome Detection - Hepatitis B Virus Genotyping (plasma) ⁽³⁹⁶⁾	207	Virus Genome Detection - Rubella Virus (cell culture lysate) ⁽³⁸⁹⁾	226
Virus Genome Detection - Hepatitis B Virus Program 1 (plasma) ⁽³⁶¹⁾	207	Virus Genome Detection - SARS-CoV-2 (cell culture lysate) ⁽⁴⁰⁹⁾	227
Virus Genome Detection - Hepatitis B Virus Susceptibility Determination (plasma) ⁽³⁹⁷⁾	208	Virus Genome Detection - Torque Teno Virus (TTV) (plasma) ⁽⁴⁰⁸⁾	228
Virus Genome Detection - Hepatitis C Virus - additional Training Program (plasma) ⁽³⁷⁹⁾	210	Virus Genome Detection - Varicella Zoster Virus (plasma) ⁽³⁶⁶⁾	228
Virus Genome Detection - Hepatitis C Virus - Susceptibility Determination (plasma) ⁽³⁹⁹⁾	210	Virus Genome Detection - West Nile Virus (cell culture lysate) ⁽³⁹¹⁾	229
Virus Genome Detection - Hepatitis C Virus Genotyping (plasma) ⁽³⁷⁵⁾	209	Virus Genome Detection - Zika Virus (cell culture lysate) ⁽⁴⁰³⁾	229
Virus Genome Detection - Hepatitis C Virus Program 1 (plasma) ⁽³⁶²⁾	209	Virus Immunology - Borna Viruses (Ab) (serum) ⁽⁴¹⁵⁾	230
Virus Genome Detection - Hepatitis D Virus (plasma) ⁽⁴⁰⁰⁾	211	Virus Immunology - Chikungunya Virus (Ab) (cell culture lysate) ⁽⁴⁰²⁾	230
Virus Genome Detection - Hepatitis E Virus (plasma) ⁽³⁸⁰⁾	211	Virus Immunology - Cytomegalovirus (Ab) (serum) ⁽³⁵¹⁾	231
Virus Genome Detection - Herpes Simplex Virus Type 1/Type 2 (plasma) ⁽³⁶³⁾	212	Virus Immunology - Dengue Viruses (Ab and NS1 Antigen) (serum) ⁽³⁵⁰⁾	231
Virus Genome Detection - HIV-1 (RNA) - additional Training Program (plasma) ⁽³⁸²⁾	212	Virus Immunology - Epstein Barr Virus (Ab) (serum) ⁽³⁵²⁾	232
Virus Genome Detection - HIV-1 (RNA) Program 1 (plasma) ⁽³⁶⁰⁾	213	Virus Immunology - Hantaviruses (Ab) (serum) ⁽³⁵⁵⁾	232
Virus Genome Detection - HIV-1 Drug Susceptibility Determination (plasma) ⁽³⁸³⁾	213	Virus Immunology - Hepatitis A Virus (Ab) (serum) ⁽³⁴³⁾	233
Virus Genome Detection - HIV-2 (RNA) (plasma) ⁽³⁹⁵⁾	214	Virus Immunology - Hepatitis B Virus Program 1 (HBsAg, Anti-HBs, Anti-HBc) (serum) ⁽³⁴⁴⁾	233
Virus Genome Detection - Human Herpesvirus 6 (HHV-6) (cell culture lysate) ⁽⁴⁰⁵⁾	215	Virus Immunology - Hepatitis B Virus Program 2 (Anti-HBc-IgM, HBeAg, Anti-HBe) (serum) ⁽³⁴⁵⁾	234
Virus Genome Detection - Human Herpesvirus 8 (HHV-8) (cell culture lysate) ⁽⁴⁰⁶⁾	215	Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) (serum) ⁽³⁴⁶⁾	234
Virus Genome Detection - Human Metapneumovirus (cell culture lysate) ⁽³⁸⁵⁾	216	Virus Immunology - Hepatitis D Virus (Ab) (serum) ⁽³⁴⁷⁾	235
Virus Genome Detection - Human Papilloma Viruses (cell culture lysate) ⁽³⁷³⁾	216	Virus Immunology - Hepatitis E Virus (Ab) (serum) ⁽³⁴⁸⁾	235
Virus Genome Detection - Human Rhinoviruses (cell culture lysate) ⁽³⁹³⁾	217	Virus Immunology - Herpes Simplex Viruses (Ab) (serum) ⁽³⁵⁴⁾	236
Virus Genome Detection - JC Virus (plasma / urine) ⁽³⁹⁴⁾	217	Virus Immunology - HIV-1 p24 Antigen (serum) ⁽³³⁷⁾	236
Virus Genome Detection - Measles Virus (cell culture lysate) ⁽³⁸⁶⁾	218	Virus Immunology - HIV-1/HIV-2 (Ab) (serum) ⁽³³⁵⁾	237
Virus Genome Detection - Mumps Virus (cell culture lysate) ⁽³⁸⁷⁾	220	Virus Immunology - HTLV-1/HTLV-2 (Ab) (serum) ⁽³³⁹⁾	237
Virus Genome Detection - Norovirus (suspensions of feces) ⁽³⁸¹⁾	220	Virus Immunology - Measles Virus (Ab) (serum) ⁽³⁵⁷⁾	238
Virus Genome Detection - Panel for Viral Meningitis / Encephalitis for Multiplex Tests (cell culture lysate) ⁽⁴³³⁾	221	Virus Immunology - Mumps Virus (Ab) (serum) ⁽³⁵⁶⁾	238
Virus Genome Detection - Parainfluenza Viruses (cell culture lysate) ⁽³⁸⁸⁾	222	Virus Immunology - Parvovirus B19 (Ab) (serum) ⁽³⁴²⁾	239
Virus Genome Detection - Parechovirus (cell culture lysate) ⁽⁴⁰⁷⁾	222	Virus Immunology - Rabies Virus (Tollwutvirus) (Ab) (serum) ⁽³³⁶⁾	239
Virus Genome Detection - Parvovirus B19 (plasma) ⁽³⁶⁷⁾	223	Virus Immunology - Rubella Virus (Ab) (serum) ⁽³⁴¹⁾	240
Virus Genome Detection - Rabies Virus (Tollwutvirus) (lyophilised) ⁽³⁹⁰⁾	223	Virus Immunology - SARS-CoV-2 (Ab) (serum) ⁽⁴¹⁶⁾	240
Virus Genome Detection - Respiratory Syncytial Virus (Antigen/Genome) (cell culture lysate) ⁽³⁵⁹⁾	199	Virus Immunology - Tick-Borne Encephalitis (TBE/FSME) Virus (Ab) (serum) ⁽³⁵⁸⁾	241
Virus Genome Detection - Respiratory Virus Panel 1 for Multiplex Tests (cell culture lysate) ⁽⁴³¹⁾	224	Virus Immunology - Varicella Zoster Virus (Ab) (serum) ⁽³⁵³⁾	241
		Virus Immunology - Zika Virus (Ab) (serum) ⁽³³⁸⁾	242
		Virusgenome-Detection □ SARS-CoV-2-VOC-Analysis (cell culture lysate) ⁽⁴¹⁷⁾	227
		Vitamin C ⁽¹⁷¹⁾	156
		Vitamin C (plasma) ⁽²⁹⁶⁾	159

INDEX

Vitamins (lyophilized whole blood) (291)	160
Vitamins (plasma) (187, 296)	158, 159
Vitamins (serum) (290)	159
VKORC1 (775)	35
VLDL-cholesterol (POCT: Abaxis Piccolo) (810)	145
VOC-Analysis (cell culture lysate) (417)	227
von Willebrand factor (DNA) (678)	54
von Willebrand syndrome (DNA) (678)	54
Voriconazole (198)	130
VRE (Bacterial genome) (546)	170
VWF (DNA) (678)	54
vWS (678)	54
VZV (366, 433, 463)	123, 221, 228
West Nile Virus (cell culture lysate) (391)	229
white blood cell (WBC) morphology (212)	87
white blood cells (WBC) (171, 209, 211, 213, 217, 612, 617)	86, 87, 88, 90, 92, 93, 156
Whooping cough (317, 532)	161, 171
Willebrand Factor (227)	99
WNV (391)	229
Yeasts (living cultures) (490, 491)	190, 191
Yersinia (antibody, serum) (315)	183
Yersinia enterocolitica (548)	168
Yersiniosis (315)	183
Yt system [YT] (DNA) (235)	26
Zika fever (338)	242
Zika Virus (cell culture lysate) (403)	229
Zika Virus (serum) (338)	242
Zinc (lyophilized whole blood) (208)	146
Zinc (plasma) (206)	147
Zinc (urine) (205)	153
Ziprasidone (862, 873)	131, 137
Zonisamide (872)	129
Zoonosis (325, 331, 338, 339, 340, 355, 385, 404, 535, 537, 538, 539, 542, 543)	161, 164, 165, 167, 167, 169, 175, 180, 200, 202, 216, 232, 237, 242



INSTAND International GMBH is distributing EQA Schemes globally as a subsidiary of INSTAND e.V. and is based in Germany.

INSTAND e.V. is an interdisciplinary, non-profit, scientific-medical professional association. It operates as a reference institution according to the Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations – Rili-BÄK. INSTAND is based in Germany and has more than 300 members worldwide. INSTAND is a member of numerous national and international professional societies and standardization committees, including DIN, CEN, and ISO. INSTAND's excellent global scientific network is a valuable tool to draw upon for research projects for quality assurance. INSTAND is accredited according to DIN EN ISO/IEC 17043.



INSTAND

INSTAND International GMBH

Address: Ubierstr. 20, 40223 Duesseldorf, Germany

Telephone: +49 211 876 3529 0

E-mail: info@instand-international.com